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10 Chapter 1
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
Cardiovascular disease
Worldwide, cardiovascular disease is still the number one cause of  death, with an an-
nual death toll of  17,5 million lives. Fairly ironic, in most African and Asian countries 
this rate is augmented each year with enhanced prosperity1, 2. Acute myocardial infarc-
tion and ischemic stroke account for a large proportion of  cardiovascular disease and 
subsequent morbidity and mortality. A major cause of  both events are atherosclerotic 
plaques vulnerable to rupture or erosion. In the case of  myocardial infarction this un-
stable plaque is typically located in the coronary arteries. The subsequent thrombotic 
process diminishes myocardial tissue perfusion by reduced coronary artery flow 3. In the 
case of  ischemic stroke, occlusion is often the result of  plaque instability in a carotid 
artery resulting in a downstream thrombo-embolic process. Our view of  the pathogen-
esis of  atherosclerosis has shifted radically in recent decades. Although long presumed 
as a disease in lipid storage, we now recognize that inflammation is a key contributor to 
atherosclerosis. Inflammatory cells and mediation in the vascular wall play an important 
role in disease progression eventually leading to plaque instability and cardiovascular 
events. As a result, plaque instability is closely related to intra-plaque inflammation4, 5. 
Nonetheless we are still awaiting the results of  the first large randomized clinical trials 
that subject anti-inflammatory interventions to the test6, 7. 
The pathophysiology of  plaque rupture on the one hand and occluding thrombus on the 
other provides the rationale for disease management. Examples of  preventive therapies 
that focus on the vessel wall component are e.g. cholesterol lowering statin treatment 
and life style advices. In the more acute setting of  infarction, percutaneous coronary in-
tervention with stenting or surgical revascularization is often used to restore the patency 
of  the vessel wall and subsequent flow. Anti-thrombotic agents are used preemptively 
to prevent blood clot formation and subsequent cardiovascular events, which are being 
augmented by thrombosuction or fibrinolytic approaches in an acute setting. Besides this 
continuously expanding arsenal, the foundation of  treatment of  cardiovascular events 
still predominantly encompasses damage control or tertiary prevention, once an event 
can occur. Clinicians show great interest in identifying those patients at high risk for an 
event in order to intervene before myocardial damage has occurred. This is especially 
promising because it seems that there is a window of  opportunity to treat vulnerable or 
even ruptured plaques before they become clinically overt (i.e. primary prevention vs 
tertiary prevention) and thus potentially reduce morbidity and mortality. Studies have 
shown for instance, that sudden coronary occlusion is often preceded by a variable pe-
riod of  plaque instability and/or thrombus formation, underlining the possibility of  
identifying and treating thrombus initiation and early progression before actual infarc-
Proefschrift_v10.0.indd   10 02-11-17   12:14
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tion 8. In order to properly use this window, it is crucial to understand what factors cause 
enhanced intra-plaque inflammation leading to vulnerable plaques. 
In the search for these factors an important discovery was made that pointed towards 
systemic over local triggers of  plaque destabilization. It was demonstrated that patients 
with acute myocardial infarction harbor multiple complex coronary plaques, which are 
associated with adverse clinical outcomes 9. This finding indicates that plaque instabil-
ity is not a feature of  a single lesion, but it develops in a multifocal pattern, resulting 
in multiple complex, unstable plaques in anatomically remote locations. Any of  these 
single lesions might progress to total occlusion of  a vessel and emerge as the cause of  an 
infarct 9. This observation supports the concept that plaque instability is not merely a 
local vascular accident but probably reflects more generalized pathophysiologic triggers 
with the potential to destabilize atherosclerotic plaques throughout the coronary9, 10 and 
carotid vasculature11.
This concept leads us to the next question: what are possible triggers of  widespread/
ubiquitous destabilizing of  atherosclerotic plaques? Can we understand and thereby pre-
dict and prevent increased plaque instability that causes plaque rupture and subsequent 
thrombosis? Besides very proximate triggers, that cause immediate elevated risk prob-
ably via increased myocardial oxygen demand or vasospasm, such as cocaine abuse12, 
extreme emotional reactions13, short term exposure to air pollution14, sexual activity15 or 
physical exercise16, we are still unaware of  the mechanisms that cause these sustained 
periods17 of  widespread plaque instability. 
One possible trigger merits discussion: systemic inflammation. We already described that 
local inflammatory processes are key in atherosclerotic plaque formation, progression 
and rupture18. Intra-plaque inflammation contributes to many of  the characteristics of  
plaques that are prone to rupture or erode and also plays a role in thrombogenesis5, 7. In 
recent years, it has become more and more obvious that there is a link between systemic 
inflammation and local plaque enhancement. For instance, several chronic inflammato-
ry states such as systemic lupus erythematosus19 and rheumatoid arthritis20 cause plaques 
to be more vulnerable and therefore could be considered as chronic risk factors for 
cardiovascular events. In addition, acute infections are suggested to cause an inflam-
matory activation in the plaque, leading to bursts of  pro-inflammatory, proteolytic and 
prothombotic activity, although definitive evidence is lacking to confirm such a chain of  
events21, 22. In this thesis we study acute systemic inflammation as a factor that may facili-
tate the initiation of  cardiovascular events. Clinical observations predominantly point to 
an elevated cardiovascular event risk shortly after episodes of  acute systemic inflamma-
tion. By expanding our understanding of  the interaction between acute systemic inflam-
mation and atherosclerotic plaques we may be able to explain the observed increased 
risk of  cardiovascular events as well as provide new leads for preventative therapy. 
Proefschrift_v10.0.indd   11 02-11-17   12:14
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Acute systemic inflammation and cardiovascular events
Observational epidemiological studies have confirmed what experienced clinicians sus-
pected for many years: cardiovascular events can be triggered by a variety of  com-
mon non-cardiovascular clinical conditions, particularly those that are associated with 
systemic inflammation23-25. The best documented examples of  such conditions include 
acute (mainly respiratory) infection, and major surgery. Acute systemic infection raises 
the risk of  myocardial infarction by approximately fivefold23, and risk of  stroke by eight-
fold26. The majority of  this excess risk is confined to the first days to two weeks after the 
onset of  illness. A post-operational state is another common clinical condition, which 
increases early cardiovascular risk. A recent nationwide cohort study indicated that the 
risk of  myocardial infarction in patients undergoing total hip or knee replacement is in-
creased by no less than 25-fold, again predominantly during the first days to two weeks24
This phenomenon of  cardiovascular events occurring in patients hospitalized for 
non-cardiovascular conditions is clearly important, but the causal mechanisms are un-
clear, and thus so are targeted preventive strategies. Factors like pain, ‘stress’, reactive 
prothrombotic changes, anesthesia and fluid shifts have been invoked, but if  any of  these 
are indeed important is unknown.
The acuteness of  the increased postoperative cardiovascular risk suggests an effect on 
atherosclerotic plaque stability and/or erosion27. Several studies indeed show that at 
least half  of  the cases of  myocardial infarction following e.g. non-cardiac surgery origi-
nate from rupture of  unstable plaques28-30. Why plaques could become more prone to 
rupture in these cases is unclear. We do know that plaque instability is related to factors 
such as fibrous cap strength, intra-plaque hemorrhage and necrotic core area which, in 
turn, are all influenced by intra-plaque inflammation4, 31, 32. 
Hence, atherosclerotic inflammation after infection or surgery is a plausible explanation 
for increased risk. We thus hypothesize that such intra-plaque inflammation may occur 
as a result of  systemic to plaque spreading of  inflammatory activity. Not only infection, 
but also major surgery is associated with a marked systemic inflammatory response (the 
median C-reactive protein on day 3 after knee arthroplasty, a procedure that is well-doc-
umented to increase risk24, is 189 mg/dl33). Conceivably, circulating pro-inflammatory 
cytokines are responsible for causing inflammatory contamination of  atherosclerotic le-
sions. One study showed that plaque area increased in mice after a single injection of  
serum amyloid A peptide, a marker and mediator of  inflammation 34 Furthermore a 
landmark paper on the role of  acute systemic inflammation in atherosclerosis showed 
increased plaque area and intra-plaque inflammation in mice, briefly after acute myo-
cardial infarction, another form of  acute systemic inflammation35. 
We thus believe that systemic infection and major surgery share a common pathway 
towards increased early cardiovascular event risk by causing plaque inflammation and 
plaque growth. 
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13
To evaluate this hypothesis, we conduct several mouse and human studies of  which we 
report in this thesis. In these studies, we focus on atherosclerosis, but also evaluate the 
role of  inflammation in atherothrombosis.
General outline of  thesis
Besides the larger epicardial blood vessels (the coronary arteries), the smaller intramyo-
cardial vessels are believed to play a role in the etiology of  acute myocardial infarction. 
In Chapter 2 we study the accumulation of  N(ε)-(carboxymethyl)lysine (CML) in these 
intramyocardial vessels in ageing mice. Accumulation of  CML is associated with (mi-
cro)vascular dysfunction and inflammation. The effect of  a diet intervention with the 
anti-inflammatory fish oil constituent, docosahexaenoic acid, on the accumulation of  
this advanced glycation end product is also evaluated. Next, the effect of  acute systemic 
inflammation induced by either major orthopedic surgery (Chapter 3) or a single LPS 
injection to induce sepsis (Chapter 4) on atherosclerosis is studied in mice. In Chapter 
5 we compare inflammatory cell content in atherosclerotic coronary arteries of  AMI 
patients that died with or without previous sepsis. In Chapter 6 the density of  mast cells 
in atherosclerotic lesions of  the coronary arteries after acute myocardial infarction is 
studied. Recent developments in 18-fluorodeoxuglucose positron emision tomography 
(18-FDG-PET) have opened the door to non-invasive imaging of  inflammatory changes 
in large artery atherosclerosis36, 37. In Chapter 7 we validate simplified methods for quan-
titative assessment of  18F-FDG uptake in atherosclerosis assessment of  the large arteries. 
In Chapter 8 PET/CT images of  large arteries of  human patients before and after 
major orthopedic surgery are taken. In these images the inflammation in atherosclerotic 
lesions is quantified in order to evaluate the short-term effects of  surgery on intra-plaque 
inflammation. Most acute myocardial infarctions have their origin in a ruptured plaque 
with subsequent thrombosis. In 2 chapters the role of  inflammation in intra-coronary 
thrombus formation was studied. In Chapter 9 inflammatory cell and platelet content is 
quantified and compared with thrombus age and in Chapter 10 we analyze the relation 
between thrombus age and inflammatory cell content with respect to a phenomenon of  
the smaller intramyocardial vessels: microvascular injury. A short summary and discus-
sion will be presented in Chapter 11.
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ABSTRACT
Objective: N(ε)-(carboxymethyl)lysine (CML) is one of  the major advanced glycation 
end products in both diabetics and non-diabetics. CML depositions in the microvas-
culature, has recently been linked to the etiology of  acute myocardial infarction and 
cognitive impairment in Alzheimer’s disease, possibly related to local enhancement of  
inflammation and oxidative processes. We hypothesised that CML deposition in the 
microvasculature of  the heart and brain is age-induced and that it could be inhibited by 
a diet intervention with docosahexaenoic acid (DHA), an omega-3 fatty acid known for 
its anti-inflammatory and anti-oxidative actions.
Material and methods: ApoE -/- mice (n=50) were fed a western diet and were 
sacrificed after 40, 70 and 90 weeks. Part of  these mice (n=20) were fed a western diet 
enriched with DHA from 40 weeks on. CML in cardiac and cerebral microvessels was 
quantified using immunohistochemistry. 
Results: Cardiac microvascular CML depositions significantly increased with an im-
munohistochemical score of  11.85 [5.92-14.60] at 40 weeks, to 33.17 [17.60-47.15] at 
70 weeks (p=0.005). At the same time points, cerebral microvascular CML increased 
from 6.45; [4.78-7.30] to 12.99; [9.85-20.122] (p=0.003). DHA decreased CML 
in the intramyocardial vasculature at both 70 and 90 weeks, significant at 70 weeks 
(33.17;[17.60-47.15] vs. 14.73;[4.44-28.16] p=0.037). No such effects were found in the 
brain.
Conclusions: Accumulation of  N(ε)-(carboxymethyl)lysine in the cerebral and cardiac 
microvasculature is age-induced and is prevented by docosahexaenoic acid in the in-
tramyocardial vessels of  ApoE -/- mice.
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INTRODUCTION
Advanced glycation end products (AGEs) are proteins or lipids that become glycated 
after exposure to sugars1. N(ε)-(carboxymethyl)lysine (CML) is one of  the major AGEs 
and its formation is enhanced in the presence of  inflammation and under influence of  
reactive oxygen species such as superoxide radicals and hydrogen peroxide2.Vice versa, 
it is known that CML itself  is involved in the generation of  oxidative stress and induc-
tion of  inflammation via interaction and activation of  the Receptor AGE (RAGE)3. 
Increased CML serum levels were found to correlate positively with the incidence of  
cardiovascular events such as acute myocardial infarction4. Moreover, CML depositions 
were locally detected in the major arteries2 and are believed to contribute to the devel-
opment of  atherosclerosis5, 6 through both receptor for AGEs (RAGE)-dependent and 
RAGE-independent pathways7. Moreover, intra-plaque levels of  CML were associated 
with increased risk of  plaque rupture8, supporting the concept that CML induces pro-
gression of  stable to rupture-prone plaques. 
Although age-related CML accumulation was found in atherosclerotic vessels8, it re-
mains unknown whether age-related CML accumulation also occurs in the, non-athero-
sclerotic, microvasculature of  the brain and the heart. This is of  great interest, because 
the intramyocardial blood vessels are more important in the induction of  acute events 
than previously thought9 and form a potential new therapeutic target. As for the brain, 
it is known for years that damage to the local microvasculature is related to Alzheimer’s 
disease10 and coincides with damage to the microvasculature of  the kidney and indices 
of  age and hypertension11. We have previously shown that CML deposits in the micro-
vasculature of  the brain in diabetes mellitus (DM) and in the heart in acute myocardial 
infarction9, DM12 as well as in diastolic heart failure13. However, the relation to patients 
age hasn’t been studied and the results from the macrovasculature cannot be directly 
translated to the microvasculature, since we have found in the human heart that the 
extent of  CML accumulation in the atherosclerotic epicardial coronary arteries does not 
correlate with that in the downstream intramyocardial microvasculature9.
To elucidate the role of  aging in microvascular CML accumulation, we have now studied 
CML deposition in the microvasculature in an atherosclerotic mouse model. We have 
chosen an atherosclerotic model to mimic the situation of  elderly humans. Additionally, 
we have analysed whether putative age-related effects on the microvasculature could be 
inhibited by the omega-3 (n-3) long chain polyunsaturated fatty acid, docosahexaenoic 
acid (DHA). As this fish oil constituent has been advocated as a diet intervention against 
several effects of  aging, including cognitive impairment14, 15 and cardiovascular events16, 
in part via its anti-oxidative17, 18 and anti-inflammatory19, 20 actions.




Apo E -/- mice (6–8 weeks old) were obtained from The Jackson Laboratory (Bar Har-
bor, Maine, USA). Mice were housed under specifi c pathogen-free conditions, on a 12-h 
light–dark cycle and fed a Western Diet for Rodents (5TJN – 1810842, PS Product Sup-
plies, London). The mice were divided into 5 groups (Table 1). Group 1,2 and 3 were fed 
with a western diet and were respectively sacrifi ced at 40, 70 and 90 weeks, resulting in 
extensive atherosclerotic changes of  the aorta already at 40 weeks (Fig. 1A). Group 4 and 
5 received the western diet enriched with 4% DHA (C22:6, Nu-Chek Prep, Inc, USA) 
from 40 weeks on and were sacrifi ced at 70 weeks (group 4) and at 90 weeks (group 5). 
Survival was recorded during the entire experiment by checking the animals on a daily 
basis. The survival percentages were calculated per group as the percentage of  mice 
that lived to the time point of  planned sacrifi ce opposed to mice that died preliminary. 
All procedures were approved by the Animal use and care Committee at the Georgian 
National Institute for Medical Research.
Group (n=10) Number of mice that 
reached the endpoint 
(%)
DHA Age at sacrifi ce (weeks)
1 10 (100) - 40
2 5 (50) - 70
3 9 (90) + 70
4 3 (30) - 90
5 5 (50) + 90
Table 1 Survival per group
Number and percentage of mice per group (starting with n=10) that reached the endpoint, based on age of 
sacrifi ce and docosahexaenoic acid (DHA) administration (- or +). DHA + mice received DHA from 40 weeks 
on.
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Figure 1 Examples of (immuno)histochemical analyses
Histological (Haematoxylin-eosin) staining of a cross section of the root of an atherosclerotic aorta of an 
Apo E -/- mouse at the age of 40 weeks. L: lumen of the blood vessel, fi lled with erythrocytes. I: intima; M: 
media; A: adventitia. Notice the extended calcifi cation and fi brosis showing an advanced lesion (magnifi ca-
tion 50 x). Scale bar: 225 µm. B: Immunohistochemical staining of CML (arrow) in an intramyocardial blood 
vessel of an Apo E -/- mouse at the age of 70 weeks (magnifi cation 400 x). Scale bar: 25 µm.
Immunohistochemistry
The heart and brain were embedded in paraffi  n after overnight fi xation (4 % forma-
lin). For immunohistochemical analysis, 4 µm sections were dewaxed, rehydrated and 
incubated in methanol/H2O2 (0.3%) for 30 minutes to block endogenous peroxidases. 
Antigen retrieval was performed by heat inactivation in Citrate buff er (pH 6.0) (for the 
CML staining) and in Tris/EDTA buff er (pH 9.0) (for the SOD2 staining). Previously 
it was hypothesised that heating could induce CML formation in unfi xed rat livers 21, 
however we have found no evidence that heat induced CML formation in formalin fi xed 
heart and brain tissue occurs (not shown), due to the heating pre-treatment procedure it-
self. After incubation with normal rabbit serum (1:50; Dako, Glostrup, Denmark) for the 
CML staining and with normal swine serum (1:20) for the SOD2 staining, both for 10 
minutes, sections were incubated for 60 minutes with a biotinylated anti-CML antibody 
(1:500) or an anti-SOD2 antibody (1:100 dilution). After washing in phosphate-buff ered 
saline (PBS), pH 7.4, sections were incubated for 30 minutes with a rabbit anti-mouse 
biotin-conjugated antibody (1:500; Dako) for the CML staining or biotin-conjugated 
swine-anti-rabbit antibody (1:100, Dako) for the SOD2 staining, washed in PBS, in-
cubated with streptavidin-horseradish peroxidase (HRP) (1:200; Dako) for 60 minutes 
and visualized with 3,3-diamino-benzidine-tetrahydrochloride/H2O2(DAB, 0.1 mg/
ml, 0.02% H2O2) for 10 minutes. The slides were subsequently counterstained with 
haematoxylin, dehydrated and covered. With the staining a PBS and isotype control was 
included. All these controls yielded negative results (data not shown).
Immunoscoring
Immunoscoring was performed by M.H. E.M. and H.W.N. Agreement was reached 
between observers. For intensity scoring, each positive vessel in the heart and the brain 
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was given a score according to the intensity of  staining: 1 = weak staining; 2 = mode- 
rate staining; or 3 = strong staining9, 12, 22. Subsequently, slides were scanned with a Path-
Scan Enabler IV, where after the surface area of  the tissue was measured using Quick-
PHOTO MICRO 3.0 software. To obtain the CML immunohistochemical score, the 
respective intensity scores (1, 2, and 3) were first multiplied by the amount of  blood 
vessels positive for this score. These three numbers were then added and subsequently 
divided by the surface area of  the tissue, resulting in an immunohistochemical score per 
mm2. Lastly, the number of  SOD2 positive vessels were scored with a microscope and 
divided by the surface area of  the tissue.
Statistics
Values are given as median and interquartile range. Since most of  the data were not 
normally distributed, the Kruskall-Wallis and Mann–Whitney U tests were used to test 
for differences between groups. The Fisher’s exact test was used to compare the survival 
rates between groups. Results were considered statistically significant if  the two-sided 
p-value was <0.05. Statistical analysis was performed with SPSS (20.0 for Windows, 
SPSS Inc.) and graphs were made with GraphPad (Prism 6).
RESULTS
CML accumulation in the heart
In 40 week old mice, CML was found to be present in the endothelium of  intramyocar-
dial blood vessels (Fig. 1B). These CML depositions were significantly increased in 70 
week old mice, namely from an immunohistochemical score of  11.85 [5.92-14.60] at 40 
weeks up to 33.17 [17.60-47.15] at 70 weeks (p=0.005) (Fig. 2A). This increase in CML 
was in line with an increase in the number of  CML-positive blood vessels of  all three in-
tensity scores, which was significant for intensity scores 2 and 3 (Fig. 3A). The number of  
blood vessels/mm2 with intensity score 1 (weak positive) increased from 1.98 [1,27-2.55] 
to 5.63 [2.33-8.88] (p=0.066), those with intensity score 2 (moderate positive) increased 
from 2.84;[1.46-3.60] to 5.32;[2.82-8.99] (p=0.050) and those with intensity score 3 
(strong positive) from 1.20 [0.65-1.83] to 5.63 [3.20-6.76](p=0.005) 
In the 90 week old group (n=3)., the immunohistochemical score and the number of  
CML-positive blood vessels did not further change significantly. However, compared 
with 70 week old mice, the numbers of  blood vessels with intensity score 1 were lower 
and those with intensity score 3 were higher, although not significantly. 
In 70 and 90 week old mice fed with the DHA-supplemented diet the CML immuno-
histochemical scores were lower than mice of  similar age fed with non-supplemented 
diet and comparable to the 40 week old mice (Fig. 2A). This difference was significant 
for the 70 week old mice only , namely 14.73; [4.44-28.16] in the DHA mice versus 
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33.17; [17.60-47.15] in the non-DHA mice of  the same age (p=0.037). This coincided 
with a decrease in the number of  blood vessels with intensity score 1,2 and 3, although 
this was significant only for intensity score 3, namely 2.10 [0.27-4,59] in the DHA mice 
versus 5.63; [3.20-6.76] in the non-DHA mice (p=0.039) (Fig. 4A). In 90 week old mice 
a non-significant decrease in the number of  blood vessels positive for scores 1,2 and 3 
was found.
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Figure 2 Quantification of N(ε)-(carboxymethyl)lysine (CML) in blood vessel
A: Quantitative analysis of CML in intramyocardial blood vessels B: Quantitative analysis of CML in blood 
vessels of the brain. Bars represent median immunohistochemical scores per mm² (defined in Methods).
Prevention of  age-induced N(ε)-carboxymethyl)lysine accumulation in the microvasculature
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CML accumulation in the brain
CML was also found in the non-atherosclerotic blood vessels of  the brain in 40 week old 
mice. Similar to the heart, CML accumulation in the brain was significantly higher in 70 
week old mice, namely from an immunohistochemical score of  6.45; [4.78-7.30] at 40 
weeks to 12.99; [9.85-20.122] at 70 weeks (p=0.003; Fig. 2B). This corresponded with 
a significant increase in the number of  blood vessels with intensity scores 1, 2 and 3 in 
these mice (Fig. 3B), namely for intensity score 1 from 0.87;[0.51-1.09 to 2.48;[1.95-2.59] 
(p=0.002); for intensity score 2 from 1.21;[0.88-1.60] to 1.86;[1.55-2.56] (p=0.027) and 
for intensity score 3 from 1.01;[0.77-1.17] to 2.42;[1.49-4.17] (p=0.003). 
In 90 week old mice, the immunohistochemical score and the number of  blood vessels 
with intensity score 3 were significantly higher than 40 week old mice (p<0.011 for 
both), but not 70 week old mice (Fig. 2B and 3B). ln contrast to the heart, DHA did not 
have a significant effect on the immunohistochemical scores in both 70 and 90 week old 
mice. And although the median of  intensity scores 2 and 3 was lower in DHA-treated 90 
week old mice compared with non-treated 90 week old mice, no significant differences 
were found in intensity scores between DHA-treated and non-treated mice in 70 and 90 
week old mice.
Super Oxide Dismutase
We analyzed the amount of  SOD-2 positive vessels in the hearts of  the 40 wks, 70 wks 
DHA - and 70 wks DHA + mice, since the CML scores in these groups differed most. 
SOD-2 positive blood vessels were scarce and up to a factor 10-100 lower than CML-pos-
itive vessels. SOD-2 positive vessels did not significantly differed between the groups, 
namely 0,22 [0.03-0.32] in the 40 weeks old mice, 0.06 [0.00-0.14] in the 70 weeks old 
mice without DHA and 0.47 [0.07-0.62] in 70 weeks old mice with DHA (p=0.20). 
Survival
Survival rate decreased with age from 100 % (40 weeks) to 50 % (70 weeks) to 30 % (90 weeks) 
(table 1). Interestingly, 70 and 90 week old mice that were treated with DHA had a higher 
survival rate than the respective age-related non-treated groups, i.e. 90 % versus 50 % and 
50 % versus 30% respectively. We added the survival rates of  the DHA + groups, both at 
70 and 90 weeks and compare d them with DHA - groups at 70 and 90 and found a survival 
advantage for the DHA treated group of  70 % vs. 40 % albeit not significant (p=0.111). 
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Figure 3 Intensity score of CML in 40,70 and 90 weeks old mice
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A: Quantitative analysis of the intensity scores of the CML positive intramyocardial blood vessels and B: 
quantitative analysis of the intensity scores of the CML positive the blood vessels in the brain . The 3 dif-
ferent intensity scores for CML (1 = minor; 2 = moderate; 3 = strong) are defined in detail in Methods. Bars 
represent median scores.




Figure 4 Intensity score of CML in 70 and 90 weeks old mice with and without DHA
A: Quantitative analysis of the intensity levels of the CML positive intramyocardial blood vessels and B: 
quantitative analysis of the intensity scores of the CML positive the blood vessels in the brain . The 3 dif-
ferent intensity scores for CML (1 = minor; 2 = moderate; 3 = strong) are defined in detail in Methods. Bars 
represent median scores.
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DISCUSSION
N(ε)-(carboxymethyl)lysine (CML) is believed to play a role in the development and pro-
gression of  atherosclerosis2, 5, 6 and its accumulation in atherosclerotic changed blood 
vessels increases with age. In the present study we found age-related CML accumulation 
in non-atherosclerotic microvasculature of  the heart and the brain of  atherosclerotic 
mice. Furthermore, we found that the polyunsaturated fatty acid DHA, inhibited this 
age-related microvascular CML accumulation in the heart, but not in the brain.
Age-related CML accumulation in tissue was previously shown in collagen of  the skin23, 
in human articular cartilage24 and in atherosclerotic changed arteries 2. We now add 
to this, that CML accumulates age-related in the non-atherosclerotic intramyocardial 
microvasculature. This is in line with a study that found that CML levels in human 
cardiac tissue homogenates increase with age, coinciding with diabetes and coronary 
heart disease25, without further specifying the location of  this CML. This specific loca-
tion in the heart is important in relation to the notion that CML accumulation in the 
intramyocardial non-atherosclerotic vasculature may play a role in the etiology of  Acute 
Myocardial Infarction (AMI), based on the finding that CML accumulation within the 
intramyocardial vasculature was especially found in patients that died from AMI as op-
posed to control deaths, independent of  the disease state of  epicardial coronary arteries. 
This CML accumulation occurred prior to the onset of  AMI9 and therefore is not a 
reflector of  AMI. Moreover, we have shown this CML accumulation also in diabetes12, 22 
and diastolic heart failure13.
We have previously described CML depositions in non-atherosclerotic changed vessels 
of  the brain in diabetes in humans and rats22. It has been suggested that this could 
influence the microcirculation of  the brain, contributing to the development of  cog-
nitive impairment, the so-called diabetes-associated cognitive decline22. We now have 
found age-related CML accumulation in the non-atherosclerotic microvasculature of  
the brain. Interestingly, it was described that CML accumulation in the microvascula-
ture of  the brain is related to cognitive impairment26,28. Indeed age-related functional 
effects of  CML in cultured hippocampal microvessels and cultured choroidal explants 
of  rats were described26, 27. 
There are several mechanisms by which CML may play a pathophysiological role in the 
vascular cell function28, 29, including formation of  inflammatory cytokines and growth 
factors coinciding with pro-thrombogenic alteration of  the endothelium, impaired vaso-
dilatation and increased expression of  adhesion molecules and chemokines on vascular 
cells30. The deleterious consequences of  aging in the vasculature could in part be ex-
plained through the now described age-related CML accumulation in the blood vessels. 
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Another interesting finding of  our study was the observation that the omega-3 fatty acid 
DHA, inhibited CML accumulation in the non-atherosclerotic intramyocardial vessels 
to control levels. It is believed that DHA lowers blood pressure, has antiplatelet actions 
and has anti-atherogenic effects f.i. via reduction of  triglyceride concentration, via re-
duction of  expression levels of  adhesion molecules and on smooth muscle cells prolifera-
tion and migration31-33 . It was also found that DHA has a direct antiarrhythmic effect on 
the heart34, 35. The mechanisms by which DHA prevents CML deposition in the micro-
vasculature of  the heart in our study, is unknown, but it is reasonable to assume that the 
anti-inflammatory role of  DHA in combination with its superoxide scavenging role and 
inhibition of  lipid peroxidation activity could prevent CML formation. More specific, 
it is known that DHA increases SOD activity36, 37, that in turn reduces reactive oxygen 
species38. We therefore wondered if  the effects of  DHA on CML in the heart could be 
explained by an increase in vascular SOD-2. Indeed an age-accompanied decrease with 
SOD-2 activity was found in the small vessels of  the heart, with an increase of  SOD-2 in 
the mice that were fed DHA, albeit not significant. It has to be noticed that the amount 
of  SOD-2 positive vessels is minor compared to the amount of  CML positive vessels. 
It was previously found that omega-3 fatty acid dietary administration in rats increased 
activity of  superoxide dismutase and decreased lipid peroxidation in tissue homogenates 
of  the cerebral cortex thus as such theoretically could inhibit ROS-driven CML accu-
mulation39-41, we didn’t find any significant effect of  DHA in the brain. We can only spec-
ulate why DHA did have an effect on CML depositions in the microvasculature of  the 
heart but not of  the brain. This could point to a difference in properties of  endothelial 
cells in the heart and the brain, as it is known that dependent on the location in the body, 
endothelial cells have their own molecular make up that drives basic behavior, as well as 
their responses on inflammatory stimuli42, 43. Clearly the specialized brain endothelium, 
forming the blood brain barrier, has different properties than the endothelium of  the 
intramyocardial vessels44. Obviously this interesting observation needs further research 
for a more precise explanation. The study has in our opinion one important limitation, 
namely the low survival in the 90 weeks group (n=3) that made a proper statistical com-
parison difficult. 
In conclusion, we have found that aging induces CML accumulation in the non-athero-
sclerotic microvasculature of  the heart and the brain in ApoE -/- mice and that DHA 
inhibits CML accumulation in the heart, but not in the brain. Further experiments 
are necessary to better understand the consequences of  the age-dependent increase of  
CML in non-atherosclerotic microvascular vessels and the underlying pathophysiology 
and therapeutic possibilities of  the effects of  DHA on age-related CML accumulation.
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ABSTRACT
Objective: Observational studies show a peak incidence of  cardiovascular events after 
major surgery. For example, the risk of  myocardial infarction increases 25-fold early 
after hip replacement. The acuteness of  this increased risk suggests abrupt enhance-
ment in plaque vulnerability, which may be related to an acute increase of  intra-plaque 
inflammation, thinning of  the fibrous cap and/or necrotic core expansion. We hypothe-
sized that acute systemic inflammation following major orthopedic surgery induces such 
changes.
Approach and results: Apo E-/- mice were fed a western diet for 10 weeks. Thereafter 
half  the mice underwent mid-shaft femur osteotomy followed by realignment with an 
intramedullary K-wire, to mimic major orthopedic surgery. Mice were sacrificed 5 or 
15 days post-surgery (n=22) or post-saline injection (n=13). Serum amyloid A (SAA) was 
measured as a marker of  systemic inflammation. Paraffin embedded slides of  the aortic 
root were stained to measure total plaque area and to quantify fibrosis, calcification, 
necrotic core, and inflammatory cells. Surgery mice showed a pronounced elevation of  
SAA and developed increased plaque and necrotic core area already at 5 days, which 
reached significance at 15 days (p=0.019; p=0.004 for plaque and necrotic core, respec-
tively). Macrophage and lymphocyte density significantly decreased in the surgery group 
compared to the control group at t=15 days (p=0.037; p=0.024, respectively). The den-
sity of  neutrophils and mast cells remained unchanged.
Conclusions: Major orthopedic surgery in Apo E-/- mice triggers a systemic inflamma-
tory response. Atherosclerotic plaque area is enlarged after surgery mainly due to an 
increase of  the necrotic core. The role of  intra-plaque inflammation in this response to 
surgical injury remains to be fully elucidated.
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INTRODUCTION
Observational epidemiological studies have confirmed what experienced clinicians sus-
pected for many years: cardiovascular events can be triggered by a variety of  common 
non-cardiovascular clinical conditions, particularly those that are associated with sys-
temic inflammation1-3. One of  the best documented examples of  non-infectious systemic 
inflammation causing an acute increase in cardiovascular risk is major surgery. A recent 
study indicated that the risk of  myocardial infarction in patients undergoing total hip 
or knee replacement is increased by no less than 25-fold, mainly during the first days 
to weeks post-surgery2. This phenomenon is hardly investigated and the mechanisms 
which underlie this postoperative risk remain elusive. 
The acuteness of  the increased postoperative cardiovascular risk suggests an effect on 
atherosclerotic plaque stability4. Several studies indeed show that at least half  of  the cas-
es of  myocardial infarction following non-cardiac surgery originate from rupture of  un-
stable plaques5-7. Why plaques could become more prone to rupture briefly after surgery 
is unclear. Plaque instability is not only related to factors such as fibrous cap strength 
and intra-plaque hemorrhage, but also to the necrotic core area which, in turn, are all 
influenced by intra-plaque inflammation8-11. 
Plaque area was shown to increase in mice after a single injection of  serum amyloid 
A peptide, a marker and mediator of  inflammation12. A recent study addressing the 
combined effects of  major blood loss and surgery reported increased plaque size growth 
as well as increased plaque vulnerability already after 72 hours7. Major orthopedic sur-
gery is known to cause massive systemic inflammation13. We therefore hypothesized that 
acute systemic inflammation caused by major orthopedic surgery could rapidly enhance 
plaque vulnerability by means of  increased intra-plaque inflammation, fibrous cap thin-
ning and/or necrotic core expansion, and we addressed this hypothesis in atherosclero-
sis-prone Apo E-/- mice.
MATERIALS AND METHODS 
Mouse model 
Apo E -/- mice (9-10 weeks old) were obtained from Charles River Laboratories (Cal-
co Como,Italy) and were housed in specific pathogen-free rooms, on a 12-h light–
dark  cycle. All mice were fed a high-fat diet (0.15 % cholesterol) (4022.83, AB diets, 
 Woerden, the Netherlands) for 10 weeks after which the surgery group underwent a 
mid-shaft  femur osteotomy followed by realignment with an intramedullary K-wire, to 
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mimic  major orthopedic surgery. Under general anesthesia (2% isoflurane) and analge-
sia (0.1 mg/kg buprenorfine), the femur was accessed via a lateral skin incision of  the 
greater trochanter to just proximal of  the knee joint. The femur was approached using 
microsurgical scissors and forceps. With a dental mini-cutter, a mid-shaft osteotomy was 
performed. After that a stainless steel 0.6 mm K-wire (DePuy Synthes, Amersfoort, The 
Netherlands) was retrogradely introduced into the medulla of  the femur until it exited 
medial and proximal of  the greater trochanter. This was done using an electrical rotary 
system (Model 3000, Dremel, Breda). The osteomy was reduced and the osteotomy was 
stabilized by normogradely introducing the K-wire into the medulla of  the distal femur 
until seated in the distal metaphysis. The K-wire was cut flush with the trochanter, where 
after the wound was closed by interrupted sutures (Monocryl 5-0 FS-2, Eticon) for both 
the femoral fascia and skin. During the operation bleeding was kept to a minimum by 
using bipolar radiofrequency micro-forceps (Pfizer, Valleylab Force 30). Blood was sam-
pled after a 4-hour fasting period at several time points surrounding surgery/control 
(t=-1 day, 1 day, 5 days and 15 days). Mice in both operation (n=22) and control group 
(n=13) were sacrificed 5 or 15 days post-surgery respectively post-saline injection. All 
procedures were approved by the Animal use and care Committee at the VU University 
Medical Centre of  Amsterdam. 
Analysis of  systemic inflammation and serum lipids 
Levels of  serum amyloid A (SAA), soluble VCAM-1 (CD106) and soluble E-selectin 
(CD62E) were measured by ELISA (Life Technologies, Bleiswijk, the Netherlands for 
SAA and R&D Systems, Abingdon, UK, for VCAM-1 and E-selectin). Total serum cho-
lesterol and triglyceride levels were measured in serum by commercially available enzy-
matic assays (cholesterol CHOD-PAP 11491458 and triglycerides GPO-PAP 11488872, 
Roche, Woerden, the Netherlands). For determination of  the lipid profile, pooled plas-
ma per group was fractionated using an ÅKTA fast protein liquid chromatography sys-
tem (Pharmacia, Roosendaal, the Netherlands). Fractions were collected and assayed for 
total cholesterol using an enzymatic assay cholesterol CHOD-PAP 11491458 (Roche) 
and analysed as reported14.
(Immuno)histochemistry and morphometry 
Dissected hearts including the aortic roots were embedded in paraffin after overnight 
fixation (4 % formalin) for analysis of  atherosclerosis. Serial cross-sections (4 μm) direct-
ly distal to the valve area of  the aortic root were stained with Alcian Blue (indicative 
of  glycosaminoglycans), Elastica van Gieson, Von Kossa and MAC-3, scanned with a 
PathScan Enabler IV, after which the mean surface area of  plaque and the concordant 
area of  fibrosis (EVG), calcification (Von Kossa) and macrophage area (MAC-3) was 
analysed blindly from each specimen using QuickPHOTO MICRO 3.0 software or in 
the case of  the MAC-3 staining and the fibrous cap thickness15 with ImageJ software. 
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The necrotic core area was calculated by subtracting the area of  fibrosis, calcification 
and macrophages from the total plaque area. For immunohistochemical analysis, serial 
cross-sections were dewaxed, rehydrated and incubated in methanol/H2O2 (0.3%) for 
30 minutes to block endogenous peroxidases. Antigen retrieval was performed using 
pepsin for 25 minutes at 37 °C (Ly-6G and CD206), boiling in Tris-EDTA buffer, pH 
9.0 (Caspase-3) or in citrate buffer, pH 6.0, for 15 minutes at 100 °C using a microwave 
(MAC-3 and iNOS). Sections were incubated with normal rabbit serum (1:50 dilution, 
DAKO, X0902) for 10 minutes at room temperature (RT) and subsequently with the 
primary antibody using rat-anti-mouse-MAC-3 antibody, detecting macrophages (1:30 
dilution, BD Pharmingen, clone M3/84, cat. 553322, overnight, RT) or rat-anti-mouse-
Ly6G antibody (detecting neutrophilic granulocytes) (1:200 dilution, BD Pharmingen, 
clone 1Ab, cat. 551459, 1 hour, RT) as appropriate. Thereafter, sections were incubated 
with biotinylated rabbit-anti-rat (1:300 dilution, DAKO, E0468, 30 minutes)/ Strepta-
vidin-HRP (1:100 dilution, DAKO, P0397, 1 hour). For iNOS staining (to detect type 
1 macrophages) the primary antibody polyclonal rabbit-anti-iNOS (1:200 dilution, Ab-
cam, Ab15323, 1 hour, RT) was used and for the Caspase-3 (apoptosis marker) the prima-
ry antibody polyclonal Rabbit-anti-Caspase-3 (1:500 dilution, cell signaling technology, 
cat. 9661-L, 1 hour, RT) was used. Both were followed by incubation with HRP labeled 
anti-rabbit (100 µl undiluted, DAKO, K4003) for 30 minutes. For the CD206 staining 
(detecting type 2 macrophages) the primary antibody polyclonal Rabbit-anti-mannose 
receptor CD206 (1:1000 dilution, Abcam, Ab64693, 1 hour, RT) was used, followed by 
a swine anti-rabbit HRP secondary antibody (1:100 dilution, DAKO P0217, 30 minutes, 
RT). For CD45 staining (detecting lymphocytes), antigen retrieval was performed using 
citrate buffer, pH 6.0, for 15 minutes at 100⁰C using a microwave. Sections were incu-
bated in water (97°C) for 30 minutes and subsequently incubated in methanol/H2O2 
(0.3%) for 30 minutes. Afterwards, sections were incubated with rat-anti-mouse-CD45 
antibody (1:50 dilution, BD Pharmingen, cat. 550539, overnight, 4°C), rinsed in PBS, 
incubated with rabbit-anti-rat-HRP (1:50 dilution, DAKO, P0450) for 30 minutes. All 
staining’s were visualized with 3,3-diamino-benzidine-tetrahydrochloride/H2O2(DAB, 
0.1 mg/ml, 0.02% H2O2) for 10 minutes and counterstained with haematoxylin. Mast 
cells were stained with Toluidine Blue 1%. MAC-3 area was quantified as percentage 
MAC-3 positive staining of  the total plaque area, using an automated macro in ImageJ 
software. Numbers of  Ly-6G and CD45 positive cells were manually quantified per sur-
face area of  the atherosclerotic plaque as cells/μm2. Immunoscoring was performed by 
R.L and W.W.F. and agreement was reached between both observers. 
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STATISTICS 
Statistical analysis was performed with SPSS (20.0 for Windows, SPSS Inc.). To test for 
differences in plaque area, necrotic core area and inflammatory cells between groups, 
an independent sample t-test was used when the data were normally distributed, or a 
Mann–Whitney U test if  not. All data are presented as median and interquartile range. 
Results were considered statistically significant if  the two-sided p-value was <0.05. 
RESULTS
Surgery causes acute systemic inflammation
To determine whether major orthopedic surgery was indeed accompanied by an acute 
systemic inflammatory response we measured serum SAA levels at different time points 
(t=-1 day, 4 hours, 1 day, 5 days and, in the late-sacrifice group, after 15 days) (Fig. 1A). 
SAA levels had increased 4 hours after surgery, increased by almost 100-fold after 24 
hours, and returned to baseline levels within 5 days. In contrast, SAA values in the con-
trol group remained low and stable. Endothelial inflammation markers (VCAM-1 and 
E-selectin) did not increase in response to trauma (Fig. 1B and 1C). 
Surgery transiently decreases body weight and alters lipid profile
Mice in the surgery group had weight loss (6.6%) at 5 days compared to baseline, where-
as control mice gained weight (5.8%). Serum cholesterol and triglyceride levels were 
measured at t=-1 day, 1 day, 5 days and, in the late-sacrifice group, after 15 days. We 
observed a transient lipid-lowering effect of  surgery. This effect was relatively small for 
cholesterol (Fig. 1D), but more pronounced for triglycerides (Fig. 1E). The lipoprotein 
profile for cholesterol distribution in VLDL, LDL and HDL-sized particles showed a 
slight reduction in VLDL which was paralleled by an equally small increase in LDL 
from t=5 days onward (Fig. 1F-1I).
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Surgery does not increase the content of  inflammatory cells within athero-
sclerotic lesions
We observed a significant reduction (p=0.037) of  the macrophage area relative to the 
total atherosclerotic plaque area between the surgery and control group at t=15 days 
(Fig. 2B). Subtyping of  typical type 1 macrophages (M1 - iNOS positive area) and type 
2 macrophages (M2 - CD206 positive area) relative to total macrophage area (MAC-3 
positive area) was performed (Fig. 2D and 2F). At t=5 days, a significantly lower M1 
fraction was observed in the surgery group 44% [33-54] versus 55% [47-87] in the con-
trol group; p=0.028) which increases significantly to 80% [66-121] (p=0.007) at 15 days. 
The relative density of  M2 macrophages was not affected significantly. No significant 
differences were found between surgery and control mice in the number of  neutrophilic 
granulocytes (Ly-6g) and mast cells (toluidine blue) (Fig. 2H and 2J). We did however 
observe a significant reduction in lymphocyte density (Fig. 2L) 15 days post-surgery as 
compared to the control group (p=0.024). 
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Atherosclerotic plaque and necrotic core area increase after surgery
Aortic root sections of  all experimental groups showed advanced atherosclerotic lesions 
infiltrated by macrophages and lymphocytes, with a thin fibrous cap (Fig. 3A-3D). To 
assess the effect of  surgery we measured total plaque area in the root, and evaluated 
the relative contribution of  different plaque components. At t=5 days, a non-significant 
5.5% higher plaque area was observed in the surgery group (481 x 103 μm2 [387-558] 
versus 456 x 103 μm2 [394-491] in the control group; p=0.297). This difference became 
more pronounced and statistically significant at t=15 days; (519 x 103 μm2 [485-634] 
in operated mice versus 387 x 103 μm2 [331-464] in control mice, p=0.019; Fig. 3E). 
This plaque enlargement was mainly attributable to a 160% increase in the necrotic 
core area (257 x 103 μm2 [151-315] in operated mice vs. 99.0 x 103 μm2 [71.2-155] in 
control mice, p=0.004; Fig. 3F). The area of  the other plaque histological characteristics 
(fibrosis, macrophages, calcification and apoptosis) did not significantly contribute to the 
increase in plaque area (Fig. 4). Also, we found no evidence of  fibrous cap thinning at 
t=5 days (28.7 [22.4-42.3] μm in operated mice versus 19.8 [17.5-37.2] μm in control 
mice, p=0.3), nor at t=15 days (36.7 [29.6-45.2] μm in operated mice versus 24.5 [18.7-
42.3] μm in control mice, p=0.6). In addition, we assessed old intra-plaque hemorrhage 
but only found small non-significant areas of  Fe-positivity that had only a very minor 
contribution to the total area and that did not differ between groups (data not shown). 
Finally, in the roots of  all mice (surgery and control) Alcian Blue positive staining was 
observed both in the necrotic core area and in the other regions of  the plaque, with no 
differences between the groups. 
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DISCUSSION
Major orthopedic surgery in Apo E-/- mice causes acute systemic inflammation. At 
15 days post-surgery we observed a significant increase of  plaque area, mainly due to 
necrotic core enlargement. Plaque necrosis is a characteristic hallmark of  atheroscle-
rotic lesions that cause acute atherothrombotic vascular disease9-11. Our finding of  a 
post-surgery increase of  necrotic core area may reflect increased plaque vulnerability 
and could, at least partly, explain the increased incidence of  cardiovascular events after 
major orthopedic surgery.
The surgical procedure caused a marked acute systemic inflammatory response as 
demonstrated by a rapid increase in SAA, a relatively stable inflammation marker that 
integrates the signals of  proatherogenic cytokines (IL1, TNFα, IL6), many of  which 
may have contributed to the effect on the atherosclerotic leasion16, 17. Several studies 
suggest that SAA itself  participates in the pathogenesis of  atherosclerosis and a recent 
study shows that it may contribute to plaque vulnerability18. For instance, SAA induces 
TGF-β, increases vascular biglycan content, and increases LDL retention19. SAA also 
stimulates NF-κB activation and induces the expression of  pro-atherosclerotic factors, 
such as ICAM-1, MCP-1, MMP-9 and tissue factor in macrophages20. Lastly, SAA 
displaces apoA-I from the surface of  the HDL particle, thus generating free apoA-I, 
which is cleared faster by the kidney, thus potentially affecting the anti-atherogenic 
effect of  HDL21. In addition to the effects on SAA, we observed a slight effect on cir-
culating lipoproteins (i.e. decrease in VLDL and increase in LDL) in the orthopedic 
surgery group. Although the shift toward more atherogenic particles is relatively small, 
it may have contributed to the development of  atherosclerosis in the orthopedic sur-
gery group. 
We did not find indications of  fibrous cap thinning after orthopedic surgery, which be-
sides necrotic core expansion is another hallmark of  vulnerable, inflammatory plaque8, 22. 
We cannot exclude fibrous cap thinning because it is known to be very heterogeneously 
distributed, varying between and within lesions23. In parallel, we did not find an in-
creased density of  inflammatory cells after orthopedic surgery. This may have been 
caused by the fact that we examined plaques after 5 and 15 days. We cannot exclude 
inflammatory cell infiltration taking place before these time points and that activated 
macrophages in particular had already ‘dissolved’ at 5 days, contributing to the necrotic 
core. Indeed, death of  lesional macrophages promotes the formation of  plaque necro-
sis 9, and could thus be compatible with the decreased plaque macrophage content we 
observed at later time points. Similarly, activation of  lymphocytes may cause loss of  
CD45-positive epitopes and cells can become undetectable by CD45-staining. It thus 
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remains possible that surgery-induced intra-plaque inflammation due to infiltration of  
immune cells contributed to the observed increase in the necrotic core area (and hence 
total lesion area). 
There is a growing understanding that the balance between pro- and anti-inflammatory 
macrophages in plaque is dynamic24. We found an increase in the fraction of  M1 pro-in-
flammatory macrophages at 15 days, supporting a pro-inflammatory postoperative 
plaque milieu. 
We have found no differences between the different groups and time points for Caspase-3, 
an apoptosis marker, and therefore we cannot conclude that apoptosis is a major driver 
of  the necrotic core expansion after surgery. Of  note, however, these test also do not 
exclude a role for apoptosis. Caspase-3 staining is a temporary phenomenon in apopto-
sis and after some time, Caspase-3 staining in the necrotic core could be lost. This also 
emphasizes the need for future studies addressing earlier time points and more in-depth 
characterization of  biomarker profile, and inflammatory cell activity in similar experi-
mental designs. 
Several related experimental studies merit discussion. Recently, a study in Apo E-/- 
mice addressed the combined effects of  major blood loss and surgery, and reported 
increased plaque size after 72 hours, along with signs of  plaque vulnerability 7. However, 
this effect appeared to be mainly due to excessive blood loss (20% of  body weight; which 
is substantially more than in our model), rather than surgery itself. As in our study, the 
density of  intra-plaque macrophages did not differ, but other inflammatory cell types 
were not quantified. A few experimental studies addressed the effects of  acute systemic 
inflammation on atherosclerosis. A recent murine model of  intra-abdominal sepsis sug-
gested that atherosclerotic plaque area was enhanced by sustained systemic, endothelial 
and intimal inflammation, and was not explained by infection itself25. More specifically, 
an increase in intra-plaque macrophages was observed 5 months after the induction 
of  sepsis via cecal ligation and puncture. This coincides with a sustained elevated level 
of  IL6, suggesting that this model mimics a chronic inflammatory state, in contrast to 
our model of  transient acute inflammation. No data on macrophage density at earlier 
time points (nor other inflammatory cell types) were reported. Another study in Apo 
E-/- mice showed that influenza virus infection caused subendothelial infiltration of  a 
heterogeneous population of  cells26. These cells were however not quantified per type 
and plaque area was not assessed. Lastly a study again in Apo E-/- mice demonstrated 
that the systemic inflammatory response to myocardial infarction aggravates chronic 
atherosclerosis22. Together with the results described herein, these studies support an 
important role for systemic inflammation in plaque destabilization and might thereby 
contribute to increased risk of  cardiovascular events.
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Limitations
Our goal was to evaluate effects of  major (orthopedic) surgery on atherosclerotic plaque. 
Although we found plaques changes congruent with increased event risk, the study 
wasn’t designed to clarify responsible mechanism(s). Our data are compatible with a role 
for surgery-induced inflammation, but this requires more in-depth studies. In addition, 
other, non- or indirect inflammatory effects of  surgery could be further explored. For in-
stance, hemodynamic disturbances27, sympathetic nerve system activation28 or enhanced 
platelet activity29 are potential contributors to atherosclerotic lesion development and 
increased cardiovascular risk. Furthermore it would be interesting to test our findings in 
advanced mouse models to study actual plaque complications rather than atherosclerot-
ic plaque development alone30, 31. 
CONCLUSION
Major surgery can cause a strong systemic inflammatory response and lead to an  increase 
in plaque and necrotic core area, contributing to plaque vulnerability. These findings 
may help explain the high incidence of  cardiovascular events following major surgery 
and, in a broader perspective, other clinical conditions of  acute systemic inflammation.
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ABSTRACT
Background and aims: Observational studies show a peak incidence in cardiovascu-
lar events during and early after clinical conditions associated with substantial systemic 
inflammation, such as pneumonia. The acuteness of  this increased risk suggests rapid 
plaque destabilization and associated intra-plaque inflammation. We evaluated wheth-
er LPS-evoked acute systemic inflammation would induce such detrimental vascular 
changes in murine aortas with manifest atherosclerotic lesions.
Methods and results: ApoE3*Leiden mice were fed a high cholesterol diet for 20 weeks 
to establish atherosclerosis. Thereafter, mice received a single intraperitoneal injection 
with lipopolysaccharides (LPS) to induce systemic inflammation, or saline for control. 
Mice were sacrificed 2 or 15 days post-LPS injection (n=17) or post-saline injection 
(n=13). Serum amyloid A (SAA), a sensitive marker of  systemic inflammation, increased 
250-fold in LPS-treated mice. Aortic root plaques were assessed for total plaque area, 
plaque severity and inflammatory cell content. No significant differences in total surface 
area of  atherosclerotic plaque were found between control and LPS groups sacrificed 
after 2 days (resp. 0.409±0.228 x 105 µm2 vs. 0.285±0.169 x 105 µm2) (p=0.31), and 
15 days (resp. 0.950±0.938 x 105 µm2 vs. 0.612±0.413 x 105 µm2) (p=0.80). Further-
more, plaque type and number of  lesions were unaltered and intra-plaque density of  
macrophages and lymphocytes were comparable in both groups.
Conclusions: Intraperitoneal LPS injection in ApoE3*Leiden mice triggers a profound 
systemic inflammatory response, but does not increase atherosclerotic plaque area or 
inflammatory cell density. This model of  LPS-induced inflammation in atherosclero-
sis-prone mice argues against intra-plaque alterations as an explanation for acute in-
flammation-induced cardiovascular event risk.
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INTRODUCTION
Observational epidemiological studies have shown that cardiovascular events can be 
triggered by a variety of  common non-cardiovascular clinical conditions, particularly 
those that are associated with systemic inflammation1-4. The best documented example 
of  such conditions is systemic infection. For instance, lower respiratory tract infection 
raises the early (2-14 days after onset of  symptoms)1, 2 risk of  myocardial infarction by 
approximately fivefold1, and the risk of  stroke by eightfold1-3. This phenomenon of  car-
diovascular events occurring in patients with infection is clearly important, but the caus-
al mechanisms remain unclear. Hemodynamic and hemostatic abnormalities have been 
implicated, but their exact role is unknown. 
Conceivably, acute inflammation may also affect atherosclerotic plaque stability, with 
subsequent risk of  plaque rupture5-7. It is, however, unclear whether acute systemic 
inflammation affects plaque morphology and composition and induces a more unsta-
ble phenotype. It is well-established that plaque instability is largely determined by in-
tra-plaque inflammation8-10. Several studies support the concept of  systemic inflamma-
tion inducing detrimental intra-plaque changes. Plaque area increased in Apo E-/- mice 
16 weeks after a single injection of  serum amyloid A peptide (SAA), a marker and medi-
ator of  inflammation11. In addition, we recently described that major orthopedic surgery 
in Apo E-/- mice causes marked systemic inflammation, which was accompanied by 
increased plaque necrosis area only 15 days after surgery. Furthermore, a recent murine 
model of  intra-abdominal sepsis induced by colon ligature and puncture (CLP) has sug-
gested late (3-5 months after onset) effects on atherosclerotic plaque stability long after 
the initial infection has ceased12. Whether acute systemic inflammation induces pro-in-
flammatory changes in atherosclerotic plaques in a similar time frame as the acute car-
diovascular event risk in humans with infection has, however, not been studied to date. 
We hypothesized that LPS-evoked acute systemic inflammation would enhance plaque 
area and intra-plaque inflammation during a pro-inflammatory period of  15 days using 
ApoE*3Leiden mice with established lesions.
METHODS
Mouse model
Female ApoE*3Leiden transgenic mice (n=30) were obtained from the breeding facil-
ity of  TNO Metabolic Health Research, Leiden, the Netherlands, and were housed 
in pathogen-free rooms, on a 12-h light–dark cycle. All mice were fed a high-fat diet 
(1 % cholesterol) 4021.34, AB diets, (Woerden, the Netherlands) for 20 weeks.  Plasma 
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cholesterol and triglyceride concentrations were used to match mice in the control and 
LPS group. The control group received an intraperitoneally injection with 100µl phos-
phate buffered saline (PBS), whereas the test group was injected intraperitoneally with 
1µg/100µl LPS (Escherichia coli (E.coli) 055:B5, Sigma-Aldrich, Zwijndrecht, the Neth-
erlands) to induce systemic inflammation. The LPS dose for dyslipidemic high-fat diet 
treated mice was optimized in previous scouting experiments. To prevent the mice from 
dehydrating, all received a subcutaneous injection with 250µl NaCl 0.9% on the first 
day after receiving LPS/PBS injection. Blood was collected after a 4 hours fasting peri-
od at several time points around the LPS/PBS injection (t=-1 days, 2 days, 7 days and 
15 days) to determine SAA levels. Mice in both LPS and PBS group were sacrificed by 
the use of  a CO2box (100% CO2), either 2 or 15 days after injection. All procedures 
were approved by the Animal Use and Care Committee at the VU University Medical 
Centre of  Amsterdam. 
Analysis of  SAA and serum lipids 
Levels of  serum amyloid A (SAA) were measured by ELISA (Life Technologies, Bleis-
wijk, the Netherlands). After 16 weeks of  diet total serum cholesterol and triglyceride 
levels were measured in serum by commercially available enzymatic assays (cholesterol 
CHOD-PAP 11491458 and triglycerides GPO-PAP 11488872, Roche, Woerden, the 
Netherlands), to match mice in the control and LPS group. 
(Immuno)histochemistry and morphometry
Atherosclerosis was analysed by observers blinded to group allocation in 4 serial Elastica 
von Gieson stained cross-sections (4 μm, at 56 μm intervals) of  the valve area of  the aor-
tic root. Next, morphometric analysis of  lesion number and area was measured using 
the Pathscan Enabler IV (Meyer Instruments, Houston, TX) with QuickPhoto Micro 
software (windows version 3.0, Promicra, Prague, Czech Republic). Grading of  lesion 
severity was performed according to the adapted classification of  the American Heart 
Association (AHA)13 as reported in ApoE*3Leiden mice14. This scoring system distin-
guishes 5 lesion types: Type I (early fatty streak): up to 10 foam cells of  a single lesion in 
the intima (magnification 40 x), no other changes; Type II (regular fatty streak): 10 or 
more foam cells in a single lesion in the intima (magnification 40 x), no other changes; 
Type III (mild plaque): foam cells in the intima with presence of  a fibrotic cap; Type IV 
(moderate plaque): progressive lesion, infiltration into media, elastic fibers intact; Type 
V (severe plaque): structure of  media severely disrupted with fragmented elastic fibers, 
cholesterol crystals, calcium deposits and necrosis may be present.
For immunohistochemical analysis, serial cross-sections were dewaxed, rehydrated and 
incubated in methanol/H2O2 (0.3%) for 30 minutes to block endogenous peroxidases. 
For both MAC-3 (macrophages) and CD45 (lymphocytes) staining, antigen retrieval was 
performed with citrate buffer, pH 6.0, for 15 minutes at 100 °C using a microwave. In 
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case of  MAC-3 staining, sections were incubated with normal rabbit serum (1:50 dilu-
tion, DAKO, X0902) for 10 minutes at room temperature (RT) and subsequently with 
the primary antibody using rat-anti-mouse-MAC-3 antibody, detecting macrophages 
(1:30 dilution, BD Pharmingen, clone M3/84, cat. 553322, overnight, RT). For CD45 
staining (detecting lymphocytes) sections were incubated with rat-anti-mouse-CD45 an-
tibody (1:50 dilution, BD Pharmingen, clone 30-F11, cat. 553076, overnight, 4°C) and 
rinsed in PBS. Both staining’s use rabbit-anti-rat immunoglobin/Horespradish peroxi-
dase (HRP) (1:50 dilution, DAKO, cat. P0450, 30 minutes at RT) as secondary antibody, 
followed by visualisation with 3,3-diaminobenzidine-tetrahydrochloride/H2O2(DAB, 
0.1 mg/ml, 0.02% H2O2) for 10 minutes and counterstaining with haematoxylin. With 
each staining slides were included incubated without a primary antibody as a negative 
control and all these controls yielded negative results. MAC-3 area was quantified as 
percentage MAC-3 positive staining of  the total plaque area, using QuickPHOTO MI-
CRO 3.0 software (windows version 3.0, Promicra, Prague, Czech Republic). Numbers 
of  CD45 positive cells were manually quantified per surface area of  the atherosclerotic 
plaque as cells/μm2. Immunoscoring was performed by I.P.A.Z and W.W.F. 
Statistics 
Statistical analyses were performed using Graphpad Prism software, version 6.0 (La 
Jolla, CA, USA). To evaluate differences in plaque area, plaque type, lesion number and 
inflammatory cells between groups, an independent sample t-test was used if  the data 
were normally distributed, or a Mann–Whitney U test if  not. Results were considered 
statistically significant if  the two-sided p-value was <0.05.
RESULTS
LPS causes acute inflammation and loss of  body weight
LPS-injected mice gave signs of  moderate to severe distress15 starting within 1 hour after 
injection. They appeared depressed, had squinted eyes, walked hunched and slowly and 
developed a rough hair coat. These symptoms peaked between day 1 to 3 after injection 
and gradually resolved within 3 to 5 days after injection. To determine whether the 
single LPS injection was indeed followed by an acute systemic inflammatory response 
we measured serum SAA levels at different time points (t= -1 day, 2 days, and, in the 
late-sacrifice group, after 7 and 15 days) (Fig. 1A). On day 2 after LPS injection, medi-
an SAA levels had increased 250-fold, from 13.9 [9.6-16.7] to 3598 [2567-7288] ug/
mL, and returned to baseline levels, 9.5 [8.8-11.0] ug/mL on day 7. SAA values in the 
control group remained low and were stable. In the LPS group median body weight 
decreased from 26.3 [24.0-27.5] to 22.6 [21.7-24.2] gram at day 3 post-injection, re-
turning largely to baseline levels at day 15 (Fig. 1B) which is in line with acute distress 
and recovery. In the control group, body weight remained stable as expected. 
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Figure 1 A single LPS injection transiently increases SAA levels and decreases body weight 
A: Serum SAA levels in µg/ml and B: body weight in grams of control mice (black) and LPS mice (red) at 
baseline and at different time points after LPS (n=17) or control (n=13) injection. The vertical dotted line 
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LPS-evoked acute systemic inflammation does not alter atherosclerotic 
plaque area, number, or severity
Atherosclerotic lesion area, severity and number were quantified histologically in the 
valve area of  the aortic root. Aortic root sections of  all experimental groups showed 
atherosclerotic lesions (Fig. 2A) of  variable severity (type I to type V). 
First, the total atherosclerotic plaque area at the level of  the aortic valves in the root 
was measured (Fig. 2B). No significant differences in total surface area of  atherosclerot-
ic plaque were observed between the control and LPS groups sacrificed 2 days (resp. 
0.409±0.228 x 105 µm2 vs. 0.285±0.169 x 105 µm2) (p=0.31), and 15 days (resp. 
0.950±0.938 x 105 µm2 vs. 0.612 ± 0.413 x 105 µm2) (p=0.80) after saline/LPS injection 
While saline treated groups showed no further progression of  atherosclerosis between 
day 2 and 15, treatment with LPS increased the total lesion area with borderline signif-
icance (P=0.055). The number of  atherosclerotic plaques and percentage of  lesion free 
segments were comparable in both groups (Fig. 2C and 2D).
In a subsequent more refined analysis, lesion severity was scored and lesions were graded 
on basis of  their morphology and cellular composition. The plaque area per lesion 
type was quantified. No significant difference in plaque area was observed between 
the experimental groups sacrificed at day 2, with a comparable load of  mild plaques 
(0.839±0.424 x 105 µm2 vs. 0.764±0.397 x 105 µm2, respectively; p=0.79), and severe 
plaques (0.743±0.641 x 105 µm2 vs. 0.400±0.318 x 105 µm2, respectively; p=0.23; Fig. 3). 
Similarly, no differences were found between the control and LPS groups sacrificed at 
day 15, both with respect to mild plaques (1.007±0.536 x 105 µm2 vs. 0.992±0.369 x 
105 µm2, respectively; p=0.95), and severe plaques (resp. 1.683±1.349 x 105 µm2 vs. 
1.220±1.103 x 105 µm2, respectively; p=0.35). Consistent with the global atherosclerosis 
analysis, the lesion area of  mild and severe lesions was greater in mice sacrificed at day 
15 as compared to the mice sacrificed at day 2, with most pronounced effects for the 
severe plaques (respectively p=0.33 in the control mice and p=0.075 in the LPS mice). 
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Figure 3 LPS does not increase total atherosclerotic plaque severity
Total surface area (x105 μm2) of the atherosclerotic plaques per plaque type at the aortic root of mice 
sacrificed at t=2 days post-LPS (n=8) or control (n=4) or t=15 days post-LPS (n=9) or control (n=9). Data 
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LPS-induced systemic inflammation does not increase the content of  in-
flammatory cells within atherosclerotic lesions
To evaluate whether LPS injection enhances intra-plaque inflammation, the density of  
macrophages and lymphocytes in atherosclerotic plaques was determined (Fig. 4). The 
MAC-3 positive area (indicative of  macrophages) divided by total plaque area was com-
parable in both groups and after 2 days 68.16±7.51% in control vs. 65.37±8.67% in 
LPS group (p=0.60) and after 15 days 65.16±10.99% vs. 59.97±8.51% (p=0.28). Next, 
the percentage of  macrophage area in the different plaque types was evaluated (Fig. 4B). 
No significant differences were found between the control and LPS group sacrificed at 
day 2 or day 15, neither in the mild nor in the severe plaque types. The modest increase 
of  macrophage density in severe plaques in the LPS groups at both time points was not 
statistically significant (p=0.21 at 2 days and p=0.43 at 15 days). 
The number of  lymphocytes per surface area of  atherosclerotic plaques appeared high-
er in the control group than in the LPS group sacrificed at day 2 (3.5±2.9 x 10-4 μm2 
vs. 1.1±0.70 x 10-4 μm2), but this difference was not statistically significant (p=0.37) 
(Fig. 4C). The lymphocyte density was also comparable in the groups sacrificed after 15 
days (2.3±1.0 x 10-4 μm2 vs. 2.3±1.7 x 10-4 μm2) (p=0.91). The percentage of  lympho-
cyte-covered area in the different plaque types was evaluated (Fig. 4D) but no significant 
differences were found between the control and LPS group at both time points, and 
irrespectively of  the severity of  the plaques. 
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DISCUSSION
A single LPS injection in ApoE3*Leiden mice triggered a substantial systemic inflamma-
tory response but did not evoke intraplaque changes in size or inflammatory cell density. 
Thus, this model cannot help explain the high incidence of  cardiovascular events fol-
lowing acute systemic inflammation in clinical patients in the early phase of  the disease. 
The LPS-injection caused a marked acute systemic inflammatory response as demon-
strated by mice behavior, weight loss and a rapid increase in SAA, a relatively stable 
and sensitive inflammation marker that integrates the signals of  several pro-atherogen-
ic cytokines, such as IL1, TNFα, and IL616, 17. Several studies suggest that SAA itself  
participates in the pathogenesis of  atherosclerosis18 and a recent study showed that a 
single SAA injection in ApoE-deficient mice, a model of  spontaneous atherosclerosis, 
increases atherosclerotic plaque area 16 weeks later11. Similar evidence for a long-term 
effect of  acute inflammation on plaque development also comes from a model of  intra- 
abdominal sepsis in ApoE-deficient mice caused by colon ligature and puncture (CLP) 
in which atherosclerotic plaque area was enhanced at 3 and 5 months and suggested 
increased intra-plaque macrophage infiltration at 5 months12. The aforementioned long-
term studies suggest that acute inflammation enhances plaque growth and inflammation 
after several months, but do not address the question if  acute plaque changes occur 
days after the onset of  inflammation, which would help explain the acute event risk in 
humans with systemic infection. Data is scarce, but some studies have evaluated vessel 
wall changes shortly after inflammation. The earlier mentioned study using the CLP in 
ApoE -/- model also described elevated mRNA expression for cytokines and adhesion 
molecules (TNF-a, CCL2, ICAM-1, VCAM-1) in the aorta’s of  wild type mice, 1-5 days 
after CLP, but these observations were not evaluated at a protein level. This finding was 
however not confirmed in the atherosclerotic mouse model and therefore could be a sign 
of  systemic infection induced pan-aortitis and does thus not prove or disprove enhanced 
intra-plaque inflammation and atherogenesis. In advance, a study in Apo E-/- mice sub-
jected to an influenza virus infection showed subendothelial infiltration of  a heteroge-
neous population of  inflammatory cells within 10 days after infection19. These cells were 
however not quantified per type and plaque area was not assessed. So whether acute 
systemic inflammation induces pro-inflammatory changes in atherosclerotic plaques in 
a similar time frame as the acute cardiovascular event risk in humans with infection has, 
however, not been studied to date. In an attempt to mimic the situation in the clinic, we 
established an acute systemic inflammatory condition in mice with established lesion by 
injection of  LPS that resulted in markedly elevated  levels of  SAA. Under these condi-
tions, we found no evidence for acute morphological or structural changes of  lesions in 
the vessel wall which would indicate pro-atherogenic or intra-plaque pro-inflammatory 
effects, for which we propose three possible, non-mutually exclusive explanations:
Proefschrift_v10.0.indd   61 02-11-17   12:14
62 Chapter 4
Firstly, our hypothesis that acute systemic inflammation evokes similarly acute pro- 
inflammatory changes in plaques may be incorrect. 
Secondly, our LPS-induced systemic inflammatory response could have been inappro-
priate to disprove the hypothesis. An actual infection model may more closely resemble 
the pathophysiological process of  sepsis than the LPS model20. These infection models 
however are very hard to mimic and to translate to clinically relevant situations. In fact, 
sepsis is one of  the most difficult clinical conditions to model in animals as is also shown 
by the fact that many promising therapeutic agents that were effective in animal studies 
failed to demonstrate a similar benefit in human clinical trials20, 21. Although LPS causes 
an acute systemic inflammatory response, it may not mimic real infection sufficiently 
enough, because it is strictly TLR4 mediated, has a higher and shorter increase in cyto-
kines and has a different hemodynamic response compared to human sepsis21, 22. There 
are some indications that actual infection models, such as the often used CLP model, 
may better mimic human sepsis21, 23. We did however not choose CLP or other models 
based on alteration of  the endogenous protective barrier of  the animal 24, because with 
this technique it remains difficult to control the magnitude of  the septic challenge. As a 
result sepsis is highly variable in severity21. 
Thirdly and finally, inflammatory cell content of  plaque could be an inappropriate read-
out parameter for acute plaque inflammation. The premise that inflammation is always 
appropriately reflected by inflammatory cell content may be incorrect, particularly in 
very acute circumstances. Inflammatory cells may for example decrease in number due 
to apoptosis after a brief  phase of  activation. This is known to occur with intra-plaque 
macrophages, which degrade to necrotic core after activation and LDL uptake25, 26. Our 
recent study in Apo E-/- mice also seems to suggest a similar phenomenon, as ma-
jor orthopedic surgery caused a strong systemic inflammatory response and lead to an 
 increase in plaque and necrotic core area with concomitant decrease of  macrophage 
and lymphocyte density at day 15 post-surgery27. Hence, the activation state rather 
than cell density may represent the best parameter of  acute intra-plaque inflammation. 
There is, however, limited consensus as to how to quantify pro-inflammatory activity of  
relevant immune cells, in particular macrophages and lymphocytes. 
Strengths and limitations
A strength of  this study is that we in contrast to others have focused on the early effects of  
systemic inflammation on the vessel wall, thus specifically addressing the clinical obser-
vation of  increased cardiovascular risk shortly after onset of  acute inflammation. To our 
knowledge we are the first that quantify plaque area short (days rather than months) after 
LPS-induces inflammation. Next, we have chosen, the ApoE3*Leiden model as in these 
mice plaques grow in a slower, more human-like pace than the ApoE -/- model28, 29 and 
because the ApoE protein itself  plays a role in controlling the physiological responses 
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during inflammation such as leukocyte migration30. Furthermore ApoE is important for 
hepatic clearance of  LPS and the absence of  this apolipoprotein enhances the immune 
response to LPS31-33. Therefore our study may reflect LPS effects more realistically than 
conditions in which ApoE is fully knocked out. Several limitations of  our design merit 
discussion. We based the number of  mice per group on the scarce literature on this 
topic. Mouse numbers are consequently relatively small and the risk of  a type 2 fault is 
present. Although we could not observe differences that approach significance, including 
more mice would have made the conclusion stronger. And lastly since atherosclerotic 
plaque rupture in the ApoE3*Leiden model it is not seen in the aortic root it would have 
been interesting to analyze the effect is of  LPS in experimental models that study actual 
plaque complications rather than atherosclerotic plaque development alone34, 35.
SUMMARY
We hypothesized that acute systemic inflammation provoked by lipopolysaccharides 
rapidly enhances plaque area and intra-plaque inflammation, and we addressed this hy-
pothesis in atherosclerosis-prone ApoE*3Leiden mice. LPS mice showed a pronounced 
elevation of  SAA indicating a marked systemic inflammatory conditions, but no signifi-
cant differences in plaque area, type and number of  lesions were observed 2 and 15 days 
after LPS injection. In parallel, the plaque density of  macrophages and lymphocytes 
remained unchanged in the early phase. Our study argues against structural/morpho-
logical intra-plaque alterations as an explanation for acute inflammation-induced car-
diovascular event risk. 
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ABSTRACT
Objective: Cardiovascular events show a peak incidence early after episodes of  severe 
systemic inflammation, such as infection. The acuteness of  this increased risk suggests 
intra-plaque inflammation and subsequent plaque instability. We hypothesized that 
acute systemic inflammation induces such changes and addressed this hypothesis in an 
autopsy study of  patients with acute myocardial infarction (AMI) and with or without 
infection at time of  death. 
Methods: We selected AMI patients with (n=18) and without (n=16) non-cardiac 
acute inflammation (AI) at time of  death. Since infarct duration itself  may influence 
plaque inflammation, we divided the groups by estimated time since AMI (3-6 hours vs. 
6 hours-14 days). Stenosis, plaque stability and intra-plaque hemorrhage were assessed 
in coronary sections. Infiltration of  lymphocytes (CD45), macrophages (CD68), mast 
cells (tryptase) and neutrophilic granulocytes (MPO) in the intima, media and adventitia 
were assessed.
Results: In 289 coronary artery sections, we found no difference in stenosis, plaque sta-
bility characteristics or density of  most inflammatory cells between AMI patients with or 
without AI. Mast cells, however, were more numerous in the intima and media of  early 
AMI patients with AI compared to AMI without AI (1.14 [0.47-3.28] vs. 2.26 [1.43-
4.66] p=0.021 in the intima, and 0.00 [0.00-0.76] vs. 0.63 [0.00-3.17] p=0.004 in the 
media, respectively). Lymphocyte and macrophage density increased with advancing 
infarct duration, with no clear difference between the AI and non-AI groups.
Conclusions: Acute non-cardiac inflammation may enhance mast cell influx in the inti-
ma and media of  atherosclerotic coronary arteries and thus contribute to the pathogen-
esis of  acute MI. Our results argue against a role for other inflammatory cells in plaque 
during acute inflammation. We observed an increase in coronary wall inflammation 
later in the post-MI period, independent from the presence of  systemic infection.
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INTRODUCTION
Observational epidemiological studies show that cardiovascular events can be triggered 
by clinical conditions that are associated with systemic inflammation1-4. Respiratory tract 
infection, for instance, raises the early (2-14 days after onset of  symptoms)1, 2 risk of  
acute myocardial infarction (AMI) by approximately fivefold1, and the risk of  stroke by 
eightfold1, 3. 
The causal mechanisms behind inflammation-induced cardiovascular event risk remain 
elusive, but its acuteness suggests an effect on atherosclerotic plaque stability5-7. If  this 
indeed occurs and, if  so, by which mechanism is unclear. We do however know that 
intra-plaque inflammation plays an important role in the progression and destabiliza-
tion of  atherosclerotic plaques8-11. It is thus worth investigating whether acute systemic 
inflammation has short-term effects on plaque inflammation.
Several studies previously addressed the issue of  acute inflammation and its effect on 
atherosclerosis, but most focused on intermediate to long-term effects. For example, 
plaque area was increased in Apo E -/- mice 16 weeks after a single injection of  serum 
amyloid A peptide, a biomarker and inducer of  systemic inflammation.12 Furthermore, 
a recent murine model of  abdominal sepsis showed effects on atherosclerotic plaque 
stability months after the initial infection had ceased.13 Whether acute systemic inflam-
mation induces similar pro-inflammatory intra-plaque changes in humans has, however, 
not been studied to date. 
Given the short-term effects of  systemic inflammation on cardiovascular event risk, 
we hypothesized that an acute episode of  infection rapidly enhances intra-plaque in-
flammation. In the coronary arteries, such changes could act in two ways. First, they 
could contribute to the occurrence of  a primary AMI. Secondly, they could enhance 
the pro-inflammatory plaque changes evoked by recent MI itself, thus bearing relevance 
for patients who have infection in the early post-MI period14, 15. We concluded that both 
hypotheses could be addressed by analyzing inflammatory cell content in atherosclerotic 
plaques in coronary arteries of  patients who died at different time intervals after AMI, 
with or without signs of  systemic infection. 
METHODS
The study included deceased patients referred to the Department of  Pathology for clin-
ical autopsy, which was performed within 24 h after death. Relatives of  patients pro-
vided written consent for the use of  autopsy material for scientific research. All patients 
showed macroscopical evidence of  recent AMI, as identified by lactate dehydrogenase 
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(LDH) decolouration of  myocardial tissue. Patients diagnosed with chronic inflamma-
tory disease (e.g. systemic lupus erythematosus or rheumatoid arthritis) , recent surgery 
(<6 months) and metastatic disease were excluded, since these conditions could influ-
ence inflammatory status4, 16-19. Patients with clinically and autopsy proven sepsis or se-
vere systemic infection at time of  death (acute non-cardiac systemic inflammation; AI) 
were selected and compared to patients with no signs of  infection (no acute non-cardiac 
systemic inflammation; non-AI). Myocardial tissue specimens were obtained from the 
center of  the infarct area in AMI patients and after formalin-fixation, embedded in 
paraffin and used for immunohistochemical analyses. AMI patients were categorized 
into two phases of  post-AMI duration based on microscopic criteria: the early post-AMI 
phase (3-6 hrs old; macroscopic LDH decolouration but no extravasation of  neutro-
philic granulocytes in the infarct area) and the mid-term to late post-AMI phase (6 hrs 
to 14 days old; extravasation of  neutrophilic granulocytes in the infarct area and/or 
granulation tissue formation20-23. 
In all patients, the left and right coronary arteries were excised from their root to the 
point where they enter the myocardium. Sections with the most severe stenosis were 
identified macroscopically and subsequently processed separately for histological and 
immunohistochemical analyses. Selected tissue cross-sections were fixed in 4% parafor-
maldehyde, decalcified in buffered formic acid, and embedded in paraffin. 
(Immuno)histochemistry 
Paraffin tissue sections (4 µm) of  the coronary segments were stained with Elastica von 
Gieson (EVG) and haematoxylin-eosin (HE) for histological analyses. The degree of  
stenosis of  each individual segment was determined based on EVG stained cross-section 
as percentage of  luminal surface area compared to surface area defined by the internal 
elastic lamina. All atherosclerotic plaques were evaluated microscopically to verify the 
presence of  a thin fibrous cap. Plaques were classified as unstable if  the fibrous cap was 
thin and/or if  multiple inflammatory cells reached up to the luminal endothelial layer 
of  the plaque24, 25. If  neither of  these characteristics were present, plaques were classified 
as stable. To classify intraplaque hemorrhage (IPH) all coronary segments where stained 
for erythrocytes with the immunohistochemical GLUT-1 staining and for iron using the 
histochemical Perls staining. Using a microscope with 250 × magnification, fresh IPH 
was identified by the presence of  >10 extravascular localized intact erythrocytes per 
plaque, while old IPH was identified by the presence of  iron and/or erythrocyte frag-
ments24, 25. Ongoing IPH was defined as both fresh and old hemorrhage25. Subsequent-
ly, all coronary segments were stained with antibodies detecting GLUT-1 (erythrocytes), 
CD45 (lymphocytes), CD68 (macrophages), MPO (neutrophils) and tryptase (mast 
cells). For this, the sections were first deparaffinized, rehydrated and blocked for endog-
enous peroxidases by incubation in H2O2 (0.3%) diluted in methanol for 30 minutes. 
Antigen retrieval was performed by heat inactivation in sodium-citrate buffer (10 mM, 
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pH 6.0) for slides to be stained for CD68, MPO and tryptase or in a Tris/EDTA buffer 
(pH 9.0) for slides to be stained with GLUT-1. Slides to be stained for CD45 required 
no antigen retrieval step. The slides were incubated with either or rabbit-anti-human 
Glut-1 (1:100, Thermo Scientific RB-9052-P), mouse-anti-human CD45 (1:100, Dako 
M0701), rabbit-anti-human CD68 (1:400, Dako M0814), mouse-anti-human MPO 
(1:1500, Dako A0398) or mouse-anti-human Tryptase (1:500, Dako M7052) for 1 h 
at room temperature. The sections were then washed with phosphate-buffered saline 
and incubated with Real EnVision HRP α-mouse/rabbit (undiluted; Dako) for 30 min 
at room temperature. The staining was visualized using 3,3′-diaminobenzidine (DAB) 
(0.1 mg/ml, 0.02% H2O2). The sections were then counterstained with hematoxylin, 
dehydrated, and covered. With each staining, a phosphate-buffered saline control and 
an isotype control were included. All these controls yielded negative results (not shown).
Quantification of  immune cells and morphometric analysis 
In all individual segments of  each coronary artery the total surface area of  the intima 
and media and adventitia were determined on the scanned slides using the Panoramic 
Desk scanner and analyzed with Pannoramic Viewer 1.15.2 software (3DHistech, Buda-
pest, Hungary). The surface area of  adventitia was measured from the external elastic 
lamina until 100 µm into the tunica externa. 
Lymphocyte and macrophage infiltration was analyzed with the ImageJ 1.47 software 
(National Institutes of  Health, USA) using a color threshold to determine the surface 
area of  positive anti-CD45 staining respectively anti-CD68 staining and dividing it by 
the surface areas of  the relevant intima, media and adventitia. CD68 positive area was 
quantified only in the intima, since there were no (large) areas of  positive staining pres-
ent in the media an adventitia. The numbers of  extravascular mast cells and neutro-
philic granulocytes were counted using a light microscope using a 25x magnification 
objective (Zeiss, Germany) and then calculated per mm2 of  the surface areas of  the 
intima, media and adventitia. 
Statistics 
To evaluate differences in plaque area, plaque type, lesion number and inflammatory 
cells between groups, independent sample t-tests and Mann–Whitney U tests were used 
as appropriate. Statistical analyses were performed using GraphPad Prism version 7.00 
for Windows, (GraphPad Software, La Jolla California USA). Results were considered 
statistically significant if  the two-sided p-value was <0.05.




34 AMI patients with a total of  289 coronary slides were included and categorized into 
4 groups based on infarction duration and the presence of  acute systemic inflammation 
(Table 1). Additional clinical details regarding co-morbidity and type of  infection in the 
AI group, are given in supplemental table A.
Variable represent median [interquartile range], percentage of total patients (%). DM2, type 2 diabetes; AF, 
atrial fibrillation; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease.
















Age (years) 67 (56-74) 81 (57-86) 64 (51-72) 72 (69-82)
Male, n (%) 11 (92) 4 (80) 5 (83) 7 (64)
Cardiovascular history
Hypertension, n (%) 1 (8) 0 (0) 0 (0) 4 (36)
DM, n (%) 1 (8) 2 (40) 2 (33) 2 (18)
Previous infarction, n (%) 3 (25) 0 (0) 1 (17) 3 (27)
Coronary slides used for analysis (n) 120 31 45 93
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Gender age Infarct duration
Non-cardiac acute systemic 
inflammation on autopsy report Secondary pathologies
M 81 3-6 hrs Sepsis with pneumonia, arthritis of 
the knee and fasciitis necroticans 
upper leg
DM2; aortic prothesis; cholecystectomy; 
prostate and colon cancer (no metastasis)
M 90 3-6 hrs Sepsis with betahemolytic 
Streptococ. group A in blood
AF
F 37 3-6 hrs Bilateral pneumonia with Staph. 
Aureus
Systemic sclerosis (dermal tightening, 
Raynaud, myocardial fibrosis, right heart 
failure), AF
M 82 3-6 hrs Pneumonia Prostate cancer (no metastasis)
M 77 3-6 hrs Pneumonia DM2
M 72 6-12 hrs Sepsis with pneumonia CABG and mitral valve prothesis  
(7 yrs < death)
M 69 6-12 hrs Sepsis with pneumonia, peritonitis CABG (2 yrs < death); kidney failure with 
peritoneal dialysis; hypertension
M 64 6-12 hrs Sepsis none
M 89 1-3 days Pneumonia Previous AMI (27 yrs < death); vascular 
dementia; hypertension
F 82 1-3 days Pneumonia none
F 81 1-3 days Bilaterial pneumonia Breast cancer with mastectomy (no 
metastasis); hypertension;
hypercholesterolemia; appendectomy; AF
M 69 5-7 days Sepsis Aortic prothesis; DM2; hypercholesterolemia
F 69 5-7 days Pneumonia + urinary tract infection Breast cancer with lumpectomy (27 yrs < 
death); CABG (10 yrs < death);
stomach cancer with gastrectomy (8 yrs < 
death)
M 88 7-14 days Bilateral pneumonia Gastrectomy; aortic valve stenosis
F 75 7-14 days Sepsis with infected grafts 
 femoropopliteal bypass
Fempop (3 months < death); COPD; DM2; 
hypertension; AMI (5 yrs < death); AF; kidney 
failure
M 55 7-14 days Pancreatitis AMI (3 x) last 1 month before death
F 95 3-6 hrs no Trauma capitis
M 60 3-6 hrs no none
M 66 3-6 hrs no COPD; AF
M 90 3-6 hrs no COPD; hypertension; DM2; systemic 
amyloidosis (no cardial involvement)
M 54 3-6 hrs no none
M 74 3-6 hrs no Lungcarcinoma with surgery (7 yrs < death; 
AMI (5 yrs < death);
3-6 hrs heart failure (3 yrs < death); Aortic valve 
stenosis
M 74 3-6 hrs no Cholelithiasis
M 64 3-6 hrs no AF; previous AMI
M 67 3-6 hrs no Dilated cardiomyopathie (ICD); alcoholic 
fibrosis of heart and liver
M 43 3-6 hrs no none
M 71 3-6 hrs no Previous AMI with CABG
M 55 3-6 hrs no none
M 60 1-3 days no none
M 67 1-3 days no none
M 72 1-3 days no none
M 52 5-14 days no DM2; alcohol abuses; prostate cancer with 
prostectomy (1 yrs < death)
M 47 7-14 days no DM2; sarcoidosis (no cardial involvement); old 
infarctions
F 72 7-14 days no Livercirrhosis; aortic valve stenosis with left 
ventriculair hypertrophy
Supplemental table A included patients
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Infarcted area, stenosis, plaque stability and intra-plaque hemorrhage
In patients with acute MI (3-6 hrs old) and late MI (6 hrs-14 days), no significant differ-
ences between the non-AI and AI groups were observed for infarct area, stenosis, plaque 
instability and intra-plaque hemorrhage (Fig. 1A-1D and suppl. Table B). 
Figure 1 Infarcted area, stenosis and stability per group. 
Total surface area (x105 μm2) of the atherosclerotic plaques per plaque type at the aortic root of mice 
A: Infarcted area of the left ventricle divided by total area of left ventricle (%). B: Stenosis expressed as 
percentage of the surface area of the lumen divided by the surface area of the intima ending at the internal 
elastic lamina. C: Number of unstable plaques divided by number of unstable + stable plaques. Percentag-
es are given as well as absolute number of plaques. D: Number of plaques without and with (fresh, old or 
ongoing) hemorrhage. Percentages are given as well as absolute number of plaques. Groups are based on 
infarct duration (3-6 hrs vs 6hrs-14days) and the presence of non-cardiac acute inflammation (AI) diagnosed 







p=0.11 p=0.61 p=0.60 p=0.62
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6 hrs - 14 
days
AI
6 hrs - 14 
days
Lymphocytes (surface area, %)
Intima 0.26 [0.07-0.70] 0.11 [0.02-0.48] 0.89 [0.37-2.34] 0.31 [0.10-0.98]
Media 0.05 [0.01-0.15] 0.02 [0.00-0.17] 0.20 [0.08-0.59] 0.09 [0.02-0.25]
Acventitia 0.70 [0.27-1.51] 0.53 [0.24-1.49] 3.23 [0.89-5.49] 0.96 [0.33-2.07]
Macrophages (surface area, %)
Intima 0.40 [0.12-1.56] 0.36 [0.08-1.13] 0.73 [0.34-5.24] 0.83 [0.17-5.04]
Neutrophilic granulocytes (cells/mm2)
Intima 1.22 [0.44-2.80] 2.03 [0.37-3.72] 1.57 [0.80-4.58] 1.10 [0.36-2.52]
Media 0.00 [0.00-1.05] 0.00 [0.00-2.49] 0.77 [0.00-3.71] 0.14 [0.00-1.77]
Acventitia 4.02 [0.99-7.67] 3.75 [2.00-9.19] 6.20 [2.66-13.9] 3.96 [1.83-7.65]
Mast cells (cells/mm2)
Intima 1.14 [0.47-3.28] 2.26 [1.43-4.66] 1.75 [1.16-3.14] 0.85 [0.21-2.02]
Media 0.00 [0.00-0.76] 0.63 [0.00-3.17] 1.85 [0.00-4.18] 0.41 [0.00-3.33]
Acventitia 14.8 [7.59-43.4] 18.4 [10.5-24.2] 16.1 [9.58-21.6] 11.2 [3.03-27.1]
Supplemental Table B Inflammatory cell densities
Data represented as median [interquartile range]
In the non-AI and AI groups combined, late-MI patients (6 hrs-14 days old) were char-
acterized by a higher percentage of  unstable plaques (63% versus 52% in the acute MI 
group; p=0.05, with no differences between the no-AI and AI groups), but no significant 
differences in any of  the other plaque characteristics were found (data not shown).
Lymphocyte infiltration 
In patients with acute MI, no significant differences between the non-AI, and the AI 
group were found (p=0.08; p=0.37; p=0.62, for intima, media and adventitia, respec-
tively; Fig 2A-2C and suppl. Table B). In patients with late MI, lymphocyte densities 
were significantly higher in the non-AI group (p=0.001; p=0.005; p<0.0001, for inti-
ma, media and adventitia, respectively). Overall, lymphocyte densities were significantly 
higher in late-MI patients in all layers (suppl. Table C and D).
Macrophage infiltration
In both patients with acute MI and late MI, the density of  intimal macrophages was 
similar between the non-AI and AI group (Fig. 2D and suppl. Table B). Overall, mac-
rophage density was higher in the late MI versus the early MI patients (suppl. Table C 
and D).
Proefschrift_v10.0.indd   75 02-11-17   12:14
76 Chapter 5
Figure 2 Lymphocyte and macrophage density per group
Percentage of CD45 positive area (indicative of lymphocytes) A: in the intima, B: media and C: adventitia. D: 
Percentage of CD68 positive area (indicative of macrophages) in the intima. Groups are based on infarct 
duration (3-6 hrs vs 6hrs-14days) and the presence of non-cardiac acute inflammation (AI) diagnosed at 
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Supplemental Table C Inflammatory cell densities early vs. late
3-6 hrs 6 hrs - 14 days p-value
Lymphocytes (surface area, %)
Intima 0.25 [0.06-0.64] 0.55 [0.15-1.48] 0.001
Media 0.05 [0.01-0.15] 0.12 [0.03-0.34] < 0.001
Acventitia 0.66 [0.26-1.49] 1.35 [0.51-3.13] < 0.001
Macrophages (surface area, %)
Intima 0.40 [0.10-1.38] 0.76 [0.18-5.08] 0.002
Neutrophilic granulocytes (cells/mm2)
Intima 1.25 [0.44-3.02] 1.30 [0.46-2.90] 0.833
Media 0.00 [0.00-1.23] 0.39 [0.00-2.13] 0.020
Acventitia 4.00 [1.24-7.77] 4.10 [2.16-8.80] 0.125
Mast cells (cells/mm2)
Intima 1.51 [0.51-3.84] 1.30 [0.41-2.65] 0.253
Media 0.00 [0.00-0.86] 0.78 [0.00-3.51] < 0.001
Acventitia 15.6 [7.77-32.4] 13.2 [5.64-25.4] 0.125
Data represented as median [interquartile range] 








6 hrs-14 days P-value
Lymphocytes (surface area %)
   Intima 0.26 [0.07-0.70] 0.89 [0.37-2.34] <0.001 0.11 [0.02-0.48] 0.31 [0.10-0.98] 0.016
   Media 0.05 [0.01-0.15] 0.20 [0.08-0.59] <0.001 0.02 [0.00-0.17] 0.09 [0.02-0.25] 0.062
   Adventitia 0.70 [0.27-1.51] 3.23 [0.89-5.49] <0.001 0.53 [0.24-1.49] 0.96 [0.33-2.07] 0.153
Macrophages (surface area %)
   Intima 0.40 [0.12-1.56] 0.73 [0.34-5.24] 0.005 0.36 [0.08-1.13] 0.83 [0.17-5.04] 0.062
Neutrophilic granulocytes (cells / mm2)
   Intima 1.22 [0.44-2.80] 1.57 [0.80-4.58] 0.043 2.03 [0.37-3.72] 1.10 [0.36-2.52] 0.159
   Media 0.00 [0.00-1.05] 0.77 [0.00-3.71] 0.013 0.00 [0.00-2.49] 0.14 [0.00-1.77] 0.993
   Adventitia 4.02 [0.99-7.67] 6.20 [2.66-13.9] 0.009 3.75 [2.00-9.19] 3.96 [1.83-7.65] 0.672
Mast cells (cells / mm2)
   Intima 1.14 [0.47-3.28] 1.75 [1.16-3.14] 0.115 2.26 [1.43-4.66] 0.85 [0.21-2.02] 0.002
   Media 0.00 [0.00-0.76] 1.85 [0.00-4.18] <0.001 0.63 [0.00-3.17] 0.41 [0.00-3.33] 0.982
   Adventitia 14.8 [7.59-43.4] 16.1 [9.58-21.6] 0.746 18.4 [10.5-24.2] 11.2 [3.03-27.1] 0.321
Supplemental Table D Inflammatory cell densities early vs. late subdivided by non-AI and AI
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Neutrophilic granulocyte infiltration
In patients with acute AMI, no significant differences in neutrophil density was found 
between the non-AI and the AI groups (p=0.32; p=0.22; p=0.35 for intima, media and 
adventitia, respectively (Fig. 3A-3C and suppl. Table B). Acute systemic inflammation, 
however, did affect neutrophil densities in late-MI patients, with lower densities in the 
intima and adventitia in patients with AI (p=0.02 and p=0.04, respectively). Only in the 
tunica media, late-MI patients showed overall higher neutrophilic granulocyte density 
compared to acute MI patients (suppl. Table C and D).
Figure 3 Neutrophil density per group
Percentage of MPO positive area (indicative of neutrophils) A; in the intima, B: media and C: adventitia. 
Groups are based on infarct duration (3-6 hrs vs 6hrs-14days) and the presence of non-cardiac acute inflam-
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Mast cell infi ltration
In acute MI patients, mast cells were signifi cantly more dominant in the intima and 
media in the AI group than in the non-AI group (p=0.02 and p=0.004, respectively), 
but not in the adventitia (Fig. 4A-4C and suppl. Table B). In late MI patients, systemic 
infl ammation only aff ected mast cell density in the intima, with signifi cantly lower mast 
cell counts in the AI versus the non-AI group. In the non-AI and AI groups combined, 
late-MI patients showed a marked increase in mast cell density in the media compared 
to early MI patients (suppl. Table C and D). 
Figure 4 Mast cell density per group
Percentage of tryptase positive cells (indicative of mast cells) A; in the intima, B: media and C: adventitia. 
Groups are based on infarct duration (3-6 hrs vs 6hrs-14days) and the presence of non-cardiac acute infl am-
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DISCUSSION
Given the short-term effects of  systemic inflammation on cardiovascular event risk, we 
hypothesized that an acute episode of  infection rapidly enhances coronary wall inflam-
mation and plaque instability. In addition, the presence of  infection could contribute to 
pro-inflammatory changes in the arterial wall evoked by recent MI itself  14.
In acute MI, we found that the presence of  acute systemic infection was associated with 
an increased mast cell density in the intima and media of  atherosclerotic coronary arter-
ies. The density of  other inflammatory cells, however, was not increased, nor was there a 
clear effect on histopathological signs of  plaque instability. To our knowledge, we are the 
first to describe an increase of  mast cells in coronary arteries as a result of  infection. This 
increase is of  potential interest since mast cells in the coronary arterial walls are linked to 
plaque destabilization26 and cardiovascular risk27. Although mast cells are mostly found 
and studied in the adventitia, it has recently been suggested that mast cells in the intima 
and media of  atherosclerotic coronary lesions may contribute to the onset of  MI through 
plaque-destabilizing or spasm-inducing properties26, involving the release of  mediators 
such as histamine, chymase, tryptase, growth factors, and pro-inflammatory cytokines28, 
29. In several studies in atherosclerotic mouse models, inhibition of  mast cells reduced 
plaque instability30-34 whereas activation of  mast cells had the opposite effect31, 34, 35. More-
over, the number of  mast cells in human carotid atherosclerotic plaques was shown to 
be predictive for the occurrence of  cardiovascular events, irrespective of  their level of  
activation27. In addition, via release of  vasoactive mediators, especially histamine, mast 
cells have been implicated in provoking coronary contraction or even spasms, which can 
reduce coronary flow, but also destabilize the plaque36-39. Thus, our finding of  enhanced 
mast cell density in the media of  AMI patients with acute infection may at least partially 
explain the increased cardiovascular event risk seen shortly after infection 1. 
Why only mast cells and not the other inflammatory cells infiltrate the coronary arteries 
of  patients with infection is not clear. This finding does, however, not fully exclude a 
role for activated lymphocyte and macrophage detection, because their activation may 
cause loss of  epitopes and cells can become less detectable by CD68 and CD45-staining, 
respectively 18. Alternatively -and perhaps more likely- is that decreased lymphocyte and 
macrophage density is a true representation of  their role in early AMI occurring during 
acute infection. This may, for example, be explained by preferential recruitment of  these 
cells in infected tissue elsewhere in the body. 
With respect to the mid- to longer-term changes in coronary inflammation after acute 
MI, our findings corroborate earlier murine and human studies suggesting that MI  itself  
contributes to more widespread plaque inflammation and instability14, 26. We did not find 
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evidence that infection enhanced these post-MI pro-inflammatory changes. An effect 
of  post-AMI infection on plaque stability and subsequent cardiovascular event rate has 
been proposed15, but our findings argue against a dominant role for plaque inflamma-
tion in this phenomenon.
Important limitations have to be taken into consideration. Firstly, the total number of  
studied patients is low, particularly in subgroups. This study is the first of  its kind, but 
can, in view of  the limited size, only be hypothesis-generating. In addition, the optimum 
time after MI to study coronary arteries with respect to inflammatory activity is un-
known. A maximum period of  6 hours may not fully preclude effects of  infarction event 
itself. For the patients that died between 6 hrs and 14 days after onset of  AMI, infection 
could have been present either pre-AMI, or developed post-AMI at any given time. 
In conclusion, we found that the presence of  infection enhances mast cell infiltration in 
the intima and media of  coronary arteries, but does not seem to cause recruitment of  
other inflammatory cells or increase plaque instability. Mast cell involvement may be a 
partial explanation for the increased cardiovascular event risk seen shortly after infec-
tion. We re-established that AMI enhances pro-inflammatory changes of  the vessel wall, 
but did not observe an effect of  infection hereon.
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ABSTRACT
Objective: Mast cells (MCs) may play an important role in plaque destabilization and 
atherosclerotic coronary complication. Here we have studied the presence of  MCs in 
the intima and media of  unstable and stable coronary lesions at different time points 
after myocardial infarction (MI).
Methods: Coronary arteries were obtained at autopsy from patients with acute MI (up 
to 5 days old; n=27) and with chronic MI (5 - 14 days old; n=18) as well as sections from 
controls without cardiac disease (n=10). Herein, tryptase-positive MCs were quantified 
in the intima and media of  both unstable and stable atherosclerotic plaques in infarct- 
related and non-infarct-related coronary arteries. 
Results: In the media of  both acute and chronic MI patients, the number of  MCs was 
significantly higher than in controls. This was also found when evaluating unstable and 
stable plaques separately. In patients with chronic MI the number of  MCs in unstable 
lesions was significantly higher than in stable lesions. This coincided with a significant 
increase in the relative number of  instable plaques in patients with chronic MI com-
pared with control and acute MI. No differences in MC density were found between 
infarct-related and non-infarct-related coronary arteries in patients with MI.
Conclusions: The presence of  MCs in the media of  both stable and unstable atheroscle-
rotic coronary lesions after MI suggests that MCs may be involved in the onset of  MI 
and, on the other hand, that MI triggers intra-plaque infiltration of  MCs especially in 
unstable plaques, possibly increasing the risk of  re-infarction.
Proefschrift_v10.0.indd   86 02-11-17   12:14
87
Mast cells are increased in the media of  coronary lesions in patients 
with myocardial infarction and may favour atherosclerotic plaque
INTRODUCTION
Myocardial infarction (MI) most often is the result of  coronary atherosclerotic plaque 
rupture and resultant thrombus formation. Plaques that are prone to cause MI, so-called 
unstable or vulnerable plaques, are characterized by a thin fibrous cap and/or an exten-
sive presence of  inflammatory cells, including macrophages, lymphocytes and mast cells 
(MCs). Although best known for their role in allergic reactions, MCs have been shown to 
be involved in the initiation and progression of  atherosclerosis1, 2. Notably, MCs may also 
play an important role in the destabilization of  atherosclerotic plaques and coronary 
atherosclerotic complication. MCs accumulate in the vulnerable shoulder region of  hu-
man coronary atheromas, at the predilection sites of  atheromatous erosion/rupture3 
and at the sites of  erosion or rupture in infarct-related coronary arteries4. 
How MCs induce atherosclerotic complications is not completely known. However, 
evidence supports a role for MCs in the destabilization of  atherosclerotic plaques via 
the local release of  vasoactive, neurosensitizing, pro-angiogenic, pro-atherogenic and 
pro-inflammatory mediators, such as histamine, chymase and tryptase. Release of  these 
mediators can cause vasospasms5, intraplaque hemorrhage6, intraplaque neo-vascular-
ization7, 8 and/or collagen degradation via activation of  metalloproteinases resulting in 
weakening of  the fibrous cap9. The role of  MCs in plaque destabilization was further 
highlighted in atherosclerotic apolipoprotein E-deficient mice, wherein local activa-
tion of  MCs resulted in increased intraplaque hemorrhage, macrophage apoptosis and 
monocyte recruitment10, whereas inhibition of  chymase enhanced plaque collagen con-
tent and reduced necrotic core size and intraplaque hemorrhage11.
It has been suggested that in particular MCs located in the adventitia are associated with 
coronary atherosclerotic complications. In coronary arteries MCs were found predom-
inantly in the adventitia, i.e. 10 times more as compared to the intima12. Furthermore, 
an increased number of  degranulated MCs was found in the adventitia surrounding 
ruptured plaques in infarct-related coronary arteries in patients with MI13. However, 
knowledge regarding a putative relation between MCs present in the intima and media 
of  vulnerable and stable coronary lesions and MI is scarce. As many of  the aforemen-
tioned plaque-destabilizing properties of  MC take effect in the intima and media of  
lesions, we hypothesized that MCs located in these layers could be involved in plaque 
instability. For this, we quantified MCs in these vessel layers of  non-ruptured unstable 
and stable coronary lesions at different time points after MI and compared those with 
control patients.




A total of  55 patients who were referred to the Department of  Pathology of  the VU 
University Medical Center for clinical autopsy between 1999 and 2003, were retrospec-
tively included in this study. In this period approximately 1000 clinical autopsies were 
conducted at the VU university medical center. In an estimated 10 to 20 % of  these cas-
es a recent MI was found. Sections of  coronary arteries were obtained at autopsy from 
patients with acute MI (infarct of  up to 5 days old; n=27) and chronic MI (infarct of  5 
to 14 days old; n=18) or as a control from patients without cardiac disease (n=10, Table 
1 and 2). Control patients were age-matched and sex-matched. All MI patients showed 
macroscopical evidence for a recent left ventricular MI, as identified by reduced nitro 
blue tetrazolium (NBT) staining, indicative for a loss of  lactate dehydrogenase (LDH) 
of  the injured myocardial tissue, of  a mid-ventricular cross section of  the heart. The 
patients were subsequently categorized into two phases of  post-AMI healing based on 
the following microscopic criteria14, 15: acute MI patients showed microscopical evidence 
of  jeopardized myocardium (cardiomyocyte condensation, combined with loss of  nuclei 
and cross striations), with or without evidence of  extravasation of  neutrophilic granu-
locytes in the infarction area corresponding to an infarct age of  between approximately 
3 hours to 5 days after MI. chronic MI patients showed microscopical evidence of  cell-
rich granulation tissue formation and collagen deposition in the infarction area corre-
sponding to an infarct age of  approximately 5 to 14 days after MI. The control patients 
showed normal NBT staining.
Table 1 Characteristics of coronary artery tissue samples
Control Acute MI(< 5 days old)
Chronic MI
(5-14 days old)
Number of patients 10 27 18
Age (mean, range) 62.6 (37 – 94) 67.4 (24 – 84) 62.8 (31 – 82)
Sex, male / female (n) 6 / 4 18 / 9 13 / 5
Total number of lesions 35 70 46
Number of unstable lesions 16 32 32
Number of stable lesions 19 38 14
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Table 2 Patient characteristics
Patient Sex Age Primary cause of death Secondary pathologies
Control patients without cardiac disease
1 M 71 Sepsis Cholecystitis, peritonitis
2 M 73 Pneumonia Prostate carcinoma
3 M 80 Subdural hemorrhage Alcohol abuse
Liver cirrhosis
COPD
4 F 38 Pneumonia Cervical cancer
5 F 94 Intracranial hemorrhage Pneumonia
6 M 37 Not found -
7 M 67 Respiratory insufficiency Lung cancer
8 F 52 Pulmonary hypertension CREST syndrome
9 M 55 Sepsis Pyelonephritis
10 F 59 Pneumonia Oesophageal cancer
Control patients with myocardial infarction (< 5 days old; aMI)
1 M 80 AMI DM
Hypertension
Hypercholesterolemia
2 M 65 AMI DM
COPD
Hypethyroidism
3 F 83 AMI Burn wounds
4 F 81 AMI DM
Hypertension
Thyrotoxicosis
5 F 71 AMI -
6 M 57 AMI + pulmonary embolism -
7 F 84 AMI Pneumonia
DM
Hypertension
8 M 43 AMI Systemic scleroderma
9 F 72 AMI -
10 F 72 AMI + intestinal necrosis -
11 M 55 AMI + pulmonary embolism Colon cancer
12 M 72 AMI + pulmonary embolism Stomach cancer
13 M 70 AMI -
14 M 60 AMI -
15 M 58 AMI + sepsis Enterolcolitis
16 M 79 AMI -
17 M 51 AMI -
18 M 79 AMI + intracerebral hemorrhage Thyroiditis
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19 F 59 AMI + liver and kidney failure Alcohol abuse
Liver cirrhosis
20 M 75 AMI + ruptured aneurysm Laryngeal cancer
DM
21 F 71 AMI Pneumonia
22 M 75 AMI -
23 M 65 AMI Laryngeal cancer
24 M 24 AMI Alcohol abuse
Cocaine abuse
Heroin abuse
25 M 82 AMI Laryngeal cancer
Pneumonia
26 F 74 AMI Hypertension
Hypercholesterolemia
27 AMI + aspergillus infection DM
Polymyositis (prednisolone use)
Control patients with myocardial infarction (5-14 days old; cMI)
1 M 48 AMI Fever e.c.i.
2 M 62 AMI -
3 M 56 AMI -
4 F 76 AMI + a. femoralis hemorrhage COPD
Hypertension
Excessive anticoagulants
5 M 78 AMI -
6 M 67 AMI Hypercholesterolemia
DM
7 M 48 AMI Hypertension
8 M 74 AMI + cardiac tamponade -
9 M 71 AMI + sepsis Pneumonia
Hemorrhagic gastritis
10 F 60 AMI + kidney failure DM
Hypertension
11 M 56 AMI -
12 F 48 AMI + pulmonary embolism Acute myeloid Leukemia
13 M 65 AMI -
14 M 82 AMI -
15 F 61 AMI -
16 F 78 AMI + cardiac tamponade -
17 M 31 AMI + pneumonia -
18 M 69 AMI + sepsis Ischemic enteritis
M: male. F: female. AMI: acute myocardial infarction. DM: diabetes mellitus. COPD: chronic obstructive 
pulmonary disease.
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All patients were autopsied within 24 hours after death. From all patients, the left and 
right coronary arteries were excised from their root at the aorta to the point where they 
enter the myocardium. Sections with the strongest stenosis were identified macroscopi-
cally and subsequently processed separately for histological and immunohistochemical 
analyses. For this, the selected cross tissue sections were fixed in 4% paraformaldehyde 
and subsequently decalcified in buffered formic acid, where after the sections were 
 embedded in paraffin. 
As ruptured culprit lesions or intra-coronary thrombi are rarely found at autopsy in pa-
tients with MI, the infarct-related coronary arteries were identified based on the location 
of  the infarcts. The infarct location was determined based on the area of  reduced NBT 
staining, indicative for a loss of  LDH, of  a mid-ventricular cross section of  the heart. 
The branch of  the coronary artery responsible for perfusion of  the area of  the heart 
wherein the infarct is situated was then identified as the infarct-related coronary artery. 
In the VU University Medical Center patient material can be used for research after 
completion of  the diagnostic process as part of  the patient contract and, in case of  
autopsy, after relatives have given explicit written consent. This is conform the ethical 
guidelines set up by the World Medical Association (The declaration of  Helsinki). 
Immunohistochemistry 
Coronary artery tissue sections (4 µm thick) were mounted on microscope slides and 
 deparaffinized for 10 min in xylene at room temperature and dehydrated through de-
scending concentrations of  ethanol. Endogenous peroxidase activity was blocked by in-
cubation in 0.3% (v/v) H2O2 in methanol for 30 minutes. Tissue sections were subjected 
to antigen retrieval by boiling in 10 mmol/L sodium citrate buffer, pH 6, for 10 minutes 
in a microwave oven. The antibodies and normal serum were diluted in PBS containing 
1% (w/v) bovine serum albumin (BSA). Tissue sections were pre- incubated for 10 min-
utes with normal rabbit serum, followed by incubation with mouse-anti-human tryptase 
mAb (Dako, clone AA1, 1:1000 dilution) for 1 hour. After washing in PBS the slides were 
incubated with biotin-conjugated rabbit anti-mouse antibody (Dako, 1:500 dilution) for 
30 minutes. After washing in PBS the slides were incubated with streptavidin–biotin 
complex (1:1000 dilution) for 1 hour, followed by incubation with biotinylated tyramine 
(1:1000 dilutions) for 20 minutes. Staining was visualized with 3, 3’-diaminobenzidine 
(0.1 mg/mL, 0.02% H2O2). Slides were counterstained with haematoxylin and mount-
ed with Depex.
Quantification of  the MCs was performed by three independent investigators (KK, 
WWF, HWMN). Tryptase-positive MCs were quantified in the intima and media. For 
each lesion one cross section was scored. Subsequently the surface areas of  the scored 
intima and media were measured with a Leica DM/LM microscope, using QProdit v3.2 
(Leica Microsystems, Wetzlar, Germany) as analytical software to present the number 
of  MCs per mm2. 
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Plaque stability was determined on HE stained slides. For this, after deparaffinization 
and dehydration, the slides were incubated in haematoxylin for 5 minutes and then 
rinsed in water. The slides were then incubated in eosin for 2 minutes, rinsed in water 
with 1% ammonia and the covered. We defined unstable lesions as an atherosclerotic 
plaque with a thin fibrous cap and/or inflammatory cells infiltrating up to the endothe-
lial layer of  the intima16. 
Statistical analysis
Data analysis was performed with GraphPad Prism 4.0 and SPSS version 20 statistics 
software. Differences in MC number between the different groups in the different layers 
of  the arterial wall as well as between the intima, media or adventitia within the groups 
were analyzed with an One-way ANOVA and independent samples t-tests when normal 
distributed, respectively with a Kruskal-Wallis test and subsequent Mann-Whitney U 
tests, if  not. For the comparison between groups of  the relative distribution (%) of  sta-
ble vs. unstable plaques, crosstabs were used resulting in a Fisher’s exact test generated 
p-value. A p value (two sided) of  less than 0.05 was considered to be significant. 
RESULTS
We quantified MCs per mm2 in the intima and media of  stable and unstable athero-
sclerotic lesions in coronary arteries at different time-points after onset of  MI. Unstable 
lesions show a thin fibrous cap and inflammatory cells that migrate up to the endothelial 
layer of  the intima Fig. 1A), whereas stable lesions show a profound fibrous cap (Fig. 1B). 
Tryptase-positive MCs were present scattered throughout the intima and media of  cor-
onary atherosclerotic lesions (Fig. 1C). 
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A: Example of an Hematoxylin and Eosin-stained unstable lesion. The atherosclerotic Plaque area shows a 
thin fibrous cap and inflammatory cells that infiltrate up to the endothelial layer of the intima (arrows). Original 
magnification 200x. B: Example of an Elastica von Gieson-stained stable lesion with a profound fibrous cap 
(arrow). Original magnification 100x. C: Representative image of tryptase-positive mast cells in the intima 
(solid arrows), media (broken arrows) of a coronary artery. Original magnification 100x.
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In all analyzed lesions of  MI patients, the density of  MCs in the intima was lower than 
in the media, but not significantly. In contrast, in controls the density of  MCs in the in-
tima was significantly higher than in the media (p=0.004). In the intima of  all analyzed 
patients (Fig. 2), there were no significant differences in MC density between control 
patients, patients with acute MI and patients with chronic MI (controls: 0.9 (0.3-2.7); 
aMI: 1.2 (0.3-2.8); cMI: 1.5 (0.6-4.6). The density of  MCs in the media of  both acute 
and chronic MI patients however, was significantly higher than in controls (controls: 0.0 
(0.0-0.9); aMI: 2.4 (0.0-6.5); cMI: 2.3 (0.0-6.8); aMI p=0.001; cMI p=0,009.
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Quantification of tryptase-positive mast cells in the intima and media of coronary lesions in control patients, 
patients with acute MI (aMI; < 5 days old) and patients with chronic MI (cMI; 5 to 14 days old). Shown are the 
numbers of mast cells per mm2. Bars represent median and interquartile range.
Figure 2 .
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Next, the density of  MCs in the intima and media of  unstable and stable lesions was 
analyzed separately (Fig. 3). In the intima we observed no significant differences in MC 
density between stable and unstable lesions, not in controls nor in patients with MI (not 
shown). In contrast, in the media of  unstable lesions the MC density was significantly 
higher in patients with acute and chronic MI than in controls (controls: 0.0 (0.0-0.8); 
aMI: 2.7 (0.4-6.5); cMI: 3.5 (0.0-8.3); aMI p=0.004; cMI p=0,023). Similarly, stable le-
sions of  acute MI patients had a significantly higher MC density in the media than those 
of  controls (controls: 0.0 (0.0-1.5); aMI: 2.5 (0.4-7.7; p=0.022). However, in chronic MI 
patients this medial MC density of  stable lesions was significantly lower than in patients 
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Comparison between the density of tryptase-positive mast cells in the media of unstable and stable coronary 
lesions in control patients, patients with acute MI (< 5 days old) and chronic MI (5 to 14 days old). Shown are 
the numbers of mast cells per mm2 in control patients, patients with acute MI and chronic MI. Bars represent 
median and interquartile range.
Figure 3 .
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In controls and acute MI patients, no significant differences were observed in the densi-
ty of  MCs in the media between stable and unstable lesions. However, in patients with 
chronic MI the density of  MCs in unstable lesions was significantly higher than in stable 
lesions (p=0.024).
We subsequently analyzed for differences in the number of  infiltrated MCs between 
the non-infarct and the infarct-related coronary arteries of  both acute and chronic MI 
patients. In both patient groups we did not find significant differences in the number of  
MCs between infarct- and non-infarct-related coronary arteries. We then compared the 
number of  MCs in unstable lesions, between the coronary arteries of  control patients 
and the non-infarct-related and the infarct related coronary arteries of  both aMI and 
cMI patients. Both in the intima and media, we found no significant differences between 
the number of  MCs between the infarct-related and non-infarct-related arteries both in 
acute and chronic MI patients. In the intima, these numbers of  MCs did not differ sig-
nificantly compared to control coronary arteries either. However, the numbers of  MCs 
in the media of  the infarct-related coronary arteries of  acute MI patients (Fig .4A) and 
the non-infarct-related coronary arteries in chronic MI patients (Fig. 4B) were signifi-
cantly higher than in the coronary arteries of  control patients. Moreover, the number of  
MCs in the media of  non-infarct-related coronary arteries of  chronic MI patients was 
significantly higher than in acute MI patients. 
Remarkably, the relative distribution of  stable versus unstable plaques differed signifi-
cantly between acute and chronic MI patients (Fig. 5). Patients with chronic MI had rel-
atively more unstable plaques as opposed to stable plaques than patients with acute MI 
(p=0.010) and control patients (p=0.040). No significant difference in this distribution 
was found between patients with acute MI and controls.
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Comparison between the density of tryptase-positive mast cells in the media of unstable lesions, A: between 
the coronary arteries of control patients and the non-infarct-related and the infarct related coronary arteries of 
acute MI patients (< 5 days old), B: the coronary arteries of control patients and the non-infarct-related and 
the infarct related coronary arteries of chronic MI patients (5 to 14 days old) and C: the non-infarct-related and 



























































































Comparison of the relative distribution (%) of stable and unstable coronary lesions between control patients 
(control), patients with acute MI (aMI: < 5 days old) and patients with chronic MI (cMI: 5 to 14 days old). P-val-
ues are based on crosstabs and the Fisher’s exact test.
Figure 5 .
Finally, we have found no obvious differences in comorbidity occurrence between the 
groups that could account for the differences in MC density or plaque stability we have 
observed between the groups (Table 2).
DISCUSSION
Atherosclerotic coronary artery complication most often underlies the induction of  MI. 
Evidence supporting a critical role for MCs in coronary plaque destabilization is accu-
mulating. Perivascular MCs in particular have been associated with coronary athero-
sclerotic complication12, 13. In the present study we found both in the acute and chronic 
stage after MI a significantly increased presence of  MCs compared with controls in 
the media. Interestingly, in unstable lesions MCs were increased significantly after MI, 
especially in the chronic stage. In contrast, in the stable lesions a significant decrease 
was found in the density of  MCs in the chronic MI patients. This coincided with a sig-
nificantly higher percentage of  unstable plaques in chronic MI patients compared with 
controls and acute MI patients.
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The increase in MCs in the media in unstable lesions of  the infarct related coronary 
artery we describe here suggests that these cells may contribute to plaque destabilization 
and thereby to the onset of  MI. MCs most likely contribute to plaque destabilization 
and atherosclerotic coronary complication via the release of  atherogenic and vasoactive 
mediators such as histamine, chymase, tryptase, growth factors and pro-inflammatory 
cytokines17, 18. Indeed, in several studies in atherosclerotic mouse and hamster models 
inhibition of  MCs reduced plaque instability11, 19-21, whereas activation of  MCs increased 
plaque instability6, 10, 19, via effects on intraplaque collagen degradation, vascular smooth 
muscle cell apoptosis, monocyte infiltration and intraplaque hemorrhage. Moreover, the 
number of  MCs in human carotid atherosclerotic plaques was shown to be predictive 
for the occurrence of  cardiovascular events irrespective of  their activation8. In addition, 
via release of  vasoactive mediators, especially histamine, MCs have been implicated 
in provoking coronary spasms which can lead to MI directly or indirectly via spasm- 
induced destabilization followed by complication of  unstable coronary lesions5, 22-24. Our 
finding of  increased MC infiltration in the media, especially in unstable lesions of  acute 
and chronic MI patients, directly supports such a role. Although a causal relationship 
between this finding and plaque instability or sensitivity towards spasms remains to be 
established. These mast cells may migrate into the media from the vaso vasorum. Previ-
ous studies have indeed shown high densities of  MCs in the adventitia10, 13.
Given that many of  the plaque-destabilizing properties of  MCs take effect in the intima 
and that intraplaque MC numbers in carotid lesions were shown to associate with future 
cardiovascular events8, an increased density of  MCs in the intima of  unstable coronary 
lesions may have been expected. Remarkably however, we observed no differences in 
MC density in the intima between stable and unstable lesions or between infarct-related 
and non-infarct-related coronary arteries in any of  the groups, nor between the groups. 
MC densities were shown before to correlate positively with plaque progression, both 
in coronary7 and carotid arteries7, 25. However, intimal MC densities between stable and 
unstable lesions that we describe here, were to the best of  our knowledge never analyzed 
before. 
Albeit not significant, we observed that the MC density in the media of  specifically 
unstable coronary lesions increased in time after MI. This increase was significant in 
non-infarct-related coronary arteries. This suggests that MI itself  somehow triggers the 
infiltration of  MCs into coronary lesions. Consequently, through their plaque destabiliz-
ing properties these infiltrated MCs may cause further coronary plaque destabilization 
over time and increase the likelihood of  recurrent ischemic events. This hypothesis is 
strengthened by our finding of  a significantly more frequent occurrence of  unstable 
plaques in the coronary arteries in patients with chronic MI as compared to controls 
and acute MI patients. Indeed, re-infarction is a common event in patients with MI and 
was shown in a representative trial to occur in 54% of  patients within the first year after 
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MI26. Recently, interest is increasing regarding the concept that MI can affect distant 
vascular remodeling. This concept was first demonstrated in mice wherein MI-induced 
inflammation augmented neointimal hyperplasia in a remote injured artery27. The same 
research group subsequently showed in humans that luminal narrowing of  non-culprit 
coronary arteries after MI was progressed in comparison with stable angina pectoris, 
indicative of  augmented atherosclerosis28. Similarly, in a mouse model, MI caused en-
hanced inflammation in aortic atherosclerotic plaques29. We observed similar propor-
tions of  unstable plaques in the coronary arteries of  control patients and in acute MI 
patients. It is known that not all vulnerable plaques lead to plaque rupture30 and that 
multiple ‘active’ plaques often reside in the coronary and other arteries31. Moreover, it 
was shown in patients with unstable angina that inflammation of  the coronary arteries 
was widespread across the coronary vascular bed, regardless of  the location of  the cul-
prit stenosis32. These findings are in line with our findings of  increased MC density in 
media throughout the coronary lesions and challenge the concept of  a single vulnerable 
plaque in coronary syndromes, but perhaps more point to the atherosclerotic burden 
and specifically the proportional presence of  vulnerable lesions as well as the level of  
plaque inflammation across the coronary vascular bed as factors that increase the like-
lihood of  developing MI. 
Finally, as a limitation of  the study we would like to point out that the number of  stud-
ied lesions was relatively small especially from control patients. Further observations in 
other patients cohorts are warranted to strengthen these results.
In conclusion, in this study we show a presence of  MCs in the intima and media of  
both stable and unstable atherosclerotic coronary lesions after MI, especially significant-
ly increasing in the media of  unstable plaques in the patients with chronic MI. These 
results suggest that MCs present in coronary lesions, may contribute to the onset of  MI 
through their plaque-destabilizing or spasm-inducing properties. MI, in turn, may trig-
ger intra-plaque infiltration of  MCs, thereby inducing the transition of  stable plaques 
into unstable plaques resulting in an increased risk of  re-infarction.
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ABSTRACT
Background: The risk of  atherosclerotic events, such as myocardial infarction and stroke, 
is determined by the stability of  atherosclerotic plaques in large arteries which, in turn, 
correlates with inflammatory activity in these plaques. [18F]-2-fluoro-2-deoxy-D-glucose 
(18F-FDG) imaging using positron emission tomography (PET) provides a non-invasive 
assessment of  inflammation and, as such, could be a valuable imaging biomarker in 
atherosclerosis. Systemic inflammation may affect pharmacokinetics of  18F-FDG uptake 
in atherosclerotic plaques causing inaccurate quantitative assessment using simplified 
methods. The aim of  the present study was therefore to validate the use of  simplified 
quantitative 18F-FDG uptake parameters for evaluation of  inflammation in atheroscle-
rotic plaques before and after major surgery, which can be viewed as a  model for system-
ic inflammation caused by localised tissue damage/inflammation.
Methods: Five patients scheduled for a total knee or hip replacement were included in 
this prospective observational study. Patients underwent 18F-FDG PET/CT scanning on 
2 separate occasions: one day prior to surgery and 2 days after surgery. Dynamic scans 
were acquired and three venous blood samples were collected during the scan to mea-
sure plasma and whole blood radioactivity concentrations. Simplified measures (stan-
dardized uptake value [SUV] and tissue-to-blood ratio [TBR]) were correlated with 
fully quantitative measures derived from kinetic modeling using the ascending aorta as 
image derived input function. 
Results: Overall, arterial TBR calibrated using venous blood samples showed the stron-
gest correlation with non-linear regression (NLR) based Ki for carotid artery, ascending 
aorta and most diseased segment (R2 > 0.7). Performance of  TBR was not affected by 
major surgery. Only SUV normalized to the area under the curve of  the arterial input 
function (SUVAUC) also correlated well with Ki. All other simplified methods (Patlak, 
uncalibrated TBR and SUVbw) showed no correlation with NLR based Ki (R
2 <0.6) and 
were highly dependent on VOI definition method.
Conclusions: TBR calibrated using venous blood samples could be used as surrogate 
simplified measures to assess changes in 18F-FDG uptake in atherosclerotic plaques of  
patients recovering from major orthopaedic surgery and, more general, patients with 
systemic inflammation. 
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INTRODUCTION
The risk of  atherosclerotic events, such as myocardial infarction and stroke, is deter-
mined by the stability of  atherosclerotic plaques in large arteries which, in turn, cor-
relates with inflammatory activity in these plaques1, 2. 18F-2-fluoro-2-deoxy-D-glucose 
(18F-FDG) positron emission tomography (PET) allows for non-invasive imaging of  in-
flammatory changes in large artery atherosclerosis (particularly carotid, aortic and ile-
ofemoral regions)3, 4. In general, tissue-to-blood ratio (TBR) is used as an indicator of  ar-
terial wall inflammation5. Using this ratio, it has indeed been possible to identify patients 
at risk for vascular events6-8. In addition, this ratio showed high inter- and intra-observer 
agreement and low variability over 2 weeks9, 10.
An area of  particular interest in cardiovascular research is the sharply increased cardio-
vascular event risk during and shortly after acute systemic inflammation, caused by for 
example infection or tissue damage due to trauma or surgery. It has been proposed that 
acute systemic inflammation enhances plaque inflammation2, 11. 18F-FDG PET of  the 
arterial wall appears particularly suited to test this hypothesis in man. However, there is 
an important caveat in the use of  simplified uptake measures, as systemic inflammation 
may modify 18F-FDG kinetics due to competing uptake in inflamed tissues, potential-
ly leading to changes in plasma clearance of  18F-FDG12 13. These changes in plasma 
 kinetics are accounted for when analysing data using full kinetic modeling. This, howev-
er, requires dynamic scanning over a single bed position. For clinical studies survey of  a 
larger part of  the body may be of  interest, but whole body scans can only be analysed 
using simplified 18F-FDG uptake measures. To assess the potential impact of  systemic 
inflammation on the use of  simplified 18F-FDG uptake measures, validation against full 
kinetic modeling is necessary14. The aim of  this study was therefore to assess the validity 
of  simplified quantitative 18F-FDG parameters, such as TBR and SUV, for quantifica-
tion of  inflammation in atherosclerotic plaques before and after major surgery, which 




Patients (n=5) scheduled for total knee or total hip replacement, aged > 65 years, were 
included from the outpatient clinic of  the orthopaedic department of  the VU University 
Medical Center (VUmc). Exclusion criteria were: delirium or other cognitive  impairment 
(acute or chronic) that impaired patient judgement, self-reported or  objective discomfort 
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in supine position, recent myocardial infarction (< 6 months), current infections, current 
use of  corticosteroid or non-steroidal anti-inflammatory drugs, chronic inflammatory 
and/or auto-immune diseases, and renal insufficiency (eGFR <30 mL/min/1.73m2). 
Patients underwent 18F-FDG PET/CT scans on 2 separate occasions: one day prior to 
surgery and 2 days after surgery. Concomitant blood samples were gathered to evaluate 
inflammatory parameters. Written informed consent was obtained and all study pro-
cedures were conform the Helsinki declaration and approved by the VUmc Medical 
Ethics Review Committee. 
PET Imaging
PET/CT scans were obtained using either an Ingenuity TF-128 or a Gemini TF-64 
PET/CT scanner (Philips Healthcare, Eindhoven, The Netherlands), both with an axial 
field of  view of  18.4 cm. In all individual patients both pre- and post-surgery scans were 
obtained using the same scanner. All patients were asked to fast for at least 6 hours prior 
to the PET scan. Patients were scanned arms down and the field of  view was positioned 
over the thorax such that both ascending aorta and carotid arteries where included. First 
a low-dose CT during tidal breathing was performed for attenuation correction, imme-
diately followed by a 60 minutes dynamic 18F-FDG PET scan. At the start of  the latter 
scan a 170 MBq bolus of  18F-FDG (5 mL) was injected at a rate of  0.8 mL/s, which was 
followed by a flush with 35 mL NaCl 0.9% at 2.0 mL/s. The dynamic 18F-FDG data 
were reconstructed into 19 time frames (1x15, 3x5, 3x10, 4x60, 2x150, 2x300, 4x600 s) 
using a 3-dimensional row-action maximum-likelihood reconstruction algorithm15. All 
scans were corrected for dead time, decay, scatter and randoms. During the 18F-FDG 
scan 3 venous blood samples were drawn at 35, 45 and 55 minutes post injection to 
measure plasma and whole blood radioactivity concentrations12. The entire scanning 
procedure was repeated 2 days after surgery. 
PET Data Analysis 
Volumes of  interest (VOIs) were generated for ascending aorta, carotids and visibly most 
diseased segment (MDS) both on low-dose CT and PET images of  the baseline and 
post-surgery 18F-FDG scans. For PET based VOI definition, an early frame (25-30s post 
injection) was used in which the arterial structures were clearly visible. Two different 
methods for delineating the arterial wall of  the ascending aorta were assessed: 1) whole 
aorta, including the lumen, and 2) only the outer 1-2 voxels of  the aorta (Fig. 1). For both 
carotids and MDS only the whole artery was used, as the spatial resolution of  PET/CT 
does not allow for separate delineation of  the arterial wall. Time activity curves (TAC) 
were generated both for each of  the slices in a region (i.e. aorta, carotid or MDS) sepa-
rately and for all slices of  a region combined by projecting the VOIs onto the frames of  
the dynamic PET scan. Image derived input functions (IDIFs) were obtained by placing 
8x8 mm VOIs (2x2 voxels) on the centre of  the ascending aorta in 5 consecutive slices. 
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Again, corresponding TACs were obtained by projecting these VOI onto the dynamic 
PET scan. IDIFs were scaled using whole blood activity concentrations and calibrated 
using the plasma-to-blood radioactivity concentration ratios obtained from the venous 
blood samples (median ratio: 0.92; range: 0.82-1.00).
Non-linear regression (NLR) analyses of  the TACs were analysed using non-linear 
 regression (NLR) and the conventional irreversible 2-tissue compartmental plasma in-
put model with an additional parameter for blood volume. For all VOIs the net rates 
of  influx (Ki) were calculated from the individual rate constants: Ki = K1 ∙ k3 / (k2 + 
k3). In addition, several simplified measurements were derived from the data: SUV cor-
rected for bodyweight (SUVbw), uncalibrated arterial and venous ( TBR, arterial TBR 
calibrated using venous blood samples, SUV normalized to the area under the curve of  
the calibrated arterial input function (SUVAUC) and Patlak based Ki16 (Table 1). Arterial 
and venous tissue-to-blood ratios (TBR) were calculated by normalizing the SUV of  the 
region of  interest to the SUV of  the arterial VOI and the superior vena cava (8x8 mm 
VOIs in 5 consecutive), respectively. All SUV and TBR parameters were calculated for 
two time intervals, i.e. 40-60 and 50-60 min post injection and Patlak was evaluated for 
25-60 and 30-60 min post-injection. 
The two delineation methods for assessing the arterial wall of the ascending aorta. Here only one slice is 
shown, but for analysis VOIs of four consecutive slices were used for both methods. 
Figure 1 .
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Table 1 Simplified parameters
Simplified models
SUVbw Activity concentration in the VOI normalized by injected dose and body-weight
Arterial uncalibrated TBR SUVbw normalized to the same interval of the uncalibrated IDIF of the 
ascending aorta
Venous uncalibrated TBR SUVbw normalized to the same interval of the uncalibrated IDIF of the 
superior vena cava
Calibrated TBR SUVbw normalized to the same interval of the IDIF of the ascending aorta 
calibrated using whole blood and plasma-to-blood radioactivity concen-
trations
SUVauc SUVbw normalized to the area under the calibrated IDIF
Ki Influx rate constant for an irreversible model (min
-1)
Statistical Analysis 
Normality of  the data was assessed visually using quantile-quantile plots and histograms. 
The Wilcoxon signed-rank test was used to assess differences in patient and scan charac-
teristics between both scan time points. Differences in uptake metrics between ascending 
aorta and carotid arteries were evaluated. For all VOIs, simplified uptake metrics were 
compared with corresponding Ki results obtained from linear regression analysis. In 
addition, skewness in the comparison of  these metrics was assessed using Bland-Altman 
plots. These analyses were performed for pre and post-surgery scans separately to iden-
tify any changes in 18F-FDG kinetics over time. All statistical analyses were performed 
using SPSS 20 (IBM Corp., Armonk, NY, US).
RESULTS
Five consecutive patients were included (demographics are presented in Table 2). One 
patient missed the post-surgery scan because he was transferred to another hospital for 
logistical reasons. Baseline scans were obtained at the morning of  surgery, except for 
one, which was performed one day prior to surgery. All follow-up scans were obtained 
2 days post-surgery. 
TBR: tissue-to-blood ratio, IDIF: image derived input function, SUV: standardized uptake value.
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Table 2 Patient’s baseline characteristics
Characteristics
Patients (n) 5
Age (years, range) 74 (70-77)
Male, n (%) 2 (40)
Length (cm) 160 (157-179)
Weight (kg) 68 (59-83)
Injected activity scan 1 (MBq) 161.8 (149-181)
Injected activity scan 2 (MBq) 163.7 (150-172)
Current smoking, n (%) 1 (20)
Hypercholesterolemia 1 (20)
Hypertension, n (%) 3 (60)
Diabetes Mellitus, n (%) 1 (20)
History of CVE, n (%) 2 (40)
Prior CVA, n (%) 2 (40)
Prior MI, n (%) 1 (20)
Laboratory data
Platelets 10E9/L 198 [181-220]
Leucocytes 10E9/L 52 [51-70]
Lymphocytes 10E9/L 171 [90-213]
Neutrophilic granulocytes 10E9/L 2.8 [2.8-4.2]
CRP mg/L 15 [4-31]
ESR mm/hour 4 [3-17]
Total cholesterol mmol/L 4.2 [3.0-5.2]
HDL cholesterol mmol/L 1.2 [0.97-1.6]
LDL cholesterol mmol/L 2.2 [1.7-3.0]
Triglycerides mmol/L 1.0 [0.8-1.6]
Variable represent median [interquartile range] or percentage of total patients (%). CVE, cardiovascular event; 
CVA, cerebral vascular event; MI, myocardial infarction; CRP, C-reactive protein; ESR erythrocyte sediment 
rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
Non Linear Regression
Typical TACs of  arterial wall, carotid artery and MDS with associated NLR fits are 
shown in Fig. 2. As expected a high blood volume fraction was seen (Vb ~ 0.41 ± 0.20). 
The large blood pool within or near the VOI may compromise the precision of  the 
fitted rate constants. 46 of  the 390 VOIs had to be excluded because of  a high degree 
of  uncertainty in estimating the individual kinetic parameters K1, k2, k3 and Vb (SD >2 
times the parameter). Results of  both full kinetic modeling and simplified methods can 
be found in Table 3. 
Validation of  simplified 18F-FDG uptake metrics for quantitative assessment 
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Simplified Methods
Arterial TBR calibrated using venous blood samples showed the strongest correlation 
with NLR based Ki for all tissues and strong correlations for both pre- and post-surgery 
were found for PET-based VOIs of  the carotid arteries (R2: 0.78 – 0.79), ascending 
aorta (R2: 0.73 – 0.90) and MDS (R2: 0.92 – 0.95) (Fig. 3-5 and supplementary data). 
Bland-Altman plots showed that data were not skewed (not shown). A difference in ac-
curacy between pre- and post-surgery scans was seen only for the ascending aorta, pri-
marily affecting the CT based VOIs (R2: 0.57 vs. 0.90) (Table 4). This discrepancy was 
not seen for MDS, although (in the denominator) the ascending aorta was also used for 
all these VOIs. VOI delineation methods (wall only vs. whole artery) have a limited effect 
on calibrated TBR performance as seen in Table 4. In contrast to expectations the ef-
fects of  analyzing per slice or stack of  slices were limited. Two outliers in the correlation 
between NLR based Ki and arterial calibrated TBR (>2 SD) were excluded from the 
reported R2 (Fig. 3 and 5). If  these regions were included, accuracy of  calibrated TBR 
slightly decreased for the carotid arteries (R2 >0.67 vs. R2 >0.74) and MDS (R2  >0.80 
vs. R2 >0.88) (supplemental Table 1). An overview of  the results of  all possible combi-
nations of  the delineation and analyses methods mentioned above for each of  the ana-
tomical regions can be found in supplemental Table 2-4.
When SUVAUC, instead of  calibrated TBR, was used for quantification of  
18F-FDG up-
take, similar correlations with Ki were found, and R
2 remained ≥ 0.7 for most VOI 
delineation methods. The effect of  delineation method (wall only vs. whole artery) on 
performance of  SUVAUC was larger than for calibrated TBR. Patlak based Ki showed a 
weak correlation with the NLR based Ki for all time intervals (R
2 < 0.6). Moreover, high 
variability between pre- and post-surgery results was seen, as well as within different 
tissues and VOI methods. 
Using only static images without venous blood sample data decreases correspondence 
with NLR Ki. Correlation of  SUVbw with NLR Ki was poor independent of  VOI defi-
nition method or time interval after injection used (R2 < 0.5). This was also true for 
both baseline and post-surgery measures separately. Normalizing SUV of  the region of  
interest to either arterial or venous blood SUV to obtain uncalibrated TBR improved 
correlation for certain cases (Table 3). Yet, large variability in performance between 
different regions was seen (R2: <0.3 – 0.9) with, in general, improvements limited to 
carotid arteries. Moreover, large but inconsistent differences were seen between pre- 
and post-surgery scans. TBR values were similar when normalized to either arterial or 
venous blood activity. 
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Table 4 Correlation of various simplified methods with Ki derived from non-linear regression.
* For the Carotid artery only the whole artery was assessed, TBR: Tissue-to-blood ratio, SUVAUC: SUV nor-
malized to the area under the curve of the calibrated arterial input function
 Carotid artery Ascending aorta MDS
 Baseline Post-surgery Baseline Post-surgery Baseline Post-surgery
Simplified models R2 Slope R2 Slope R2 Slope R2 Slope R2 Slope R2 Slope
PET or CT based VOI             
Calibrated TBR (PET) 0.78 92.9 (71.7-114.1) 0.79 123.4 (90.6-156.2) 0.73 43.8 (35.0-52.6) 0.90 68.7 (59.9-77.6) 0.92 81.8 (72.5-91.0) 0.95 87.4 (77.8-97.0)
Calibrated TBR (CT) 0.82 91.0 (72.6-109.3) 0.88 113.3 (91.8-134.9) 0.57 47.0 (34.6-59.5) 0.90 64.2 (54.9-73.4) 0.87 67.9 (58.2-77.5) 0.90 86.4 (73.1-99.7)
SUVAUC (PET) 0.81 1.09 (0.8-1.31) 0.73 1.00 (0.70-1.32) 0.60 0.37 (0.27-0.46) 0.86 0.68 (0.58-0.79) 0.88 0.87 (0.75-0.98) 0.90 0.64 (0.54 -0.73)
SUVAUC (CT) 0.86 1.09 (0.90-1.27) 0.86 0.96 (0.76-1.15) 0.56 0.42 (0.30-0.53) 0.82 0.66 (0.52 -0.80) 0.83 0.70 (0.59-0.817) 0.82 0.62 (0.49-0.75)
Arterial uncalibrated TBR (PET) 0.52 51.7 (30.4-73.0) 0.45 74.0 (32.3-115.7) 0.33 19.6 (10.3-28.8) 0.54 27.1 (17.4-36.8) 0.71 45.4 (34.7-56.2) 0.49 30.0 (16.18 -43.8)
Arterial uncalibrated TBR (CT) 0.89 78.0 (66.3-89.8) 0.71 87.9 (58.8-116.9) 0.30 27.1 (14.2-39.9) 0.45 24.6 (12.6-36.5) 0.64 32.2 (23.5-40.9) 0.27 27.7 (7.18 -48.3)
Venous uncalibrated TBR (PET) 0.35 84.4 (34.6-134.3) 0.32 61.0 (15.5-106.5) 0.47 25.1 (16.3 33.9) 0.37 19.3 (9.5-29.0) 0.29 36.6 (15.3 -57.8) 0.04 6.27 (-7.54-20.1)
Venous uncalibrated TBR (CT) 0.64 86.0 (58.2-113.9) 0.54 76.2 (39.9-112.4) 0.29 27.8 (14.3-41.41) 0.25 16.8 (3.84-29.7) 0.22 24.9 (7.8-41.9) 0.01 3.23 (-18.5-25.0)
Wall only or whole artery             
Calibrated TBR (Wall)* - - - - 0.68 50.7 (40.0-61.4) 0.95 75. 8 (68.8-82.8) 0.83 77.1 (63.1-91.0) 0.88 81.7 (67.2-96.1)
Calibrated TBR (Whole) 0.81 91.3 (78.5-104.2) 0.83 114.0 (96.3-131.7) 0.69 29.6 (23.1 -36.1) 0.88 54.5 (45.6-63.3) 0.91 73.1 (65.1-81.1) 0.96 94.8 (86.9-102.7)
SUVAUC (Wall)* - - - - 0.72 0.43 (0.35-0.52) 0.90 0.74 (0.64-0.84) 0.83 0.73 (0.60-0.86) 0.86 0.59 (0.47 -0.70)
SUVAUC (Whole) 0.85 1.09 (0.95-1.22) 0.80 0.95 (0.79 -1.11) 0.64 0.20 (0.15-0.25) 0.81 0.58 (0.45-0.70) 0.86 0.79 (0.68-0.89) 0.88 0.70 (0.59-0.81)
Arterial uncalibrated TBR (Wall)* - - - - 0.51 26.2 (18.1-34.2) 0.80 36.2 (29.1 -43.3) 0.50 36.1 (22.0-50.2) 0.55 21.9 (12.1-31.8)
Arterial uncalibrated TBR (Whole) 0.80 71.8 (61.5-82.1) 0.60 81.4 (59.1-103.7) 0.05 5.85 (-2.84 -14.5) 0.32 11.7 (4.22-19.2) 0.72 39.5 (31.4-47.6) 0.33 37.8 (15.1-60.5)
Venous uncalibrated TBR (Wall)* - - - - 0.46 29.6 (19.7-39.6) 0.78 25.1 (19.7-30.5) 0.19 -5.85 (-22.6 -10.9) 0.00 0.65 (-11.0-12.3)
Venous uncalibrated TBR (Whole) 0.54 85.7 (62.6-108.7) 0.46 70.0 (44.1-95.9) 0.11 10.0 (1.71-18.3) 0.15 8.10 (-0.46-16.7) 0.39 41.0 (24.3-57.6) 0.04 11.5 (-11.9-35.0)
Multiple slices or per slice             
Calibrated TBR (Multiple slices) 0.72 84.9 (41.6-128.2) 0.74 121.9 (49.3-194.5) 0.54 42.7 (21.7-63.7) 0.94 67.7 (55.3-80.1) 0.89 24.7 (57.4-86.9) 0.93 92.5 (71.5-113.6)
Calibrated TBR (Per slice) 0.83 92.1 (78.2-106.1) 0.85 112.2 (94.2-130.2) 0.69 45.5 (37.9-53.1) 0.90 66.6 (59.4-73.7) 0.89 74.5 (66.8-82.1) 0.92 85.6 (76.7-94.6)
SUVAUC (Multiple slices) 0.84 1.08 (6.70-1.47) 0.68 0.96 (0.30-1.62) 0.47 0.36 (0.16-0.57) 0.88 0.75 (0.54-0.96) 0.85 0.75 (0.56-0.93) 0.88 0.65 (0.45 -0.85)
SUVAUC (Per slice) 0.85 1.09 (0.94-1.23) 0.83 0.95 (0.79-1.12) 0.61 0.39 (0.31 -0.47) 0.84 0.66 (0.67-0.75) 0.86 0.79 (0.70-0.88) 0.85 0.62 (0.53-0.71)
Arterial uncalibrated TBR (Multiple slices) 0.79 63.04 (36.7-89.4) 0.44 72.7 (-8.98-154.4) 0.24 20.8 (1.01-40.6) 0.36 21.3 (0.02-42.5) 0.64 37.9 (21.7-54.0) 0.35 27.8 (-3.41-58.9)
Arterial uncalibrated TBR (Per slice) 0.81 72.9 (61.2-84.5) 0.64 83.3 (59.2-107.2) 0.32 22.6 (14.3-30.8) 0.52 26.8 (18.7-34.9) 0.69 39.4 (31.8-47.1) 0.36 29.3 (15.7-42.9)
Venous uncalibrated TBR (Multiple slices) 0.43 86.9 (5.72-168.0) 0.31 57.3 (-28.2-142.8) 0.24 23.9 (1.02-46.8) 0.11 14.5 (-7.44-36.5) 0.20 24.7 (-3.98-53.3) 0.00 0.68 (-29.2-30.6)
Venous uncalibrated TBR (Per slice) 0.56 85.4 (60.4-110.4) 0.49 72.1 (44.0-101.4) 0.39 26.5 (18.3-34.7) 0.33 18.9 (10.5-27.4) 0.30 33.9 (19.0-48.9) 0.02 6.00 (-8.51-20.4)
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 Carotid artery Ascending aorta MDS
 Baseline Post-surgery Baseline Post-surgery Baseline Post-surgery
Simplified models R2 Slope R2 Slope R2 Slope R2 Slope R2 Slope R2 Slope
PET or CT based VOI             
Calibrated TBR (PET) 0.78 92.9 (71.7-114.1) 0.79 123.4 (90.6-156.2) 0.73 43.8 (35.0-52.6) 0.90 68.7 (59.9-77.6) 0.92 81.8 (72.5-91.0) 0.95 87.4 (77.8-97.0)
Calibrated TBR (CT) 0.82 91.0 (72.6-109.3) 0.88 113.3 (91.8-134.9) 0.57 47.0 (34.6-59.5) 0.90 64.2 (54.9-73.4) 0.87 67.9 (58.2-77.5) 0.90 86.4 (73.1-99.7)
SUVAUC (PET) 0.81 1.09 (0.8-1.31) 0.73 1.00 (0.70-1.32) 0.60 0.37 (0.27-0.46) 0.86 0.68 (0.58-0.79) 0.88 0.87 (0.75-0.98) 0.90 0.64 (0.54 -0.73)
SUVAUC (CT) 0.86 1.09 (0.90-1.27) 0.86 0.96 (0.76-1.15) 0.56 0.42 (0.30-0.53) 0.82 0.66 (0.52 -0.80) 0.83 0.70 (0.59-0.817) 0.82 0.62 (0.49-0.75)
Arterial uncalibrated TBR (PET) 0.52 51.7 (30.4-73.0) 0.45 74.0 (32.3-115.7) 0.33 19.6 (10.3-28.8) 0.54 27.1 (17.4-36.8) 0.71 45.4 (34.7-56.2) 0.49 30.0 (16.18 -43.8)
Arterial uncalibrated TBR (CT) 0.89 78.0 (66.3-89.8) 0.71 87.9 (58.8-116.9) 0.30 27.1 (14.2-39.9) 0.45 24.6 (12.6-36.5) 0.64 32.2 (23.5-40.9) 0.27 27.7 (7.18 -48.3)
Venous uncalibrated TBR (PET) 0.35 84.4 (34.6-134.3) 0.32 61.0 (15.5-106.5) 0.47 25.1 (16.3 33.9) 0.37 19.3 (9.5-29.0) 0.29 36.6 (15.3 -57.8) 0.04 6.27 (-7.54-20.1)
Venous uncalibrated TBR (CT) 0.64 86.0 (58.2-113.9) 0.54 76.2 (39.9-112.4) 0.29 27.8 (14.3-41.41) 0.25 16.8 (3.84-29.7) 0.22 24.9 (7.8-41.9) 0.01 3.23 (-18.5-25.0)
Wall only or whole artery             
Calibrated TBR (Wall)* - - - - 0.68 50.7 (40.0-61.4) 0.95 75. 8 (68.8-82.8) 0.83 77.1 (63.1-91.0) 0.88 81.7 (67.2-96.1)
Calibrated TBR (Whole) 0.81 91.3 (78.5-104.2) 0.83 114.0 (96.3-131.7) 0.69 29.6 (23.1 -36.1) 0.88 54.5 (45.6-63.3) 0.91 73.1 (65.1-81.1) 0.96 94.8 (86.9-102.7)
SUVAUC (Wall)* - - - - 0.72 0.43 (0.35-0.52) 0.90 0.74 (0.64-0.84) 0.83 0.73 (0.60-0.86) 0.86 0.59 (0.47 -0.70)
SUVAUC (Whole) 0.85 1.09 (0.95-1.22) 0.80 0.95 (0.79 -1.11) 0.64 0.20 (0.15-0.25) 0.81 0.58 (0.45-0.70) 0.86 0.79 (0.68-0.89) 0.88 0.70 (0.59-0.81)
Arterial uncalibrated TBR (Wall)* - - - - 0.51 26.2 (18.1-34.2) 0.80 36.2 (29.1 -43.3) 0.50 36.1 (22.0-50.2) 0.55 21.9 (12.1-31.8)
Arterial uncalibrated TBR (Whole) 0.80 71.8 (61.5-82.1) 0.60 81.4 (59.1-103.7) 0.05 5.85 (-2.84 -14.5) 0.32 11.7 (4.22-19.2) 0.72 39.5 (31.4-47.6) 0.33 37.8 (15.1-60.5)
Venous uncalibrated TBR (Wall)* - - - - 0.46 29.6 (19.7-39.6) 0.78 25.1 (19.7-30.5) 0.19 -5.85 (-22.6 -10.9) 0.00 0.65 (-11.0-12.3)
Venous uncalibrated TBR (Whole) 0.54 85.7 (62.6-108.7) 0.46 70.0 (44.1-95.9) 0.11 10.0 (1.71-18.3) 0.15 8.10 (-0.46-16.7) 0.39 41.0 (24.3-57.6) 0.04 11.5 (-11.9-35.0)
Multiple slices or per slice             
Calibrated TBR (Multiple slices) 0.72 84.9 (41.6-128.2) 0.74 121.9 (49.3-194.5) 0.54 42.7 (21.7-63.7) 0.94 67.7 (55.3-80.1) 0.89 24.7 (57.4-86.9) 0.93 92.5 (71.5-113.6)
Calibrated TBR (Per slice) 0.83 92.1 (78.2-106.1) 0.85 112.2 (94.2-130.2) 0.69 45.5 (37.9-53.1) 0.90 66.6 (59.4-73.7) 0.89 74.5 (66.8-82.1) 0.92 85.6 (76.7-94.6)
SUVAUC (Multiple slices) 0.84 1.08 (6.70-1.47) 0.68 0.96 (0.30-1.62) 0.47 0.36 (0.16-0.57) 0.88 0.75 (0.54-0.96) 0.85 0.75 (0.56-0.93) 0.88 0.65 (0.45 -0.85)
SUVAUC (Per slice) 0.85 1.09 (0.94-1.23) 0.83 0.95 (0.79-1.12) 0.61 0.39 (0.31 -0.47) 0.84 0.66 (0.67-0.75) 0.86 0.79 (0.70-0.88) 0.85 0.62 (0.53-0.71)
Arterial uncalibrated TBR (Multiple slices) 0.79 63.04 (36.7-89.4) 0.44 72.7 (-8.98-154.4) 0.24 20.8 (1.01-40.6) 0.36 21.3 (0.02-42.5) 0.64 37.9 (21.7-54.0) 0.35 27.8 (-3.41-58.9)
Arterial uncalibrated TBR (Per slice) 0.81 72.9 (61.2-84.5) 0.64 83.3 (59.2-107.2) 0.32 22.6 (14.3-30.8) 0.52 26.8 (18.7-34.9) 0.69 39.4 (31.8-47.1) 0.36 29.3 (15.7-42.9)
Venous uncalibrated TBR (Multiple slices) 0.43 86.9 (5.72-168.0) 0.31 57.3 (-28.2-142.8) 0.24 23.9 (1.02-46.8) 0.11 14.5 (-7.44-36.5) 0.20 24.7 (-3.98-53.3) 0.00 0.68 (-29.2-30.6)
Venous uncalibrated TBR (Per slice) 0.56 85.4 (60.4-110.4) 0.49 72.1 (44.0-101.4) 0.39 26.5 (18.3-34.7) 0.33 18.9 (10.5-27.4) 0.30 33.9 (19.0-48.9) 0.02 6.00 (-8.51-20.4)
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Arterial TBR (tissue-to-blood ratio) calibrated using venous blood samples plotted against Ki obtained from the 
carotid artery using an irreversible two-tissue compartment model A: for PET and B: CT based VOIs. Linear 
regression analysis shown are for the single slice data points. Moreover, the outlier (>3 SD) is excluded from 
the linear regression analysis. (Blue: baseline; Red: post-surgery; ∆: multiple slices; O: single slice; * Outlier 
(single slice)). 
Figure 3 .
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Arterial TBR (tissue-to-blood ratio) calibrated using venous blood samples plotted against Ki obtained from 
the ascending aorta using an irreversible two-tissue compartment model for PET based VOIs including A: 
wall only, B: the whole artery and for CT based VOIs including C: wall only and D: the whole artery. Linear 
regression analysis shown are for the single slice data points. (Blue: baseline; Red: post-surgery; ∆: multiple 
slices; O: single slice).
Figure 4 .
Proefschrift_v10.0.indd   118 02-11-17   12:14
119
Arterial TBR (tissue-to-blood ratio) calibrated using venous blood samples plotted against Ki obtained from 
the most diseased segment (MDS) using an irreversible two-tissue compartment model for PET based VOIs 
including A: wall only, B: the whole artery and for CT based VOIs including C: wall only and D: the whole 
artery. Linear regression analysis shown are for the single slice data points. Moreover, the outlier (>3 SD) is 
excluded from the linear regression analysis. (Blue: baseline; Red: post-surgery; ∆: multiple slices; O: single 
slice; * Outlier (single slice)).
Figure 5 .
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DISCUSSION
This study investigated whether simplified 18F-FDG measures can be used as surrogate 
markers for quantitative analysis of  inflammation in atherosclerotic lesions before and 
after acute systemic inflammation in patients undergoing major orthopaedic surgery. 
Normalizing SUV to image derived arterial blood pool activity concentrations calibrat-
ed using venous blood samples, allowed for accurate quantification showing consistent 
results before and after surgery independent of  VOI definition. Therefore, this sim-
plified measure seems to be the method of  choice for evaluating changes in 18F-FDG 
uptake in the vessel wall due to major orthopaedic surgery across the whole body. With 
exception of  SUVAUC all other simplified methods showed either poor correlation with 
corresponding NLR results or high variability in performance of  different VOI defini-
tion methods for different tissue types without a clear preference. Furthermore, results 
were similar for pre- and post-surgery scans separately, suggesting no significant effects 
of  surgery on the accuracy of  simplified 18F-FDG uptake metrics. 
Accurate quantification of  18F-FDG uptake in the arterial wall using SUVbw was not 
feasible due to high blood background activity. Therefore, SUV corrected for back-
ground activity derived from the vena cava superior is often used as semi-quantitative 
measure to evaluate arterial wall inflammation 10. In the present study, however, large 
variation was seen in the correlation of  uncalibrated TBR with NLR. Correcting TBR 
using whole blood and plasma-to-blood radioactivity concentrations measured in ve-
nous blood samples enhanced correlation for all tissues and VOI types. As plasma-to-
blood radioactivity concentrations are stable over time, calibration using a single sample 
should be sufficient. Nevertheless, more blood samples are advised to avoid inaccurate 
quantification due to sampling errors. Blood samples can be drawn from the injection 
site after adequate flushing thereby limiting patient burden, whilst significantly increas-
ing quantitative accuracy17.
TBR corrected for blood activity concentrations were evaluated using both vena cava 
superior and ascending aorta. Although no clear differences were seen in performance, 
the ascending aorta could have some potential advantages over the vena cava. One of  
these potential advantages is the generally larger diameter of  the ascending aorta18, 19, 
which may decrease the effects of  motion and partial volume effects on accurate quan-
tification and ease VOI definition. In addition, from a pharmacokinetic point of  view 
arterial blood would be preferred, as this resembles tracer delivery to the target region20. 
Even if  the blood pool is only used to correct for background as is done in other articles, 
spill-in from the arterial blood pool into the VOI will probably be more abundant and 
therefore reflect true spill-in more accurately than in the vena cava. 
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Accurate quantification of  18F-FDG uptake is also possible although SUVAUC,  although 
this was inferior to calibrated TBR. In addition, quantification using SUVAUC requires 
an additional (dynamic) scan over the heart and therefore increases patient burden and 
costs. The same applies to the measurement of  Patlak based Ki, which requires a dy-
namic scan protocol and, therefore, is not applicable for whole body studies. Quantita-
tive performance of  Patlak in the present study was poor, probably due to the high Vb 
fractions. In contrast to full kinetic modeling, for Patlak all activity within the VOI is al-
located to the Ki, including those belonging to Vb. Variability of  Vb within and between 
patients increases variation and hampering the performance of  Patlak. 
The low spatial resolution is one of  the challenges when assessing the arterial wall using 
PET. Delineation of  the wall without including (spill-over from) adjacent structures is 
impossible, especially for smaller arteries. In addition, manual delineation of  the arterial 
wall is more cumbersome than using the entire artery, and a VOI containing only arteri-
al wall may also be more susceptibility to motion artefacts. On the other hand, inclusion 
of  non-arterial wall tissues leads to a higher 18F-FDG background signal, potentially 
leading to a loss in sensitivity for detecting a specific signal. An advantage of  calibrated 
TBR compared with the other simplified methods was its strong correlation with full 
kinetic modeling, independent of  VOI definition. Both delineation methods are techni-
cally feasible and further studies are needed to identify the optimal delineation method 
under different conditions. 
Results of  the present study may be relevant for other conditions with systemic inflam-
mation caused by localised tissue damage/inflammation. Nevertheless, for other inter-
ventions, these simplified methods need to be assessed again, as different interventions 
may alter pharmacokinetics in different ways and thus affect the correlation between 
simplified measures and NLR21. 
CONCLUSION
In patients suffering from systemic inflammation, accurate quantification of  the arterial 
wall is feasible using image derived arterial TBR calibrated using venous blood samples. 
Performance of  this calibrated TBR method is insensitive to VOI definition. Other sim-
plified methods, such as uncalibrated TBR and SUV, do not provide accurate uptake 
measures.
Validation of  simplified 18F-FDG uptake metrics for quantitative assessment 
of  inflammation in atherosclerotic plaques after major surgery
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ABSTRACT
Background: The risk of  cardiovascular events is sharply elevated in the first days after 
major surgery. The cause of  this increased risk is unknown, but its acuteness suggests in-
creased plaque inflammation and subsequent plaque instability. [18F]-2-fluoro-2- deoxy-
D-glucose (FDG) imaging using positron-emission tomography (PET)/computed to-
mography (CT) provides a noninvasive assessment of  large-artery plaque inflammation. 
This study assesses whether major orthopedic surgery causes increased inflammation in 
atherosclerotic lesions. 
Methods: In this prospective observational multi-center study, patients scheduled for 
total knee or total hip replacement undergo 18F-FDG-PET/CT scanning on 2 separate 
occasions: one day prior to surgery and 2 days after surgery. Venous blood samples 
are collected twice during the scanning procedure to measure plasma and whole-blood 
radioactivity concentrations in order to calibrate tissue-to-blood ratio [TBR]) for the 
aorta, carotid artery and the most diseased segment of  these arteries. The first 4 patients 
of  a larger scheduled group (n=20) are included in this preliminary report.
Results: Ki (influx rate constant of  
18F-FDG-uptake) after surgery for all arterial regions 
combined is lower, but not significantly, compared to pre-surgery (Median: 0.0075 vs. 
0.0064; P = 0.053). The correlation between absolute as well as relative change in Ki 
and calibrated TBR after surgery is strong (R2 >0.7). A significant decrease in TBR after 
surgery is observed for the ascending aorta as well as all regions combined (P ≤ 0.007), 
but the change in uptake after surgery is not statistically significant for the carotid artery 
and the most-diseased segment separately. 
Conclusions: These preliminary findings do not suggest an increase of  FDG-activity in 
the large vessels after surgery. On the contrary, this interim-analysis suggests a decrease 
of  inflammation in the aorta as a result of  major orthopaedic surgery, which most likely 
not related to putative competitive uptake by surgery-induced tissue damage. 
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INTRODUCTION
The risk of  cardiovascular events, mainly acute coronary syndrome and ischemic stroke, 
is sharply elevated in the first days after major surgery. A recent cohort study suggested 
that the risk of  myocardial infarction in patients undergoing total hip or knee replace-
ment is increased by no less than 25-fold, predominantly during the first weeks1. The 
acuteness of  the increased risk suggests plaque instability, which is closely correlated 
with the degree of  intra-plaque inflammation2. Major surgery is also associated with a 
marked systemic inflammatory response (the median C-reactive protein on day 3 after 
knee arthroplasty, is 189 mg/dl3). It thus has been hypothesized that intra-plaque inflam-
mation may occur as a result of  systemic inflammation. Indeed, we recently found that 
plaques become larger and show an increased necrotic core days after major orthopedic 
surgery in an atherosclerotic mice model4. The exact role of  intra-plaque inflammation 
however remains elusive. There are, to date, no human studies to assess the role of  in-
tra-plaque inflammation following major surgery. 
Recent developments in 18F-fluorodeoxuglucose positron emission tomography 
(18F-FDG-PET) allow for non-invasive imaging of  inflammatory changes in large artery 
atherosclerosis (particularly carotid, aortic and ileofemoral regions)5. Carotid 18F-FDG 
uptake was shown to be strongly correlated with macrophage density using CD68 im-
munohistochemistry6. Target-to-background ratio (TBR) of  18F-FDG activity is an in-
dicator of  arterial wall/plaque inflammation7, and identifies patients at risk for future 
vascular events8-10, 11. It is based on the standardized uptake value (SUV) ratio of  a de-
fined region of  interest (ROI) over the background activity, usually derived from the 
superior vena cava11, 12. We recently showed that calibrated TBR using 18F-FDG activity 
measured in venous blood samples can be used as surrogate simplified measures to assess 
changes in 18F-FDG uptake in atherosclerotic plaques of  patients recovering from ma-
jor orthopaedic surgery (under review). This allows us to assess the role of  generalized 
plaque inflammation as measured with large-artery 18F-FDG PET/CT as a contributor 
to cardiovascular event risk in patients recovering from major surgery. 
METHODS
Besides being scheduled for total knee replacement or total hip replacement, patients 
had to be above 65 years since these patients are likely to have 18F-FDG positive ath-
erosclerotic lesions10, 13, 14. Exclusion criteria are delirium or other cognitive impairment 
(acute or chronic) that impairs patient judgement, self-reported or objective discomfort 
in the supine position, recent myocardial infarction (< 6 months), current infection, 
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current corticosteroid use, chronic inflammatory diseases and/or auto-immune diseases, 
renal insufficiency (eGFR <30 mL/min/1.73m2).
PET/CT scans are obtained using either an Ingenuity TF-128 or a Gemini TF-64 
PET/CT scanner (Philips Healthcare, Eindhoven, The Netherlands). In all individual 
patients the pre- and post-surgery scan are obtained with the same scanner. All patients 
are asked to fast at least 6 hours prior to the PET scan. Patients are scanned arms down 
and the field of  view was positioned over the thorax such that both ascending aorta and 
carotid arteries are included. First a low-dose CT during tidal breathing is performed 
for attenuation correction, directly followed by a 60 minutes dynamic 18F-FDG PET 
scan (170 ± 17 MBq). 18F-FDG (5 mL) is injected at a rate of  0.8 mL/s, and flushed 
with 35 mL NaCl 0.9% at 2.0 mL/s. The dynamic 18F-FDG data are reconstructed into 
19 time frames (1x15, 3x5, 3x10, 4x60, 2x150, 2x300, 4x600 s) using a 3-dimensional 
row-action maximum-likelihood reconstruction algorithm (3D-ramla) (voxel size 4x4x4 
mm)15. All scans are corrected for usual corrections such as dead time, decay, scatter and 
randoms. During the 18F-FDG scan 3 venous blood samples are drawn at 35, 45 and 
55 minutes post injection to measure plasma and whole blood radioactivity concen-
trations16. Weight, height, total injected activity, time of  injection, residual activity and 
exact scan start time of  both time points are recorded for each session.
PET Data Analysis 
Volumes of  interest (VOIs) are drawn on PET images of  the baseline and post-surgery 
18F-FDG scan. VOIs are generated for the ascending aorta and the carotids in order to 
quantify diffuse uptake in these vessels. Additionally, a VOI is generated in the visibly 
most diseased segment (MDS) in either the aorta or in one of  the carotid arteries. We 
assess two different delineation methods for the ascending aorta and MDS: 1. Including 
the whole artery (including the lumen); 2. Including only the outer 1-2 voxels of  the 
aorta. For the carotids, the whole artery is used as the spatial resolution of  the PET/
CT scan does not allow for separate delineation of  the arterial wall. For these VOIs, 
time activity curves (TACs) are generated for each of  the slices individually in a region 
(i.e.  aorta, carotid or MDS) as well as for all slices of  a region combined by projecting 
them onto the frames of  the dynamic PET scan.
Image derived input functions (IDIFs) are obtained by placing a 8x8mm VOI (2x2 vox-
els) on the centre of  the ascending aorta in 5 consecutive slices. Corresponding TACs 
are obtained by projecting the VOI onto the dynamic PET scan. IDIFs are scaled using 
whole blood activity concentrations and calibrated using the plasma-to-blood radioac-
tivity concentration ratios obtained from the venous blood samples (median ratio: 0.92; 
range: 0.82-1.00).
Non-linear regression (NLR) analysis of  the TACs is performed using the conventional 
irreversible 2-tissue compartmental plasma input model (2T3K) with an additional cor-
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rection parameter for blood volume (Vb) (Fig. 1). For all VOIs the net rates of  influx rates 
(Ki) are calculated from the individual rate constants: Ki = K1 ∙ k3 / (k2 + k3). In addition, 
TBR is calculated by normalizing the SUV to the bloodpool activity in the aorta. The 
latter is obtained by placing a 8x8mm VOI in 5 consecutive planes of  the ascending 
aorta and calibrated using venous blood samples. TBR is calculated for the time interval 
of  50-60 min post injection.
Statistical Analysis 
Normality of  the data is assessed visually using quantile-quantile plots and histogram 
analyses. The Wilcoxon signed-rank test is used to assess differences in patient- and scan 
characteristics between both scan time points. A Wilcoxon signed rank test is used to test 
for significant differences in mean uptake between the pre- and post-surgery scan. P val-
ues of  less than 0.05 are considered significant. In addition, linear regression analysis is 
used to evaluate the correlation in between change in full kinetic outcome measures and 
TBR. All statistical analyses were performed using IBM SPSS Statistics for Windows, 
Version 21.0. (IBM Corp, Armonk, NY, USA).
RESULTS
Patients characteristics
Four consecutive patients were included in this preliminary report. Demographic char-
acteristics are presented in Table 1. Baseline scans were obtained on the morning of  
surgery or, in 1 patient, one day prior to surgery. All follow-up scans were obtained 
2 days post-surgery.
Table 1 Patient’s baseline characteristics
Characteristics
Patients (n) 4
Age (years, range) 75 (70-78)
Male, n (%) 1 (25)
BMI (kg/m2) 25.4 (24.1-26.3)
Current smoking, n (%) 1 (25)
Diabetes Mellitus, n (%) 1 (25)
History of CVD, n (%) 2 (50)
Stroke, n (%) 2 (50)
Prior MI, n (%) 1 (25)
Variable represent median [interquartile range] or percentage of total patients (%). BMI, body mass index; 
CVD, cardiovascular disease; MI, myocardial infarction
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Table 2 Laboratory data
Variable represent median [interquartile range]. CRP, C-reactive protein; ESR erythrocyte sediment rate; HDL, 
high density lipoprotein; LDL, low density lipoprotein. 
Laboratory data Pre-surgery Post-surgery
Leucocytes 10E9/L 6.0 [5.2-7.1] 9.0 [3.0-9.6]
Neutrophilic granulocytes 10E9/L 4.0 [2.8-4.3] 7.2 [6.8-7.9]
CRP mg/L 22 [7-33] 116 [40-262]
ESR mm/hour 4 [2-17] 51 [23-93]
Total cholesterol mmol/L 3.8 [2.8-4.4] 2.9 [2.2-3.9]
HDL cholesterol mmol/L 1.1 [0.94-1.6] 1.2 [0.87-1.4]
LDL cholesterol mmol/L 2.1 [1.5-2.5] 1.3 [0.85-2.1]
Triglycerides mmol/L 0.9 [0.8-1.3] 1.0 [0.65-1.2]
Parameters of  inflammation and serum lipids
To determine whether major orthopedic surgery is indeed accompanied by an acute 
systemic inflammatory response, we measured several parameters of  inflammation at 
baseline and 2 days after surgery. CRP, leucocytes, neutrophilic granulocytes and ESR 
were all increased (Table 2). Serum lipids remained unchanged, besides a moderate 
decrease in LDL cholesterol.
18F-FDG Quantitative Uptake Metrics
In every patients at least one area of  increased 18F-FDG could be distinguished (MDS). 
No new focal arterial uptake was seen post-surgery. Ki after surgery for all regions com-
bined was borderline significantly lower than pre-surgery (median: 0.0075 vs. 0.0064; 
P  = 0.053) (Fig. 2 and Table 3). Separate assessment per arterial region suggested that 
this decrease was mainly caused by a lower post-operative Ki of  the ascending aorta 
(P  = 0.052 vs. P >0.26 for carotid artery and MDS). 
The correlation between absolute as well as relative change in Ki and calibrated TBR 
after surgery was strong (R2 > 0.7) (Fig. 3). The decrease in calibrated TBR after sur-
gery was significantly different for the ascending aorta as well as all regions combined 
(P  ≤  0.007). Change in uptake after surgery was not statistically significant for the ca-
rotid artery and the MDS. 
With exception of  K1 all other pharmacokinetic parameters showed a significant change 
when all regions were combined (P <0.04). When assessed separately, differences were 
only seen in one of  the regions for each of  these parameters respectively (Table 3). 
Change in K1 after surgery did not correlate with change in Ki or TBR (Fig. 4). 
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DISCUSSION
This chapter describes the study protocol and initial results of  an 18F-FDG-PET study 
designed to assess if  major surgery can induce inflammatory activity in arterial wall, 
particularly in atherosclerotic lesions. Clearly, solid conclusions based on this inter-
im-analysis (n=4 patients) cannot be drawn. Nevertheless, these preliminary results sug-
gest that major orthopedic surgery does not evoke an increase of  FDG-activity in the 
large vessels. In fact, the initial data point towards a decrease of  inflammation in the 
aorta as a result of  major orthopaedic surgery. If  this indeed proves to be the conclusion, 
two explanations might be plausible:
Firstly, it is possible that plaque inflammation does not explain post-surgery cardiovas-
cular event risk, and that the study hypothesis is therefore incorrect. Of  note, lack of  
inflammation does not fully exclude plaque instability. An alternative explanation for 
post-surgery plaque instability could for example be increased shear-stress resulting 
from surgery or anesthesia induced hemodynamic disturbances, which may enhance 
plaque growth without necessarily increasing intra-plaque inflammation17, 18. In addi-
tion, other effects of  surgery could explain post-surgical CVD risk, such as sympathetic 
nerve system activation19 or activated primary and secondary hemostasis20.
Two murine studies merit discussion. A recent study by us in ApoE -/- mice reported 
an increase in plaque and necrotic core area early after surgery. In parallel with the 
present study, less intra-plaque inflammation, as suggested by less intra-plaque macro-
phages, was found 15 days after major surgery4. To explain these results, we suggested 
that inflammatory cell infiltration took place before this time point and that activated 
macrophages in particular had already been decomposed, contributing to the necrotic 
core9. Another murine study addressed the combined effects of  major blood loss and 
surgery, and reported increased plaque size after 72 h, along with signs of  plaque vul-
nerability. This effect appeared to be mainly due to the excessive blood loss (20% of  
body weight; substantially more than in our patients21) rather than surgery itself. In this 
study,  intra-plaque macrophages did not increase, further arguing that non-inflammato-
ry conditions, such as a hyperdynamic circulation, rather than intra-plaque inflamma-
tion cause plaque vulnerability after major surgical trauma. 
Secondly, it could be that increased plaque inflammation does occur after surgery, but 
that the 18F-FDG-PET detection technique is either not sufficiently sensitive or was 
inappropriately timed to capture this phenomenon. The aforementioned murine studies 
indeed suggest that timing is of  great importance. We choose t=2 days based on the 
finding that risk of  cardiovascular events is elevated already in the first days post-surgery, 
suggesting a fast inflammatory burst 1. We cannot however exclude inflammatory cell 
infiltration taking place before or, more likely, after t=2 days.
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A strength of  the present study is the full kinetic modeling we have performed before 
and after surgery to correct for factors such as competitive uptake of  the damaged tis-
sue, changes in glucose metabolism, blood flow, fractional blood volume, and/or plasma 
clearance of  18F-FDG. Changes in all such factors can account for altered post-sur-
gery vascular FDG-uptake. It is important for future studies to use a similar approach, 
or at least use appropriately calibrated TBRs, for example by using sampled venous 
18F-FDG activity measurements. 
To conclude, the preliminary results of  this study suggest that major orthopedic surgery 
does not induce increased inflammation in atherosclerotic plaques of  large arteries and 
therefore cannot help explain the high incidence of  cardiovascular events following such 
operations. Extension of  the sample size is, however, mandatory. 
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ABSTRACT
Background: ST-elevation myocardial infarction (STEMI) is typically caused by an 
 occlusive coronary thrombus. The process of  intracoronary thrombus formation is 
poorly understood. It is known that inflammatory cells play a role in the formation and 
resolution of  venous thrombi, however their role in coronary thrombosis is not clear. We 
therefore analyzed inflammatory cells in thrombi derived from patients with STEMI in 
relation to histologically classified thrombus age.
Methods: Thrombus aspirates of  113 patients treated with primary Percutaneous Cor-
onary Intervention were prospectively collected and classified (fresh, lytic or organized) 
based on hematoxylin and eosin staining. The density of  inflammatory cells neutrophils 
(MPO), monocytes/macrophages (CD68), lymphocytes (CD45) and the platelet area 
(CD31), were visualized using immunohistochemistry. Patients’ history, medication and 
laboratory data were registered. 
Results: Fresh thrombi (76.1 %) were the most abundant as compared to lytic (16.8 %) 
and organized (7.1 %) thrombi. Neutrophils were significantly less present in organized 
(169 cells/mm2) compared to fresh (327 cells/mm2) and lytic thrombi (311 cells/mm2). 
Monocytes/macrophages were significantly more present in lytic (471 cells/mm2) than 
in fresh (312 cells/mm2) thrombi. We additionally found that thrombi from patients 
aged <50 years as compared to >50 years old contained significant more neutrophils 
and monocytes/macrophages irrespective of  thrombus age. Furthermore, platelet area 
was smaller in patients on aspirin again irrespective of  thrombus age. No gender differ-
ences were found.
Conclusions: The composition of  inflammatory cells differs with thrombus age in 
thrombosuction material of  STEMI patients that in part depends on patient age and 
medication. 
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INTRODUCTION
Acute ST-elevation myocardial infarction (STEMI) is typically caused by occlusive cor-
onary thrombus formation superimposed on a ruptured atherosclerotic plaque1. Plaque 
disruption triggers the formation of  initial platelet aggregates that expand in association 
with an increase in fibrin formation and subsequent trapping of  erythrocytes leading to 
persistent coronary flow obstruction2. Neutrophils and monocytes are present in these 
thrombi at 3 hours after onset of  complaints. After 6 hours T-cell and B-cell infiltration 
significantly increases3-5. Of  note, inflammatory cells in thrombi were evaluated in these 
studies in relation to symptom to balloon time, which provides an inadequate estimate 
of  thrombus age6, 7. Knowledge of  the composition of  inflammatory cells would be in-
teresting since it is known that inflammatory cells play a role in the formation and res-
olution of  venous thrombi8, 9. Rittersma et al. 6 described a classification method based 
on histological characteristics which since then is considered as the gold standard for the 
estimation of  thrombus age of  coronary thrombi. They defined thrombi as: fresh (less 
than one day old) when they were composed of  layered patterns of  fibrin and intact cells 
(platelets, erythrocytes and neutrophilic granulocytes); lytic (between 1 and 5 days old) 
when areas of  colliquation necrosis and karyorrhexis of  neutrophilic granulocytes were 
present; organized (more than 5 days old) when areas of  ingrowth of  smooth muscle 
cells, with or without depositions of  young connective tissue and/or ingrowth of  capil-
lary vessels was observed. Several studies have shown that this histological appearance 
doesn’t relate to clinical infarct duration or symptom to balloon time6, 7, 10, indicative for 
a time interval of  days to weeks between plaque disturbance, thrombus formation and 
the onset of  symptoms6. This suggests that sudden coronary occlusion is often preceded 
by a variable period of  plaque instability and/or thrombus formation, underlining the 
importance of  identifying thrombus initiation and early progression before occlusion 
becomes clinically overt11, 12. In this light it is of  great importance to further elucidate the 
timescale of  thrombus formation and the factors involved.
It is known that inflammatory cells play an important role in the process of  plaque 
instability13, but their role in arterial thrombus formation is however less known. For 
this, we have studied the composition of  the aspirated thrombus material in relation to 
their histologically defined age in a large cohort of  STEMI patients undergoing primary 
Percutaneous Coronary Intervention (PCI) after sudden onset of  symptoms. We also set 
out to evaluate if  clinical variables like sex, age or medication influence the thrombus 
composition. 
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MATERIALS AND METHODS
Thrombus aspiration and clinical data
Patients who presented at the VU university medical center with a STEMI (defined 
according to the ESC guidelines for STEMI14) and from whom thrombus was aspirated 
were included in the study. All PCI’s were performed according to current standard 
guidelines for PCI. After arrival of  the ambulance or after arrival at the hospital, pa-
tients were treated with 300 mg of  aspirin and 5000 IU of  heparin intra venous (iv). On 
admission patients were directly transported to the catheterization laboratory and PCI 
was performed of  the infarct related artery and a repeat bolus of  heparin was given at 
the cathlab, based on the patient’s body weight. After passage of  the coronary artery 
occlusion with a guide wire, manual thrombectomy was performed with the Export AP 
Aspiration Catheter Medtronic, Dublin, Ireland. Typically, several suctions at the site of  
the occlusion were performed after smooth introduction and initial passage of  catheter. 
Aspirated thrombus and intracoronary material were collected in the collection bottle, 
which was provided with a filter. Additional balloon angioplasty and stent placement 
were performed at the discretion of  the operator, as was the additional use of  glyco-
protein IIb/IIIa receptor blockers. Upon thrombosuction, specimens were immediately 
fixed in formalin. The following baseline clinical data of  the patients were collected: age, 
gender, cardiovascular history, medication, cardiovascular risk factors, infarct-related ar-
tery, C-reactive protein and white blood cell count in the blood. The study conforms 
with the principles outlined in the Declaration of  Helsinki. The study protocol was ap-
proved by the medical ethical research committee at the VU university medical center.
Histology
The aspirated coronary thrombus material was embedded in paraffin after overnight 
fixation (4 % formalin). Tissues were deparaffinised, rehydrated and stained with a stan-
dard haematoxylin/eosin (HE)-staining. Thrombi were histopathologically classified 
based on the observation of  two independent observers (H.W.M.N. and A.C.W), as 
 described before6: fresh (less than one day old): completely composed of  layered patterns 
of  platelets, fibrin, erythrocytes and intact granulocytes; lytic (between 1 and 5 days 
old): areas of  colliquation necrosis and karyorrhexis of  granulocytes; organized (more 
than 5 days old): areas of  ingrowth of  smooth muscle cells, with or without depositions 
of  young connective tissue and ingrowth of  capillary vessels. Thrombus material with a 
heterogeneous composition was graded according to the age of  the oldest part. 
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Immunohistochemistry
For immunohistochemical analysis tissues were deparaffinised, rehydrated and incubat-
ed in methanol/H2O2 (0.3%) for 30 min to block endogenous peroxidases. Antigen 
retrieval was performed by boiling the slides (MPO, CD68, CD31 but not for CD45) 
for 10 min in a citrate pH 6.0 buffer. The sections were incubated with either rabbit 
anti-human myeloperoxidase (1:500, A0398 Dako, Glostrup, Denmark), mouse anti- 
human CD68 (1:400, M0814 Dako, Glostrup, Denmark), mouse anti-human CD31 
(1:40, M0823 Dako, Glostrup, Denmark) or mouse anti-human CD45 (1:50, M0701 
Dako, Glostrup, Denmark) antibody for 1 hour at room temperature (RT). Next, the 
sections were incubated with anti-mouse/rabbit Envision (Dako, Glostrup, Denmark) 
for 30 min at RT. The stainings were visualized with 3,30-diaminobenzidine (0.1 mg/
ml, 0.02% H2O2) for 10 minutes. The slides were subsequently counterstained with 
haematoxylin, dehydrated and covered. With each staining a PBS control was included. 
All these controls yielded negative results (not shown). All the slides were scanned with 
the MIRAX scan (3DHISTECH Ltd Budapest, Hungary). With the MIRAX Viewer 
software snapshots of  all tissue were made and stored for further processing with ImageJ. 
Area’s in thrombi (n=11; 9.7 %) that contained plaque material were left out of  further 
analysis. The surface area of  CD31-positive thrombocytes was quantitatively measured 
and divided by the total surface area of  the scored tissue. For the slides stained with 
MPO, CD68 and CD45 the numbers of  positive cells were scored and divided by the 
total surface area of  the scored tissue.
Statistics
Continuous variables are expressed as mean ± standard deviation (SD) for normally 
distributed or median (interquartile range) for non-normally distributed ones. Differenc-
es between the groups were tested by Student t-test for normally distributed or by the 
Mann-Whitney U (two groups) and Kruskal-Wallis (> 2 groups) test for non-normally 
distributed continuous variables. The Pearson or Spearman rank correlation coefficients 
were calculated to test the association between two variables with a normal or non-nor-
mal distribution. P<0.05 was considered statistically significant. All statistical analyses 
were performed with SPSS software (Windows version 20, IBM corp., Armonk, NY).
RESULTS
Thrombus age and the number of  inflammatory cells
Intracoronary-derived thrombus material was collected from 113 patients (see Table 1 
for patient characteristics). Histological evaluation of  the aspirated material in tissue 
sections showed that fresh thrombi (n=86; 76.1 %) were the most abundant as compared 
to lytic (n=19; 16.8 %) and organized (n=8; 7.1 %). Inflammatory cells and area of  
platelets were present (Fig. 1). 
Proefschrift_v10.0.indd   145 02-11-17   12:14
146 Chapter 9
Table 1 Patient characteristics
Characteristics
Age (years, mean ± SD) 61.1 ± 12.4
Male, n (%) 73 (82/113)
Current smoking, n (%) 38 (25/65)
Hypercholesterolemia 22 (14/65)
Hypertension, n (%) 37 (24/65)
Diabetes Mellitus, n (%) 9 (6/65)
Family history of CAD, n (%) 35 (23/65)
Chronic aspirin use, n (%) 15 (13/86)
Statin use, n (%) 13 (11/86)
Prior angina, n (%) 32 (11/34)
Prior MI, n (%) 14 (14/100)
Symptom to balloon time (hrs., 
median [IQR])
2.0 [2.0-3.0]
ST-resolution, n (%) 81 (56/69)
Drug eluting stent, n (%) 9 (8/85)
Stent diameter, mm mean ± SD 3.3 ± 0.4
Stent length, mm mean ± SD 23 ± 5
Infarct-related artery
RCA, n (%) 43 (46/106)
RCx, n (%) 12 (13/106)
LAD, n (%) 44 (47/106)
Laboratory data
Platelets 10E9/L, median [IQR] 244 [191-289]
WBC 10E9/L, median [IQR] 10.9 [8.4-13.3]
CRP mg/L 3.4 (2.5-6.2)
CK-MB IU/L 218 (117-328)
Variable represent mean (± SD), percentage of total patients (%), median [interquartile range]. CAD indicates 
coronary artery disease; MI, myocardial infarction; RCA, right coronary artery; RCx, right circumflex; LAD, left 
anterior descending coronary artery; CRP: C-reactive protein; CK-MB, creatine kinase MB
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A: CD31 positive area indicative for platelets. B: MPO positive cells indicative for neutrophilic granulocytes. 
Scale bar represents 100 µm.
Figure 1 Example of immunohistochemical staining of aspirated coronary thrombus
Figure	1 A
B
We then evaluated the density of  inflammatory cells per thrombus phase. Neutrophils 
were significantly less present in organized thrombi (169 [76.3-222] cells/mm2) com-
pared to fresh (327 [178-504] cells/mm2) (p=0.017) and lytic thrombi (311 [191- 578] 
cells/mm2) (p=0.012) (Fig. 2A). CD68 positive monocytes/macrophages, were more 
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present in lytic (471 [301-696] cells/mm2) than in fresh (312 [161-466] cells/mm2) 
(p=0.013) and organized (405 [249-569]) thrombi, although the difference between lytic 
and organized was not significant (p=0.355) (Fig. 2B). The number of  lymphocytes did 
not differ between the three groups ( fresh thrombi: 154 [72.9-284] cells/mm2, lytic 
thrombi; 200 [99.7-374] cells/mm2 and organized thrombi: 120 [38.8-281] cells/mm2). 
Also platelet areas were not significantly different among the 3 groups (fresh thrombi: 
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A: MPO positive cells indicative for neutrophilic granulocytes per thrombus area. B: CD68 positive cells indic-
ative for monocytes/macrophages per thrombus area. C: CD45 positive cells indicative for number of lympho-
cytes per thrombus area. D: CD31 positive area (indicative for thrombocytes) divided by total thrombus area in 
percentages. Thrombi are divided in age based on histology: fresh, lytic and organized thrombi. Bars represent 
median.
Figure 2 Amount of inflammatory cells and platelets per thrombus area at different time points.
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Next we evaluated symptom to balloon time in hours and thrombus composition. 
We  found no significant differences between symptom to balloon time of  fresh, lytic 
and organized thombi, respectively 2.0 [2.0-3.0], 2.8 [1.9-4.3] and 2.5 [1.6-3.8] hours 
(p=0.30). No correlation between symptom to balloon time and neutrophils (r=0.084; 
p=0.424), macrophages/monocytes (r=0.088; p=0.416) and lymphocytes (0.088; 
p=0.405) existed. We did found a moderate correlation between symptom to balloon 






































































A: MPO positive cells indicative for neutrophilic granulocytes per thrombus area. B: CD68 positive cells indic-
ative for monocytes/macrophages per thrombus area. C: CD45 positive cells indicative for number of lympho-
cytes per thrombus area. D: CD31 positive area (indicative for thrombocytes) divided by total thrombus area in 
percentages.
Figure 3 Relation between symptom to balloon time and thrombus composition 
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Clinical variables and thrombus composition
Patient age
In order to evaluate the effect of  age on inflammatory cell and platelet content in throm-
bi, we correlated patient age with neutrophils, monocytes/macrophages, lymphocytes 
and platelets. Negative, but non-significant correlations were found between patients age 
and number of  neutrophils in the thrombus (r=-0.126 p=0.190), monocytes/macro-
phages (r=-0.173 p=0.079), lymphocytes (r=-0.102 p=0.292) and platelet area (r=-0.109 
p=0.264).
Next, we divided the population into two groups using a cut-off of  50 years. This cut-off 
is arbitrary, but allowed us to evaluate possible difference between patients that suffer 
from myocardial infarction at a relatively young age versus older patients. The percent-
ages of  fresh, lytic or organized thrombi in patients younger than 50 years (median 43; 
range 27-49) and in patients older than 50 years (median 63; range 50-87) did not differ 
and were similar to percentage for all the thrombi together. The number of  neutrophils 
was significantly higher in thrombi of  younger patients (<50 yrs) as compared to older 
(>50 yrs) patients (375 [277-536] vs. 267 [140-439] cells/mm2; p=0.020) (Fig. 4A). Also 
monocytes/macrophages were more abundant in thrombi of  younger patients (<50 yrs) 
(413[311-543] vs. 310 [160-473 cells/mm2; p=0.006). The number of  lymphocytes was 
not significantly different (199 [137-295] vs. 152 [71.9-285] cells/mm2; p=0.142). We 
also observed a significant difference between the <50 years and >50 years group for 
platelet count in blood (273 [252-316] vs. 235 [187-280] 109/L, p=0.012) but this was 
not reflected by platelet area in the thrombi (30.00[21.39-42.71] vs. 26.00 [15.00-38.05] 
%; p=0.264). 
Gender
When comparing males (n=82; 73 %) and females (n=31; 27%) no differences in the 
percentages of  fresh (78 % vs. 71 %), lytic (13 % vs. 26 %) or organized (9 % vs. 3 %) 
thrombi (p=0.212) were observed. Also the number of  inflammatory cells was not differ-
ent (lymphocytes 155.36 [70.37-265.26] vs. 166.67 [98.65-341.67] cells/mm2 p=0.490, 
neutrophils 301.37 [163.67-462.66] vs. 282.65 [180.00-564.17 cells/mm2 p=0.684 and 
monocytes/macrophages 366.96 [183.50-480.00] vs. 352.45 [174.54-611.25] cells/
mm2 p=0.456). Finally, the platelet area was neither significantly different, namely 26,35 
% [11.50-42.50] vs. 27.59 % [18.00-37.00] p=0.923.
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Thrombus material compared between patients aged <50 years versus > 50 years for A: number of MPO pos-
itive cells. B: number of CD68 positive cells. C: number of CD45 positive cells. D: area of CD31 positivity (%).
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Pre-procedural medication
We wondered whether thrombus composition in all phases of  thrombi combined, would 
differ between chronic aspirin users (n=13) and patients without aspirin use (n=73). 
Platelet area was significant lower in aspirin users, namely 20.0 [7.50-31.3] vs. 27.3 
[20.3-40.1] % p=0.019. No significant differences were found for lymphocytes (163 vs. 
170 cells/mm2, p=0.902) monocytes/marcophages (355 vs. 345 cells/mm2, p=0.240) 
and neutrophils (393 [192-594] vs. 283 [159-455] cells/mm2, p=0.219) (Fig. 5). The 
blood platelet level did not differ significantly between chronic aspirin users and patients 
without a history of  aspirin use (309 vs. 249 x 109/L p=0.647). 
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We also analyzed the effect of  statin treatment that were prescribed in 11 out of  86 pa-
tients. A trend to a lower platelet area was observed in patients that used statins (18.8 
[10.3-31.6] vs. 29.7 [19.8-42.5] cells/mm2, p=0.094). Statin use had no effect on neutro-
phil content (283 [121-564] vs. 319 [169-485] cells/mm2, p=0.555), monocytes/mac-
rophage content, (300 [140-471] cells/mm2 vs. 364 [228-511] cells/mm2, p=0.295) or 
lymphocyte content (177 [23.0-337] cells/mm2 vs. 160 [76.3-295] cells/mm2, p=0.326).
A: The percentage of the CD31 positive area in aspirin users versus non-aspirin users. B: Amount of MPO pos-
itive cells/area thrombus aspirate in aspirin users versus non-aspirin users.
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Coronary risk factors and serum markers
We were interested in the different coronary risk factors and their possible influence 
on thrombus composition. We found no significant differences in inflammatory cell/
platelet content for smoking, hypertension, hypercholesterolemia, diabetes mellitus, pos-
itive family history, previous myocardial infarction or angina pectoris (data not shown). 
Furthermore the relationships between white blood cell count respectively C-reactive 
protein and the composition of  inflammatory cells was evaluated (Table 2). A weak 
(r= 0.262; p= 0.038) positive correlation was found between white blood cell count and 
monocyte/macrophage content in the thrombus was found. 
Table 2 Serum markers versus composition of thrombus
Correlations coefficients are expressed with accompanied p-values. CRP: C-reactive protein. WBC: White 
blood cell count. MPO positive cells indicative for neutrophilic granulocytes per thrombus area; CD68 
positive cells indicative for monocytes/macrophages per thrombus area; CD45 positive cells indicative for 
number of lymphocytes per thrombus area; CD31 positive area (indicative for thrombocytes) divided by total 
thrombus area in percentages.
MPO pos. area / 
mm2
CD68 pos. area / 
mm2
CD45 pos. area / 
mm2



















It is known that inflammatory cells play a role in the formation and resolution of   venous 
thrombus. However information on inflammation in the context of  coronary throm-
bosis is scarce. We therefore have analyzed inflammatory cells in thrombi derived from 
patients with STEMI in relation to histologically classified thrombus age. Thrombus 
 aspiration after STEMI revealed thrombi at different stages of  maturation (fresh 76%, 
lytic 17 % and organized 7 %). The number of  neutrophilic granulocytes was signifi-
cantly lower in organized thrombi, compared with fresh and lytic thrombi, while mono-
cytes/macrophages were significantly higher in the lytic thrombi as compared to the 
fresh thrombi. Furthermore, we found that thrombi originating from younger patients 
(age <50) had more neutrophils and monocytes/macrophages. Also, we found no gender 
differences in thrombus composition. Finally, we found that chronic aspirin use  alters, at 
least partly, thrombus composition, revealing a smaller area of  platelets.
Inflammation plays an important role in the pathophysiology of  AMI, namely in the 
initiation, progression and destabilization of  atherosclerotic plaques13, as well as in the 
onset of  plaque rupture, resulting in thrombus formation4, 15 and subsequent myocardial 
infarction16, 17. Since the introduction of  coronary thrombus aspiration devices, thrombus 
Inflammatory cell content of  coronary thrombi is dependent on thrombus 
age in patients with ST-elevation myocardial infarction
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composition was studied6, 18. Multivariate analysis showed that high neutrophil density 
in aspirated thrombus was an independent predictor of  impaired coronary microcircu-
lation (myocardial blush grade ≤ 1 and ST-segment resolution < 50 %) and myocar-
dial dysfunction (low left ventricular ejection fraction at 6 months after onset)19. It was 
furthermore suggested that systemic levels of  activated neutrophilic granulocytes were 
positively correlated with thrombus fibrin content 4. These studies thus indicate that 
inflammatory cells are not solely passively trapped in developing thrombi, but play an 
active role herein. It therefore is of  great importance to further elucidate the timescale 
of  infiltration of  inflammatory cells in thrombi. Ramaiola et al. found that the infiltra-
tion of  leukocyte subtypes changed with symptom-to-balloon time (time between onset 
of  complaints and thrombosuction). They found in coronary thrombi aspirated 3 hours 
after complaints started mainly platelets and fibrinogen, while thrombi aspirated after 
6 hours or more were characterized by reduced platelet content and increased T-cells 
and B-cells infiltration. No significant differences were found for the area of  monocytes 
and neutrophilic granulocytes3. STEMI’s are often preceded by a variable period of  
plaque instability that coincides with non-obstructive thrombi that makes classification 
of  thrombus age based on symptom to balloon time inadequate 6, 10, 20. This is in line with 
the absence of  a correlation between symptom to balloon time and histological throm-
bus age, as we observed. This may further be established by the absence of  a significant 
correlation between symptom to balloon time and inflammatory cell composition of  the 
thrombus. In order to better discriminate different phases of  thrombus development, 
we used a classification method based on histological characteristics6, 7. We found that 
lymphocytes are already present in fresh thrombi. Even more we found that neutrophils 
are more present in the fresh and lytic phase as compared to the organized phase, indic-
ative that involvement of  these cells is mainly contributed to the early phases of  arterial 
thrombosis. Such a predominance of  neutrophils in the earlier stages of  thrombus for-
mation (lytic more than fresh) was reported recently21. We found that also monocytes/
macrophages were especially found in the lytic phase, likely related to their contribution 
in the clearance of  thrombus material22, 23.
We also looked in more detail on the role of  patient age on thrombus composition, 
 regarding the well-known age-related decline in immunologic vigor24. We indeed found 
negative but non-significant correlations between the cell types and patient age, which 
fits the immunosenescence hypothesis. We even more found that the number of  neutro-
philic granulocytes and monocytes/macrophages were significantly higher in the young-
er patients (<50) compared with older patients. Whether this is due to a more active 
immune system in younger people or f.i. due to a different etiology of  infarctions still 
remains unclear.
It is known that mortality is higher in women with STEMI and can be explained by 
their unfavorable risk profile and longer symptom to balloon time25. We therefore also 
evaluated putative differences in thrombus composition in relation to gender. This we 
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however did not found, which is in line with an earlier report, that neither found sex 
differences for platelets, fibrin or erythrocytes in coronary thrombosuction material26. 
After arrival at the hospital or after arrival of  the ambulance all patients were treated 
with 300 mg of  aspirin according to standard care. Aspirin inactivates cyclooxygenase 
(COX) resulting in impaired synthesis of  prostaglandins which are involved in both 
platelet aggregation and inflammation27. A proportion of  the patients was on chronic 
aspirin treatment and since a substantial part of  the thrombus formation takes place 
before the acute aspirin dose is administered, we wondered whether chronic aspirin use 
had effect on thrombus composition. We did find that patients with chronic aspirin treat-
ment had a smaller platelet area in the thrombi, which is in line with the anti- platelet 
effect of  aspirin27. We furthermore analyzed the effect of  statin treatment, regarding its 
anti-inflammatory and anti-platelet effects as well28, 29. Although there was a general ten-
dency of  less inflammatory cells and smaller platelet area in the thrombus, no significant 
differences were found. 
In conclusion, thrombus aspiration revealed thrombi with different amounts of  inflam-
matory cells in relation to thrombus age that are at least to some extent influenced by pa-
tient age and aspirin use, but not by gender. These results are in line with the suggestion 
that inflammatory cells are not solely passively trapped in developing thrombi, but play 
an active role herein. Advancing knowledge of  the dynamic aspects of  thrombus forma-
tion and composition may contribute to tailored antithrombotic and/or anti-inflamma-
tory treatment options in various stages of  development of  acute coronary syndromes.
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ABSTRACT
Background: In a proportion of  patients with ST-elevation myocardial infarction 
(STEMI), perfusion at the microvascular level remains inadequate after successful per-
cutaneous coronary intervention. This phenomenon of  microvascular injury (MVI) is 
associated with worse clinical outcome. The pathogenesis is largely unknown, however 
inflammatory cells within the blood and coronary thrombi have been associated with 
the status of  the microvasculature and left ventricular function after STEMI. This is the 
first study that evaluated a putative relationship between the composition of  aspirated 
intracoronary thrombi and the occurrence of  MVI.
Methods: Thrombus aspirates of  69 patients treated with primary percutaneous coro-
nary intervention (p-PCI) were prospectively collected and classified (fresh or lytic) based 
on haematoxylin and eosin staining. Immunohistochemical stainings were performed 
to quantify inflammatory cells with CD68 (macrophages), CD45 (lymphocytes), MPO 
(neutrophilic granulocytes), CD31 (platelets) and GLUT1 (erythrocytes) within the 
thrombi. Cardiovascular magnetic resonance (CMR) imaging with T2-weighted and 
late gadolinium enhancement (LGE) imaging for IMH and MVO measurement, respec-
tively, was performed 3-11 days after p-PCI. 
Results: Patients with (n=39) and without MVI (n=30) had comparable demograph-
ics and cardiovascular risk profile. Patients with MVI had significantly higher symp-
tom-to-balloon times (173 vs. 115 minutes; p=0.036), significantly larger enzymatic in-
farct size (CKMB max 324 vs. 69 µg/L; p=0.001) and significantly lower left ventricular 
ejection fraction (LVEF) (49 vs. 55%; p=0.003). Patients with MVI had numerically 
more often lytic thrombi, albeit not statistically significant ((n=18; 46% vs. n=9; 30%, 
p=0.17). The number of  macrophages/monocytes (2.7 [1.4-5.6] vs. 1.6 [0.6-4.0]), lym-
phocytes (5.0 [2.5-7.7]vs. 3.5 [1.1-4.0]) and neutrophilic granulocytes (22 [11-31] vs. 13 
[10-27]) was higher in patients with MVI, however this was also not statistically signifi-
cant (resp. p=0.15; p=0.10; p=0.34). 
Conclusions: In the present study we could not demonstrate a relationship between the 
composition of  aspirated coronary thrombus and the occurrence of  MVI.
Proefschrift_v10.0.indd   160 02-11-17   12:14
161
Inflammatory cells are not significantly increased in aspirates of  coronary 
thrombi of  STEMI patients with microvascular injury
INTRODUCTION
ST-elevation myocardial infarction (STEMI) is typically caused by occlusive coronary 
thrombus formation superimposed on ruptured atherosclerotic plaques1. Plaque disrup-
tion triggers the formation of  platelet aggregates that grow in association with increased 
fibrin formation and subsequent trapping of  erythrocytes and inflammatory cells lead-
ing to coronary flow obstruction and blood coagulation2. Antithrombotic drugs have 
reduced the incidence of  STEMI in secondary prevention3 and improved the treatment 
of  patients4. However, a substantial proportion of  patients with STEMI have a poor 
restoration of  microvascular function and myocardial perfusion, despite restoration of  
epicardial vessel patency, a condition previously described as a ‘no-reflow’ phenome-
non5. It was suggested that distal embolization of  atherosclerotic plaque components 
and/or thrombotic material could induce mechanical obstruction of  microvessels but 
could also cause an inflammatory response, resulting in the release of  vasospastic and 
thrombogenic factors that further exacerbate microvascular dysfunction6-8. Further-
more, it was suggested that interactions between white blood cells (neutrophilic granu-
locytes and monocytes) and platelets likely play an important role in the pathogenesis of  
no-reflow following distal embolization9. In a pig model it was shown that blood levels of  
neutrophilic granulocyte-platelet aggregates and monocyte-platelet aggregates follow-
ing microsphere embolization occurred prior to the onset of  angiographic no-reflow9. 
In addition, it was shown in dogs that progressive leukocyte capillary plugging during 
myocardial ischemia prevents full restoration of  capillary flow upon reperfusion10 in a 
open-chest dog model, 1-5 hours after left anterior descending coronary artery occlu-
sion and reperfusion10. 
In recent years it has become clear that angiographic no-reflow is likely to be caused by 
microvascular injury (MVI), and subsequent intramyocardial haemorrhage (IMH))5, 11. 
MVI has been associated with increased risk of  hospital readmissions owing to cardiac 
failure, major adverse cardiac events, and death . Although MVI can be assessed using 
various imaging modalities including electrocardiography, myocardial contrast echocar-
diography, nuclear scintigraphy and coronary angiography, evaluation by cardiovascular 
magnetic resonance (CMR) is considered the gold standard 5. CMR is the most accurate 
modality to assess the left ventricular ejection fraction and delineate the amount of  
MVI, IMH and infarct size.
Previous studies have shown that inflammation plays an important role in the occur-
rence of  MVI. For instance, blood levels of  leukocytes and CRP were positively correlat-
ed with the size of  MVI12-14. In addition, high neutrophil density in aspirated thrombus 
was an independent predictor of  unfavourable microvascular perfusion and left ventric-
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ular ejection fraction (LVEF), as determined with angiography15. In the current study we 
studied the potential association between inflammatory cell content of  coronary throm-
bi and the occurrence of  MVI and the consequences on infarct size, as determined with 
CMR. 
METHODS AND MATERIALS
Thrombus aspiration and baseline characteristics
Patients who presented at the VU university medical center with a STEMI (defined 
according to the ESC guidelines for STEMI16) from whom analyzable thrombus was 
aspirated and in which cardiovascular magnetic resonance (CMR) with late gadolini-
um-enhanced (LGE) imaging was performed 3-11 days after p-PCI, were selected. On 
admission patients were directly transported to the catheterization laboratory and PCI 
was performed of  the infarct related artery according to current standard guidelines for 
PCI17. After passage of  the coronary artery occlusion with a guide wire, manual throm-
bus aspiration was performed with the Export AP Aspiration Catheter Medtronic, Dub-
lin, Ireland. Typically, several suctions at the site of  the occlusion were performed after 
smooth introduction of  the catheter. Aspirated thrombus and intracoronary material 
were collected in the collection bottle, which was equipped with a filter. Additional bal-
loon angioplasty and stent placement were performed at the discretion of  the operator, 
as was the additional use of  glycoprotein IIb/IIIa receptor blockers. Upon thrombus 
aspiration, specimens were immediately fixated in formalin. The following baseline clin-
ical data of  the patients were collected: age, gender, cardiovascular history, medication, 
cardiovascular risk factors, time between start of  symptoms and first balloon inflation 
(symptom to balloon time), C-reactive protein, CK-MB, blood leucocyte count, LDL 
cholesterol, creatinine and glucose. The study conforms with the principles outlined in 
the Declaration of  Helsinki. The study protocol was approved by the human research 
committee at the VU University Medical Center. 
Cardiovascular magnetic resonance
At day 3-11 after p-PCI, cardiovascular magnetic resonance (CMR) imaging was per-
formed with a 1.5-Tesla clinical magnetic resonance scanner (Avanto, Siemens, Erlan-
gen, Germany) using a phased array cardiac receiver coil. All images were ECG-gated 
and acquired during mild end-expiration breath-holding. Balanced steady-state free pre-
cession cine images were obtained in standard long- and short-axis orientations to ex-
amine left ventricular volumes, and ejection fraction. Typical parameters were in-plane 
resolution 1.6 × 2.0 mm, slice thickness/slice gap 5/5 mm, flip angle 75˚ and temporal 
resolution 35-40 ms. T2-weighted spin echo imaging was performed in short axis ori-
entation covering the whole LV to visualize IMH. Typical parameters were TR = 2 
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× RR interval, TE 61 ms and voxel size 1.5 × 2.5 × 7 mm. Hypointense areas within 
the hyperintense infarcted myocardium were considered IMH. Finally, to quantify in-
farct size and visualize MVO, LGE images were acquired with an inversion recovery 
gradient echo sequence 10-15 min after 0.1 – 0.2 mmol/kg gadolinium-based contrast 
administration (Dotarem, Guerbet, Roissy CdG, France) in short axis orientation with 
whole LV coverage. Typical parameters were in-plane resolution 1.5 × 1.5 mm, slice 
thickness 5mm, TR = 1 × RR interval, TE 4.4 ms, flip angle 25˚ and TI 250-400 
ms nulled to normal myocardium. Infarct size was assessed using the full-width half  
maximum method. MVO was defined as the areas of  hypoenhancement within the 
hyperenhanced  infarcted myocardium. All CMR analyses were performed by blinded 
experienced observers using a standardized protocol, using dedicated off-line software 
(QMassMR v7.6, Medis, Leiden, the Netherlands).
Histology
The aspirated coronary thrombus material was embedded in paraffin after overnight 
fixation (4 % formalin). Tissues were deparaffinised, rehydrated and stained with a 
standard haematoxylin/eosin (HE)-staining. Thrombi were histopathological classi-
fied based on the observation of  three independent observers (H.W.M.N., A.C.W. and 
W.W.F.), as described before18: fresh (less than one day old): completely composed of  
layered patterns of  platelets, fibrin, erythrocytes and intact neutrophilic granulocytes; 
lytic (between 1 and 5 days old): areas of  colliquation necrosis and karyorrhexis of  neu-
trophilic granulocytes; organized (more than 5 days old): areas of  ingrowth of  smooth 
muscle cells, with or without depositions of  young connective tissue and ingrowth of  
capillary vessels. It is known from literature that organized thrombi are typically less 
common, then fresh and lytic thrombi19. As we in our relatively small cohort did not 
find sufficient organized thrombi with matching available CMR images to allow proper 
comparison, organized thrombi (n=4) were excluded from this study. Thrombus materi-
al with a heterogeneous composition was graded according to the age of  the oldest part. 
Immunohistochemistry
For immunohistochemical analysis tissues were deparaffinised, rehydrated and incubat-
ed in methanol/ H2O2 0.3%) for 30 min to block endogenous peroxidases. Antigen 
retrieval was performed by boiling slides (MPO, CD68, CD31 and NET) for 10 min 
in a citrate pH 6.0 buffer and Glut-1 in TRIS EDTA pH 9.0. No antigen retrieval was 
performed on CD45. Sections were incubated with either rabbit anti-human Glut-1 
(1:100, Dako, Glostrup, Denmark), mouse anti-human CD68 (1:400, Dako, Glostrup, 
Denmark), mouse anti-human CD31 (1:40, Dako, Glostrup, Denmark), mouse anti-hu-
man CD45 (1:100, Dako, Glostrup, Denmark) or rabbit anti-human H3-histone Citrul-
line (1:100, Abcam, Cambridge, UK) antibody for 1 hour at room temperature (RT). 
Next, sections were incubated with anti-mouse/rabbit Envision (Dako, Glostrup, Den-
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mark) for 30 min at RT. Staining was visualized with 3,3’-diaminobenzidine (0.1 mg/
ml, 0.02% H2O2) for 10 minutes. The slides were subsequently counterstained with 
haematoxylin, dehydrated and covered. With each staining a PBS control was included. 
All these controls yielded negative results (not shown). 
Immunoscoring 
Immunoscoring was performed by I.S. and W.W.F. and agreement was reached between 
both observers. All slides were scanned with the Pannoramic Desk scan (3DHISTECH 
Ltd Budapest, Hungary) and were further processed with Pannoramic Viewer software. 
For quantitative analysis, picture of  each thrombus was 5x enlarged and divided into 
equal sections until the whole area of  the thrombus was covered. Next, snapshots were 
made of  each section. Snapshots were further analyzed with ImageJ software. For each 
snapshot an area of  interest (ROI) was drawn around the thrombus tissue, and athero-
sclerotic areas were excluded. Antibody positive surface area of  the selected ROI and 
thrombus area were measured for each snapshot. The total antibody positive area of  
each thrombus was then divided by total thrombus area, which provided a percentage 
of  stained area per thrombus.
Statistics
Continuous variables are expressed as mean ± standard deviation (SD) for normally 
distributed or median (interquartile range) for non-normally distributed ones. Differ-
ences between the groups were tested by Student t-test for normally distributed or by 
the Mann-Whitney U and test for non-normally distributed continuous variables. For 
the comparison between groups (MVI vs non-MVI) and the relative distribution (%) of  
gender, cardiovascular risk factors, procedure characteristics, CMR data and thrombus 
characteristics, crosstabs were used resulting in a Fisher’s exact test generated p-value. 
All statistical analyses were performed with SPSS software (Windows version 20, IBM 




Between Dec 2009 and Aug 2015, 2440 STEMI patients have undergone p-PCI and 
adjacent thrombectomy was performed in 52%, as presented in the inclusion flow chart 
(Fig. 1). Cardiovascular magnetic resonance (CMR) with LGE imaging was performed 
in 182 patients, 3-11 days after p-PCI. Our study population consisted of  69 patients 
(42 male; 27 female) with analysable CMR images and thrombus material. Patients with 
MVI (n=39) and without MVI (n=30) (Fig. 2) had comparable demographics and car-
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Figure 1 Enrollment flow diagram
p-PCI, primary percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; CMR, car-
diovascular magnetic resonance; LGE, late gadolinium enhancement. *Thrombus aspiration n=1269 (52%); 
#3-11 days post PPCI
A B
Figure 2 Example of MVI and non-MVI
Examples of short axis cardiovascular magnetic resonance (CMR) imaging with late gadolinium enhance-
ment (LGE) showing infarcted area (anteroseptal) indicated by the arrowf. In panel A the infarcted area is 
hypodense, indicative of MVI. In panel B no hypodense area is present in the infarcted area, indicative of a 
patient without MVI.
diovascular risk factors (Table 1), except for glucose levels. In MVI patients glucose levels 
(8.4 mmol/L) were significant higher as compared to no MVI patients (7.2 mmol/L), 
although no significant differences in the number of  DM patients was found. 
Patients with MVI had higher symptom-to-balloon times (173 vs. 115 minutes; p=0.036), 
larger enzymatic infarct size (CKMB max 324 vs. 69 µg/L; p=0.001), lower left ventric-
ular ejection fraction (49% vs. 55%; p=0.003) and more often had IMH (64% vs. 0.0 %; 
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Variable represent mean ± standard deviation, median (interquartile range) or number and percentage 
of total patients (%). DM2, type 2 diabetes; BMI, body mass index; LDL, low density lipoprotein; ASAT, 
L-aspartate aminotransferase; ALAT, L-alanine aminotransferase; CK, creatinine kinase; CKMB, creatinine 
kinase MB. 
MVI (n=39) no MVI (n=30) p-value
Demographics
Age (years) 57 ± 9 58 ± 10 0.59
Male, n (%) 32 (82) 20 (67) 0.14
Cardiovascular risk factors
Current smoking, n (%) 17 (44) 12 (40) 0.77
Hypertension, n (%) 9 (23) 7 (23) 0.98
Hypercholesterolemia, n (%) 6 (15) 6 (20) 0.62
DM2, n (%) 1 (3) 0 (0) 0.38
Family history, n (%) 23 (59) 11 (37) 0.07
BMI (kg/m2) 27 ± 3 26 ± 3 0.19
Laboratory measurements
Creatinin µmol/L 82 (74-89) 80 (65-88) 0.47
CRP mg/L 0 (0-3) 3 (0-5) 0.30
Glucose mmol/L 8.4 (7.4-9.3) 7.2 (6.7-8.4) 0.005
Cholesterol mmol/L 5.1 (4.7-6.2) 5.4 (4.6-6.1) 0.89
LDL mmol/L 3.4 (3.0-4.3) 3.8 (3.3-4.5) 0.41
Leucocytes 10^9/L 12 (9-15) 12 (8-15) 0.99
ASAT U/L 36 (29-61) 33 (25-70) 0.47
ALAT U/L 30 (24-39) 25 (17-41) 0.17
CK U/L 480 (155-2118) 398 (171-1058) 0.57
CKMB baseline µg/L 62 (9.4-281) 44 (29-97) 0.58
Table 1 Baseline characteristics
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MVI (n=39) no MVI (n=30) p-value
Procedure
Multivessel disease, n (%) 16 (41) 10 (33) 0.51
LAD (IRA), n (%) 17 (44) 8 (27) 0.15
TIMI 0 pre-PCI, n (%) 35 (90) 17 (57) 0.002
Number of stents 1.2 ± 0.5 1.1 ± 0.3 0.22
Symptom-to-balloon time (minutes) 173 (104-253) 115 (75-180) 0.036
Infarct size and LVEF
Days between presentation and CMR 5 (3-7) 5 (3-7) 0.62
MRI Infarct size (gram) 28 (19-46) 9 (13-6) < 0.001
MRI infarct size / LV (%) 24 (65-32) 9 (3-13) < 0.001
MRI LVEF % 49 ± 8 55 ± 9 0.003
MRI ESV ml 98 (79-132) 74 (52-86) 0.001
MRI EDV ml 189 (170-230) 166 (138-188) 0.003
IMH, n (%) 23 (64) 0 < 0.001
CKMB max µg/L 324 (155-438) 69 (43-240) 0.001
Variable represent mean ± standard deviation, median (interquartile range) or number and percentage of 
total patients (%). LAD, left anterior descending coronary artery; IRA, infarct-related artery; CMR, cardio-
vascular magnetic resonance; PCI, percutaneous coronary intervention; MRI, magnetic resonance imaging; 
LVEF, left ventricular ejection fraction; ESV, end systolic volume; EDS, end diastolic volume; IMH, intra-myo-
cardial hemorrhage; CKMB, creatinine kinase MB. 
Thrombus characteristics
We first evaluated the density of  platelets and erythrocytes in thrombi. We found a 
similar percentage of  platelets (37% vs. 32%; p=0.58) and erythrocytes (58% vs. 66%; 
p=0.47) in patients with and without with MVI.
Next we compared the relative occurrence of  fresh vs. lytic thrombus in both groups 
(Table 3). In 18 of  the 39 patients with MVI lytic thrombi were present (46%), which 
was higher but did not statistically differ from the 9 patients with lytic thrombi in the 
30  patients without MVI (30%); p=0.17. 
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We then compared the contribution of  inflammatory cells in the thrombi between pa-
tients with and without MVI. The area of  inflammatory cells was enhanced in MVI 
vs the no MVI group, but this difference was not significant: the area of  monocytes/
macrophages (%) was 2.7 (1.4-5.6) in patients with MVI and 1.6 in no MVI patients 
(0.6-4.0); p= 0.15; the area of  lymphocytes (%) was 5.0 (2.5-7.7) in patients with MVI 
vs. 3.5 (1.1-4.0) in patients without MVI; p=0.10; the area of  neutrophilic granulocytes 
(%) was 22 (11-31) in patients with MVI vs. 13 (10-27) in patients without MVI; p=0.34. 
Finally, the area of  neutrophilic extracellular traps (NETs), a pro-thrombogenic and 
pro-inflammatory mediator, was evaluated20, 21. Also no significant difference was found: 
the thrombus area composed of  NETs (%) was 44 (27-62) in patients with MVI vs. 46 
(24-52) in patients without MVI; p=0.70.
We previously have shown that thrombus age (fresh, lytic or organized) has an effect on 
the composition of  these inflammatory cells in the thrombus19. We therefore compared 
the area of  platelets, inflammatory cells and erythrocytes in the MVI and non-MVI 
groups separately for fresh and lytic thrombus. Although in lytic thrombi the number of  
CD45 positive cells was higher in MVI vs non MVI patients (Fig. 3D), and the number 
of  NET’s in fresh thrombi was higher in MVI vs non MVI patients (Fig. 3F), these dif-
ferences were not significant. In none of  the other variables, significant differences were 
found (Fig. 3), on the contrary: the non-significant increase of  monocyte/macrophages 
and neutrophilic granulocyte densities that was found when comparing the MVI with 
the non-MVI group, became less overt when thrombus age was taken into account. 
When we selected patients with MVI (n=39) categorizing them according to the amount 
of  MVI (based on the median of  1.73 grams), inflammatory cell and general contents 
of  coronary thrombus were not statistically different between patients with more pro-
nounced MVI (≥ 1.73 grams) or less pronounced MVI (< 1.73 grams) (Table 4).






Plaque components, n (%) 13 (39) 7 (32) 0.57
Platelets % 27 (27-50) 32 (10-59) 0.58
Erythrocytes % 58 (36-71) 66 (41-75) 0.47
Inflammation
Lytic thrombys, n (%) 18 (46) 9 (30) 0.17
Monocytes / macrophages % 2.7 (1.4-5.6) 1.6 (0.6-4.0) 0.15
Lymphocytes % 5.0 (2.5-7.7) 3.5 (1.1-4.0) 0.10
Neutrophylic granulocytes % 22 (11-31) 13 (10-27) 0.34
Neutrophilic extracellular trapment % 44 (27-62) 46 (24-52) 0.70
Variable represent number and percentage of total patients (%) or median (interquartile range).
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Figure 3 Thrombus composition in MVI and non-MVI patients stratified by thrombus age
Relation between platelets, erythrocytes, inflammatory cells and the occurrence of microvascular injury 
(MVI) subdivided by histological thrombus age (fresh or lytic). A: CD31 positive area (platelets); B: GLUT1 
positive area (erythrocytes); C: CD68 positive area (macrophages); D: CD45 positive area (lymphocytes); 
E: MPO positive area (neutrophilic granulocytes); F: H3cit positive area (NETs). MVI fresh (n=21), MVI lytic 
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Plaque components, n (%) 14 (70) 11 (58) 0.43
Platelets % 40 (30-54) 33 (23-44) 0.16
Erythrocytes % 55 (22-70) 60 (50-76) 0.13
Inflammation
Lytic thrombys, n (%) 11 (55) 10 (53) 0.88
Monocytes / macrophages % 2.2 (1.1-4.4) 4.1 (1.5-6.2) 0.37
Lymphocytes % 5.0 (2.4-9.0) 4.8 (3.1-6.8) 1.00
Neutrophylic granulocytes % 25 (4-31) 21 (12-36) 0.70
Neutrophilic extracellular trapment % 47 (8-64) 42 (30-61) 0.81
Variable represent number and percentage of total patients (%) or median (interquartile range).
DISCUSSION
To the best of  our knowledge we were the first to evaluate whether the inflammato-
ry cell content of  coronary thrombi is related to CMR-derived MVI. Although it is 
suggested that inflammatory cells play a major role in thrombus formation19, 22-24 and 
the occurrence of  MVI, we observed no significant differences in inflammatory cell 
composition of  obstructing coronary artery thrombi of  patients with and without MVI. 
The current study confirms previous observations11, 25-29 that MVI patients have a higher 
symptom-to-balloon time, larger enzymatic infarct size, lower left ventricular ejection 
fraction and a higher incidence of  IMH. 
This study did show a non-significant increase of  inflammatory cells in thrombus in 
patients with MVI. However, the increased monocyte/macrophages and neutrophilic 
granulocyte densities, became less overt when thrombus age was taken into account. 
This underlines the importance of  including thrombus age as a parameter in future 
research, in order to minimize the risk of  unjustly establishing a link between thrombus 
inflammatory cell density and MVI. In a previous study we found that the number of  
neutrophilic granulocytes was significantly lower in organized thrombi, compared with 
fresh and lytic thrombi, while monocytes/macrophages were significantly higher in the 
lytic thrombi as compared to the fresh thrombi19, indicating that inflammatory cell den-
sities in coronary thrombi indeed depend on thrombus age.
A recent study described that neutrophil density in aspirated thrombus was an indepen-
dent predictor of  unfavourable myocardial outcome15 visualized as blush grade<or=1, 
ST-segment resolution <50% and low left ventricular ejection fraction (LVEF) at 
6 months after onset of  AMI, albeit the actual occurrence of  MVI was not studied 
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herein 15. We however did not find increased numbers of  neutrophilic granulocytes in 
MVI compared with non-MVI patients. In our study we used the gold standard to assess 
the infarcted area and LVEF, CMR, in comparison to the less favorable blush grade 
and segment resolution used in the referred study 15. This could explain the discrepancy 
between our findings. 
Several studies have evaluated the inflammatory cell content of  the more distal 
 intramyocardial vessels. In a pig model in which distal embolization was induced via 
microsphere embolization resulting in no-reflow, elevated blood levels of  neutrophilic 
granulocyte-platelet aggregates and monocyte-platelet aggregates were found, suggest-
ing that interactions between white blood cells and platelets likely play an important role 
in the pathogenesis of  no-reflow following distal embolization9. Moreover, in a dog study 
of  again the intramyocardial vessels, it was shown that progressive leukocyte capillary 
plugging during myocardial ischemia contributes to preventing full restoration of  capil-
lary flow upon reperfusion. This thus could point to a role of  inflammatory cells in the 
process of  thrombosis in more distal blood vessels of  the heart. In humans, increased 
levels of  white blood cells were related with increased infarct size and mortality30. In 
addition, patients with increased levels of  certain inflammatory cells are also associated 
with the occurrence of  MVO and decreased recovery of  myocardial function31. The 
aforementioned studies suggest an (indirect) link between the amount of  inflammatory 
cells in the blood (sampled distal to the coronary occlusion or systemically) and MVI, 
which has given rise to our hypothesis that inflammatory cell density in thrombus would 
be increased in patients with MVI. We could not establish such a relationship. Sever-
al studies have evaluated a possible link between systemic inflammation in the blood 
 (defined by serum markers rather than inflammatory cell counts) and the occurrence of  
MVI12-14. Systemic activation of  inflammation is increased in no-reflow/MVI, visualized 
via raised serum levels of  C-reactive protein (CRP), hs-CRP, WBC and fibrinogen14. 
The blood levels of  leukocytes and CRP were furthermore shown to positively correlate 
with the size of  MVI12-14. We could however not establish a similar relationship between 
blood leucocyte and CRP levels and the occurrence of  MVI in our study. This could 
be due to the fact that these studies were designed to evaluate the relationship between 
inflammatory markers in the blood and MVI and therefore analyzed these at multiple 
time points under controlled conditions. In two of  these studies12, 14, for instance, blood 
levels were determined serially from day 1 to day 4 after symptom onset. The third study 
used inflammatory markers (CRP and leukocytes) values obtained at the day of  admis-
sion. Area’s under the curve and peak concentrations were used for statistics. We how-
ever evaluated the levels of  CRP and leukocytes retrospectively from a clinical database 
at non-specified time points after onset of  disease. So our measurements are possibly to 
heterogeneous to replicate such a result. 
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Several limitations have to be addressed. Firstly, the number of  study subjects (n=69) 
is relatively small. Beforehand, a proper power calculation was difficult to make, due 
to the exploratory character of  this study. Instead, we decided to include every patient 
from the moment we started to collect thrombus material and performed CMR. Note 
that, as a result of  the small sample size we have not analyzed the data for males and 
females separately. Secondly, we used the presence MVI (yes or no) instead of  the extent 
of  MVI, which could be used as a continuous parameter32 and might give a more subtle 
reflection of  MVI33. Lastly, it has to be noticed that the quantity of  inflammatory cells 
in the thrombus does not represent their activation status. Therefore, we emphasize that 
caution is warranted when using this data to reflect on inflammatory activity.
In conclusion, in STEMI patients with MVI, inflammatory cells are not  significantly 
 increased in coronary aspirates from epicardial coronary thrombi compared with 
STEMI patients without MVI. 
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INTRODUCTION
In this thesis, we studied the interplay between inflammation and cardiovascular dis-
ease. In several mouse and human studies we not only studied the process of  athero-
sclerosis, but also evaluated the role of  inflammation in the cardiac microvasculature 
and  atherothrombosis by using a variety of  techniques, including (immuno)histochem-
istry, enzyme-linked immunosorbent assays, positron emission tomography, computed 
 tomography and cardiac magnetic resonance imaging.
In Chapter 2 we described the inhibitory effect of  an anti-inflammatory fish oil con-
stituent, docosahexaenoic acid, on the accumulation of  the pro-inflammatory advance 
 glycation end product (AGE) N(ε)-(carboxymethyl)lysine (CML), in the microvasculature 
of  the heart. In Chapters 3-8, we studied the effect of  three different types of  inflamma-
tory responses, following orthopedic surgery, infection and acute myocardial infarction 
(AMI) on atherosclerotic plaques. In Chapter 9 and 10, we assessed the inflammatory 
cell composition of  coronary thrombi in relation to thrombus age and the occurrence 
of  microvascular injury. 
This chapter will put the previous chapters in mutual context. To visually support these 
paragraphs, we have included an overview of  our findings. First, the rationale for the 
main hypothesis will be shortly discussed, then we will summarize the main findings of  
the Chapters, address methodological issues and present directions for further research. 
We will end the general discussion with an overall conclusion. 
RATIONALE
Observational studies show a peak incidence of  cardiovascular events early after clinical 
conditions accompanied with severe systemic inflammation. For example, respiratory 
tract infections are associated with an approximate fivefold risk for early1, 2 myocardial 
infarction 1. Not only infections, but also major surgery is associated with a marked 
systemic inflammatory response3. As was shown in a recent nationwide cohort study 
indicated that the risk of  myocardial infarction in patients undergoing total hip or knee 
replacement is increased by no less than 25-fold, again predominantly during the first 
days to two weeks4. Furthermore a landmark paper on the role of  acute systemic inflam-
mation in atherosclerosis showed increased plaque area and intra-plaque inflammation 
in mice briefly after acute myocardial infarction, highlighting another form of  acute 
systemic inflammation5. The acuteness of  the increased risk in the observational studies 
suggests plaque vulnerability, which is closely correlated with intra-plaque inflammation 
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and plaque instability6, 7. Indeed, in the aforementioned mouse study intra-plaque mac-
rophage density was increased after a burst of  systemic inflammation caused by AMI5. 
Furthermore, several murine studies have shown pro-atherogenic effects of  serum 
amyloid A peptide, an important8 marker and mediator of  acute inflammation in mice9-
12, suggesting the direct effect of  inflammation on the vessel wall.
We hypothesized that systemic inflammation induces vessel wall inflammation with 
 subsequent plaque instability and addressed this hypothesis in the cardiac microvascula-
ture and aortic roots of  mice and in the atherosclerotic coronary plaques and coronary 
thrombi of  patients using three different models for acute systemic inflammatory acti-
vation: (1) major orthopedic surgery induced tissue damage, (2) systemic infection or (3) 
acute myocardial infarction itself. 
MAIN FINDINGS, METHODOLOGICAL CONSIDERATIONS AND 
DIRECTIONS FOR FURTHER RESEARCH
N(ε)-(carboxymethyl)lysine (CML) is one of  the major AGEs and its formation is en-
hanced in the presence of  inflammation13. CML is believed to play a role in the devel-
opment and progression of  atherosclerosis13-15 and its accumulation in atherosclerotic 
blood vessels, increases with age. Although age-related CML accumulation was found in 
atherosclerotic vessels16, it remained unknown whether age-related CML accumulation 
also occurs in the non-atherosclerotic microvasculature of  the brain and the heart. In 
Chapter 2 we found age-related CML accumulation in the non-atherosclerotic micro-
vasculature of  the heart and the brain of  atherosclerotic mice (Fig. 1D). Furthermore, 
we found that the omega-3 (n-3) long-chain polyunsaturated fatty acid, docosahexaenoic 
acid (DHA) polyunsaturated fatty acid DHA, the fish oil constituent known for its an-
ti-inflammatory actions, inhibited this age-related microvascular CML accumulation in 
the heart only. Intra-myocardial blood vessels are more important in the induction of  
acute events than previously thought and potentially identify new therapeutic targets in 
the treatment of  AMI17. Therefore our finding of  increased CML in these vessels is of  
great interest. The positive effects of  our study should be evaluated/validated in a large 
scale systematic future trial. Of  note, recently published trials in patients with coronary 
artery disease or after AMI did not show an effect of  omega-3 fatty acids on major 
cardiovascular endpoints (e.g. infarct induction), possibly due to state of  the art con-
comitant drug treatment18. However, as suggested by the current guidelines, omega-3 
fatty acids supplementation in patients with CAD or after MI and possibly in those with 
heart failure remains to be encouraged18. We add with our study a potential substrate/
pathway for this encouragement.
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In Chapter 3, we studied the effect of  major orthopedic surgery on atherosclerotic 
plaques. Major orthopedic surgery in ApoE -/- mice causes acute systemic inflamma-
tion. At 15 days post-surgery, we observed a significant increase of  plaque area, mainly 
due to necrotic core enlargement (Fig.A1). Plaque necrosis is a characteristic hallmark of  
atherosclerotic lesions that causes acute atherothrombotic vascular disease6, 19, 20. Thus, 
our finding of  a post-surgery increase of  necrotic core area may reflect increased plaque 
vulnerability and could, at least in part, explain the increased incidence of  cardiovas-
cular events after major orthopedic surgery. In Chapter 4 we evaluated in a similar 
approach the effects of  a lipopolysaccharide (LPS) evoked acute inflammatory response 
on atherosclerosis. LPS is part of  the outer membrane of  Gram-negative bacteria, and 
elicits strong immune responses in both animals and humans via the Toll-like Receptor 4 
(TLR4), an important route in the human inflammatory response/sepsis. We chose this 
model over an actual infection model, such as the colon ligature and puncture model 
that in theory could more closely resemble the pathophysiological process of  sepsis than 
the LPS model,21-23 since actual infection models are very hard to reproduce and there 
are issues with controlling the magnitude of  the septic challenge22. In general one could 
say that sepsis is one of  the most difficult clinical conditions to model in animals as is also 
shown by the fact that several promising therapeutic agents that were effective in animal 
studies failed to demonstrate a similar benefit in human clinical trials21, 22. In order to val-
idate our model, we measured serum amyloid A and observed indeed a marked  systemic 
inflammatory response, similar to the orthopedic surgery model. However, in contrast to 
the orthopedic surgery model, we did not observe effects on plaque area, plaque severity 
and inflammatory cell density in the atherosclerotic lesions of  the ApoE3Leiden mice at 
both t=3 and t=15 days after LPS injection (Fig. A2). 
Although these two clinical conditions (orthopedic surgery and a LPS stimulated 
 immune response) share the presence of  an acute systemic inflammatory response, they 
also have many differences. Obviously the triggers of  inflammation (surgery induced tis-
sue damage vs. LPS stimulation) and therefore the profile of  the inflammatory cascade 
differ. Furthermore, surgery, in contrast to LPS injection, was accompanied by anesthe-
sia, pain, temporarily immobilization, and breach of  the physical barrier of  skin and 
muscle. All such factors could be responsible for the observed difference. Moreover, the 
difference in observed effects between the orthopedic surgery and the LPS studies, could 
also be explained by the different mouse models used. Although both the ApoE3*Leiden 
mice and the ApoE -/- mice are established models in the atherosclerotic research field, 
there are some differences between the two. Apolipoprotein E (ApoE) is involved in 
the efficient uptake of  lipoprotein particles and as a result mediates the clearance of  
cholesterol remnants24. Normally, these remnant particles are rapidly removed from cir-
culation. However, mutations in the gene encoding for ApoE (f.i. ApoE3*Leiden) or the 
double knock-out of  the gene (ApoE -/- ) cause hyperlipidemia, which can be greatly 
enhanced with a high-fat diet, leading to an increased susceptibility for atherosclerosis. 
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It is known that in the ApoE3*Leiden model plaques grow in a slower, more human-like 
way than the ApoE -/- model24, 25 Furthermore ApoE is important for hepatic clearance 
of  LPS and the complete absence of  this apolipoprotein enhances the immune response 
to LPS26-28. This could have had effect on the positive outcome of  the study in Chapter 3 
were we used the ApoE -/- model instead of  the ApoE3Leiden model. 
Although our data in Chapter 3 are compatible with a causal role for surgery-induced 
inflammation, it would be interesting to address these findings to more in-depth studies 
that are designed to clarify inflammatory pathways. In addition, other, non- or indi-
rect inflammatory effects of  surgery should be further explored, such as hemodynamic 
disturbances29, sympathetic nerve system activation5 or enhanced platelet activity30 as 
these are potential contributors to atherosclerotic lesion development and increased car-
diovascular risk. Furthermore it would be interesting to test our findings in advanced 
mouse models to study actual plaque complications rather than atherosclerotic plaque 
development alone31, 32.
As discussed before in Chapter 3 and 4, we used mouse models to evaluate our hypoth-
esis. Mice models are crucial for the proof-of  principle of  most basic research questions 
and have shown to be invaluable for the progress of  biomedical science. However, cau-
tion is warranted when translating these studies directly to the human situation. Hereby 
overcoming for example the fact that in mice, plaques seldom rupture and therefore are 
considered less adequate to use for the evaluation of  human-like plaque complications. 
We therefore translated our findings from the aforementioned murine studies into clini-
cal studies of  which we report in Chapter 5, 6, 7, 8. 
In Chapter 5 we studied the effect of  systemic inflammation on atherosclerotic coronary 
plaques of  post-AMI patients with or without infection at time of  death. We found that 
AMI was accompanied by advanced inflammation of  human coronary atherosclerotic 
plaques in patients that died 6 hrs-14 days after onset of  AMI (Fig. B1). The presence 
of  instable plaques (thin fibrous caps and/or multiple inflammatory cells reaching up to 
the luminal endothelial layer of  the plaque) was also increased in these groups. A partic-
ularly interesting finding was that the presence of  infection (e.g. sepsis, pneumonia, pan-
creatitis, peritonitis) at time of  death enhanced the mast cell density in the intima and 
media of  coronary arteries, but this phenomenom was not accompanied by increased 
plaque instability nor an increase in other cell densities (Fig. B2). It thus seems that acute 
systemic inflammation, both cardiac and infectious, influenced atherosclerotic lesions in 
a different way.
In Chapter 6 we studied the presence of  mast cells (MCs) in the intima and media of  
unstable and stable coronary lesions at different time points after AMI. We found MCs 
in the intima and media of  both stable and unstable atherosclerotic coronary lesions 
after AMI, especially increasing in the media of  unstable plaques in the patients that died 
5-14 days after AMI (Fig B1). These results suggest that MCs present in  coronary lesions 
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might contribute to the onset of  MI through their plaque-destabilizing or spasm-in-
ducing properties. MI, in turn, might trigger intra-plaque infiltration of  MCs, thereby 
inducing the transition of  stable plaques into unstable plaques resulting in an increased 
risk of  re-infarction.
Taken together, Chapters 5 and 6 thus indicate that MCs play a role in destabilizing 
plaques and contribute to the onset of  AMI. This presumes a role for MC stabilizers, 
such as cromolyn, in the clinical management of  patients with AMI and/or patients 
at risk for AMI. MC stabilizers prevent degranulation and the subsequent release of  
histamine, tryptase and chymase. Indeed, in several atherosclerotic murine studies in-
hibition of  MCs reduced plaque instability33-36, whereas activation of  MCs increased 
plaque instability34, 37, 38. It has to be noticed that the conclusions of  our studies are based 
on a tryptase staining. Tryptase is stored in the MCs’ granules and is released when ac-
tivated39. It would be interesting to include in future projects not only the MC density, 
but also the extent of  the released MC mediators, since it is known that the mechanism 
by which MCs are activated affects the profile of  excreted MC mediators, which in 
turn could influence atherogenicity40. For example, there is a difference in the mediators 
when activated by TLR4 or components of  the complement system when compared 
to activation by IgE34, 41, 42. Under ischemic conditions, MCs are known to release more 
growth factors like VEGF instead of  tryptase40. 
In Chapter 4 and 6 we evaluated plaque stability in order to identify the so called 
vulnerable plaques which are prone to rupture. These thin-capped, macrophage rich 
plaques with large necrotic cores and signs of  hemorrhage have been an integral part 
of  our understanding on the pathophysiology of  the acute coronary syndromes (ACS) 
for  decades. The vulnerable plaque is still of  great value as a readout parameter for the 
severity of  atherosclerotic disease, it is in this context however interesting to realize that 
plaque rupture still plays an important causal role in acute coronary syndromes, but 
that superficial erosion appears on the rise43. This is most likely explained by the chang-
ing risk profile of  the studied western Caucasian population and the success of  statin 
treatment which “stabilizes” plaques44, 45. This is for instance reflected by the increase of  
non-ST segment elevation myocardial infarction46. In future research it therefore would 
be valuable to include quantification of  plaque erosion. Further it seems that the con-
sequences of  a plaque disruption depend not only on the state of  the atheromatous 
lesion itself47-50, indicated by the high amount of  ruptured and healed plaques found 
in the arteries of  already young patients50, but also on the fluid phase of  the blood, for 
example the concentrations of  fibrinogen, tissue factor, endogenous inhibitors of  fibri-
nolysis, and pro-coagulant microparticles51, 52, which is known to be potentially altered 
by inflammation itself53, 54. Future studies must include the potential role of  these factors 
in the development of  AMI.
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Next, we designed a study to replicate our finding of  pro-atherogenic effects of  major 
orthopedic surgery, in humans. In order to do so, we set out to compare large artery 
18FDG uptake in patients scheduled for total knee or total hip replacement. Patients 
underwent 18F-FDG-PET/CT scanning one day prior to surgery and two to three days 
after surgery. [18F]-2-fluoro-2-deoxy-D-glucose (FDG) imaging using positron-emission 
tomography (PET)/computed tomography (CT) provides a noninvasive assessment of  
inflammation and, as such, could be a valuable imaging biomarker in atherosclerosis. 
Major surgery may reduce 18F-FDG uptake in atherosclerotic plaques due to competi-
tive uptake of  the surgery area and change in pharmacokinetics of  18F-FDG. The aim 
of  the study presented in Chapter 7 was to validate the use of  simplified quantitative 
18F-FDG uptake parameters for evaluation of  inflammation in atherosclerotic plaques 
after surgery. We found that tissue to background ratio (TBR) calibrated using venous 
blood samples could be used as surrogate (simplified) measures to assess changes in 
18F-FDG uptake in atherosclerotic plaques of  patients recovering from major orthopae-
dic surgery. This led to further evaluation of  one of  our major research questions: does 
major orthopaedic surgery increases intra-plaque inflammation in humans? Patients are 
currently being enrolled for this study in the Alrijne hospital. Results are expected in 
2018 and will be published separately from this thesis. The preliminary results in n=4 
patients are presented in Chapter 8 and do not suggest an increase of  18F-FDG uptake 
in the major arteries of  patients recovering from major orthopaedic surgery (Fig A3). 
The process of  intracoronary thrombus formation and naturally occurring resolution 
is poorly understood. We do know that inflammatory cells play a role in the formation 
and resolution of  venous thrombi, but their role in coronary thrombosis is less clear. 
In Chapter 9, we analyzed inflammatory cells in thrombi derived from patients with 
STEMI in relation to histologically classified thrombus age. The VU University Medical 
Center thrombus aspirate collection provided us the unique opportunity to study patient 
thrombus material. We found that fresh thrombi (76.1%) were the most abundant as 
compared to lytic (16.8%) and organized (7.1%) thrombi. Neutrophils were significantly 
less present in organized compared to fresh and lytic thrombi, respectively. Monocytes/
macrophages were significantly more present in lytic than in fresh thrombi (Fig. C1). We 
additionally found that thrombi from patients aged <50 years as compared to >50 years 
old contained significantly more neutrophils and monocytes/macrophages irrespective 
of  thrombus age (Fig. C2). Furthermore platelet area was smaller in patients on aspirin, 
again irrespective of  thrombus age. To summarize, the composition of  inflammatory 
cells differs with thrombus age in thrombosuction material of  STEMI patients that in 
part depends on patient age and medication.
Angiographically successful primary percutaneous coronary intervention (p-PCI) not 
always restores cardiac microvascular blood flow. This phenomenon, called MicroVas-
cular Injury (MVI), worsens prognosis and is poorly understood. We hypothesized that 
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inflammatory cell density of  acute coronary thrombi would be increased in patients 
with MVI as presented in Chapter 10. In line with our expectations, we found a high-
er mean symptom-to-balloon time, larger enzymatic infarct size, lower left ventricular 
ejection fraction and a higher incidence of  IMH in the MVI patients. We however could 
not establish a difference in thrombus content of  platelets, erythrocytes, macrophages/
monocytes, lymphocytes, neutrophils and neutrophil extracellular traps (NETs) between 
patients with MVI and patients without MVI (Fig. C3). This study thus argues against 
inflammatory cell alterations in the coronary thrombus as a possible influence on the 
occurrence of  MVI. 
In this Chapter, as well as in Chapters 2, 3, 4, 5, 6, 9, we used inflammatory cell densities 
in order to make suggestions about inflammatory status of  atherosclerotic plaques and 
coronary thrombus. Research and diagnostics in the field of  pathology has its very origin 
in the observation and quantification of  the presence of  inflammatory cells in tissues 
and proved to be very closely related to clinical observations. However, additional analy-
sis of  the activation status of  inflammatory cells, would also be of  interest when studying 
the pathophysiology of  acute inflammation and its role in plaque destabilization and 
thrombus formation. 
CONCLUSION
In the previous sections we gave on overview of  the main findings of  this thesis and what 
we add to the existing knowledge. We also tried to carefully address several methodolog-
ical issues regarding our research. Some of  these issues are not specific for our research, 
but are experienced by most scientists in the field of  atherosclerotic research. Others give 
important clues for future projects, of  which we make note in these sections. This thesis 
provides evidence for a role of  systemic inflammation in the pathophysiology of  acute 
myocardial infarction. We found, at least in part, supportive mechanistic evidence for 
the observational studies reporting increased incidence of  cardiovascular events during 
or after clinical conditions that are accompanied by a systemic inflammatory response, 
e.g. orthopedic surgery, infection/sepsis and AMI itself. 
We describe age-induced inflammatory changes in the microvasculature of  the heart 
that can be postponed with a fish oil constituent. Furthermore, we report evidence 
concerning orthopedic surgery induced atherosclerotic plaque growth and increased 
 necrotic core area, indicative of  more vulnerable plaques. Next we show that mast cells 
(MCs) are increased in the vessel wall surrounding atherosclerotic plaques in patients 
that have signs of  infection and that MCs are associated with more unstable plaques. 
Our work also shows that MCs are elevated in the vessel wall that surrounds plaques in 
patients that died of  acute myocardial infarction. Again this was associated with a con-
comitant increase of  unstable plaques. We hypothesize a bi-directional role of  MCs as 
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they are not only a factor in the origin of  AMI, but we believe that they are also involved 
in the acceleration of  atherogenesis once an AMI has occurred. Besides increased cor-
onary  artery densities of  MCs, we also found an increased number of  macrophages, 
 neutrophilic granulocytes and lymphocytes in atherosclerotic lesions and the surround-
ing vessels wall of  patients that died more than 6 hours-14 days after myocardial infarc-
tion as opposed to patients that died immediately after a coronary event. This also high-
lights that myocardial infarction induced inflammation favors the atherosclerotic process 
and could explain the high amount of  re-infarctions. Lastly, we found a relationship 
 between immune cell composition of  the coronary thrombus and patient characteristics 
and thrombus age, indicative for a role of  inflammatory cells in atherothrombosis devel-
opment. We did not find a clear relationship between inflammatory thrombus composi-
tion and the occurrence of  the microvascular injury phenomenon. This finding argues 
against inflammatory cell involvement in the coronary thrombus as a possible influence 
on the occurrence of  MVI.
Given that 17.5 million people die each year as a result of  cardiovascular disease and 
the incidence is increased with socio-economic status, researchers should obtain a deep-
er insight in the pathophysiology of  these diseases. Paramount in this task is increasing 
knowledge about triggers of  acute destabilization of  these mostly gradually developing 
conditions and subsequently the development of  preventative strategies to postpone or 
even avoid acute myocardial infarction. This thesis provides a framework for the role of  
acute inflammation in causes and consequences of  AMI. Based on our work we believe 
that one day, accumulating knowledge on the specific link between inflammation and 
cardiovascular events, will shift the foundation of  treatment from damage control or 
tertiary prevention to primary prevention.
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Wessel Willem Fuijkschot werd geboren op 20 maart 1988 op het Oversluispad in 
Wormerveer. Halverwege zijn jeugd verhuisde hij met zijn moeder Marlon en zijn 
zus Minke naar Eemnes, waar hij verder opgroeide. Hij was aldaar actief  voor de 
Katholieke Plattelands Jongeren, waar hij door evenementen als Sterkste Man Eemnes 
en 24-uur barzitten leerde organiseren. Het VWO voltooide hij aan het Laar en Berg 
in Laren. Van 2006 tot en met 2012 studeerde hij geneeskunde aan het VUmc in 
Amsterdam. Gedurende zijn studietijd had hij veel plezier in het opzetten en geven van 
onderwijs en ontwikkelde hij een voorliefde voor de interne geneeskunde. Na stages 
in Peru en Zuid-Afrika raakte hij geïnspireerd door Dr. Abel Thijs en Prof. Dr. Yvo 
Smulders en het onderzoek dat zij deden. In 2013 startte hij zijn promotieonderzoek 
op de afdelingen interne geneeskunde en pathologie van het VUmc, onder leiding van 
Prof. Dr. Yvo Smulders, Prof. Dr. Hans Niessen en Dr. Paul Krijnen. Het resultaat van 
zijn werk heeft u in handen. Naast zijn gecombineerde basale en klinische onderzoek 
behield hij zijn voorliefde voor onderwijs en ondernemerschap. Samen met een aantal 
studiegenoten richtte hij de stichting Medical Business op. Deze stichting ontwikkelt 
onderwijs voor jonge artsen over financiën en organisatie van de zorg. Hij was verder 
eindredacteur van het boek: “Artsen met verstand van zaken” en schreef  stukken over 
dit thema voor o.a. voor het Medisch Contact en de Volkskrant. Verder is hij samen met 
Dr. Arno Bisschop en Drs. Stefan Ottenbros oprichter van KINASE, een bedrijf  dat 
artsen consultancy ervaring op laat doen. Op 1 juli 2017 is hij gestart als ANIOS interne 
geneeskunde in Alkmaar. Na het behalen van zijn doctoraat blijft Wessel actief  op het 
grensvlak van de interne geneeskunde, onderwijs en ondernemerschap. 
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Wessel Willem Fuijkschot was born the 20th of  March, 1988 in Wormerveer (Oversluis- 
pad), the Netherlands. During his childhood, he moved with his mother Marlon and 
his sister Minke to Eemnes. He was a member of  a local society called “Katholieke 
Plattelands Jongeren”, at which he developed his managerial skills during infamous 
events such as Strongest Man Eemnes and 24-hours bar sit-in race. He attended high 
school at Laar en Berg. After his graduation, he started Medical School at the VU 
University Medical Center in Amsterdam (2006-2012). During his studies, not only 
teaching and improving current education fulfilled him with great pleasure and 
ambition, but he also developed a strong passion for Internal Medicine. After 
rotations in Peru and South Africa, he was inspired by Dr. Abel Thijs, and Prof. Dr. Yvo 
Smulders and their research. In 2013, he started his PhD-training at the Departments of  
Pathology and Internal Medicine at the VU University Medical Center under 
advisory of  Dr. Yvo Smulders, Dr. Hans Niessen and Dr. Paul Krijnen. This Thesis is the 
result of  his work. Besides his combined basic and clinical research projects, his love for 
education and entrepreneurship remained, prompting him to establish the 
Medical Business foundation together with several fellow Medical students. This 
foundation develops educational programs for young medical doctors concerning the 
economics and organization of  healthcare. His strong attachment with this area of  
healthcare is further underlined by the book “Artsen met verstand van zaken”, for which 
he was editor-in-chief  and his publications about this topic in e.g. Medisch Contact and 
Volkskrant. In addition, together with Dr. Arno Bisschop en Drs. Stefan Ottenbros, 
he founded KINASE, a company that allows doctors to gain experience working as a 
healthcare consultant. On July 1st he started as a junior doctor (not in training) at the 
department of  Internal Medicine in Alkmaar. After finishing his PhD, he will remain 
active at the intersection of  Internal Medicine, education and entrepreneurship. 
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Van alle tradities in het wetenschappelijk onderzoek is het uitbrengen van een dank-
woord misschien wel de mooiste. Het stelt de onderzoeker in staat welgemeende dank 
te betuigen aan de totstandkoming van zijn of  haar proefschrift. Waar in het geprodu-
ceerde wetenschappelijke werk de meeste tekst opgaat aan mitsen en maren, is het dank-
woord verstoken van enige kritiek. Het is een lofzang op de samenwerkingen en relaties 
die belangrijk waren in het proces. Het gaat over mensen. Er zit emotie in. Misschien 
is het daarom dat dit deel voor velen het lekkerst leest. Voor de lezer is het doorgaans 
belangrijk om er in genoemd te worden. Voor de schrijver om niemand te vergeten. Dat 
laatste is waarschijnlijk ook mij niet gelukt. 
Traditiegetrouw als eerste dank voor de proefpersonen die het klinische deel mogelijk 
hebben gemaakt. Direct gevolgd door de donateurs, belastingbetalers en het VUmc die 
investeerden in dit onderzoek. Dank ook aan de leden van de leescommissie voor de 
aandacht die zij schonken aan mijn proefschrift.
Vervolgens, dank voor mijn promotieteam. Yvo, jouw creativiteit, schrijfvaardigheid en 
vasthoudendheid zijn een groot goed. Dank voor jouw vertrouwen en begeleiding van 
het naïeve begin tot en met het bittere eind. Hans, jouw efficiëntie is ongeëvenaard, je 
academisch ego opvallend in toom en de passie voor de pathologie enorm. Bedankt voor 
het laten afkijken van die eigenschappen. Paul, jouw ontspannen manier van werken 
en heldere “biologische” geest zijn van grote waarde geweest, tijdens de hele rit. Dank 
daarvoor. 
Abel, jij zorgde voor de broodnodige spinazie. Toen ik 5 jaar geleden een wetenschap-
pelijke stage moest kiezen, had ik de keuze tussen een uitgestippeld pad of  een avontuur 
met een breedsprakige internist die om de andere zin zijn ongeschiktheid als onder-
zoeker benadrukte. O ja, hij had geen geld en dat zou er ook niet snel komen vanwege 
het eeuwenoude middel dat we gingen onderzoeken. Ik wist het zeker: Aspirine met 
Abel natuurlijk. Er is in die jaren weinig geweest waar we niet over konden discussiëren. 
Keer op keer bewees je jouw geschiktheid als onderzoeker, doordat je niet alleen in-
houdelijk een ster bent, maar juist omdat je iets van mensen af  weet en daar ook iets 
mee doet. Dank. 
Al heel snel kwam Jeske bij het aspirineteam en wat een lol hadden we. Jij was zo mo-
gelijk nog bijdehanter dan ik. Een uur voor de congresdeadline stuurde we ons eerste 
abstract langs Yvo met het verzoek het na te kijken, zodat we naar ons eerste congres in 
Israël konden. Als groentjes sleurden we de grijze koppen de dansvloer op en strikte jij 
de grote plaatjesbaas om de fout in onze poster te vinden. Later leerden we ook om op 
elkaar te steunen als het wat minder vlot liep. Dank voor jouw aanstekelijke optimisme, 
ambitie en plezier. 
Het Aspirineteam is inmiddels flink uitgebreid met onderzoekers, maar vooral ook stu-
denten die hun talent benutten. See one, do one, teach one geldt ook in het onderzoek. Be-
dankt: Karlinde, Katelijne, Cati, Vera, Estella. Jullie maken het werk leuker en beter. 
Datzelfde geld voor de studenten van de pathologie, zonder wie dit proefschrift er nooit 
was geweest. Veel dank: Rianne, Amber, Danae, Ilse, Baback, Ivan, Fabian. 
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Dan mijn kamergenoten. De eerste 2 jaar in kamer 0E36 op de afdeling pathologie. Ik 
moest aan jullie wennen en jullie zo mogelijk nog meer aan mij. We hebben veel mooie 
momenten gehad en ik ben jullie oneindig veel dank verschuldigd voor de steun bij het 
praktische werk en het uitbreiden van mijn biochemische kennis. Dank: Linde, Ibrahim, 
Elisa, Mark, Reindert en Ellis. De laatste 2 jaar zat ik op kamer 4A45 op de afdeling 
interne geneeskunde. Het aantal mensen per vierkante meter was hier zo mogelijk nog 
groter. Edmée, dank voor het welkom en jouw aanstekelijke non-conformisme. Nada, 
dank voor de tussendoorgesprekjes tijdens lange statistiekdagen. Martine, dank voor de 
diepgang en natuurlijk onze midpromotie-tenerific-bergtrip. Elke keer als ik moet tank-
en, zal ik aan je denken.
Dan kom ik gelijk aan bij mijn andere maatje van de interne. Koen, toen jij naar de VU 
kwam kreeg ik al een heads-up dat je lachen was en niets bleek minder waar. Rondjes 
lopen op een festival of  in het Amsterdamse Bos tijdens de pauze. Samen kwamen we er 
altijd wel uit. Dank voor jouw vriendschap tijdens deze promotiejaren en  wat gaaf  dat 
ik straks naast je mag staan tijdens jouw verdediging. 
Dank ook aan alle coauteurs voor de hulp bij de uitvoering  van het onderzoek en het 
schrijven van de manuscripten. In het bijzonder wil ik noemen: Gem, aan wie ik grote 
dank verschuldigd ben voor de hulp bij de nucleaire studies en Martine, voor de hulp bij 
het muizenwerk. Heerlijk om met jullie samen op te trekken.
Vervolgens wil ik mijn beide paranimfen bedanken. Rense, we hebben samen het nodige 
doorleeft. Sinds de eerste dag van de middelbare school maken we elkaar aan het lachen 
en sta jij voor me klaar. We zijn nog steeds diezelfde plagende pubers maar dan met 
een serieuze baan. Jij bent altijd positief, trouw tot op het bot en ziet de dingen soms 
verrassend scherp. Dank dat je straks naast me staat. Rik, het is fijn om een vriend als 
jij te hebben. Doordat jij steeds net iets verder bent dan ik, kan ik veel van je leren. Dat 
begon eigenlijk al toen ik coassistent bij je was (en jij eigenlijk ook), op de kinderafdeling. 
Je bent altijd dichtbij, al zit je zo nu en dan in New York. Ik ben er trots op dat jullie mijn 
paranimfen zijn, jongens.
Dan de gym matties: Niels, Rense, Kirsty, Lennart, Rutger, Ron en ook Marjolijn. Het 
sporten en samen eten na een dag cellen tellen op de VU was essentieel om de vaart erin 
te houden. Op de Sloterkade vormde we een vrolijke, verknipte familie. Dank voor het 
lachen en dank voor de support. Kirsty, jij in het bijzonder bedankt voor het helpen met 
de lay-out van het proefschrift en de schouder om op te huilen. Niels en Marjolijn succes 
met jullie proefschrift, Ron met jouw bedrijf, Lennart met jouw kersverse Meesterschap 
en Rutger met jouw reis en straks jouw nieuwe baan. Ik kijk uit naar het feest met jullie! 
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